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ABSTRACT OF THE DISSERTATION 
 
CLINICAL TRANSLATION OF A HAND-HELD OPTICAL IMAGER 
  
FOR BREAST CANCER DIAGNOSTICS:  IN VITRO AND IN VIVO  
 
TOMOGRAPHY STUDIES 
 
by 
 
Sarah J. Erickson 
 
Florida International University, 2011 
 
Miami, Florida 
 
Professor Anuradha Godavarty, Major Professor 
 
Optical imaging is an emerging technology towards non-invasive breast cancer diagnostics.  
In recent years, portable and patient comfortable hand-held optical imagers are developed 
towards two-dimensional (2D) tumor detections.  However, these imagers are not capable of 
three-dimensional (3D) tomography because they cannot register the positional information 
of the hand-held probe onto the imaged tissue.  A hand-held optical imager has been 
developed in our Optical Imaging Laboratory with 3D tomography capabilities, as 
demonstrated from tissue phantom studies.  The overall goal of my dissertation is towards 
the translation of our imager to the clinical setting for 3D tomographic imaging in human 
breast tissues.  A systematic experimental approach was designed and executed as follows: (i) 
fast 2D imaging, (ii) coregistered imaging, and (iii) 3D tomographic imaging studies.  (i) Fast 
2D imaging was initially demonstrated in tissue phantoms (1% Liposyn solution) and in vitro 
(minced chicken breast and 1% Liposyn).  A 0.45 cm3 fluorescent target at 1:0 contrast ratio 
was detectable up to 2.5 cm deep.  Fast 2D imaging experiments performed in vivo with 
healthy female subjects also detected a 0.45 cm3 fluorescent target superficially placed ~2.5 
  
 vi 
cm under the breast tissue.  (ii) Coregistered imaging was automated and validated in 
phantoms with ~0.19 cm error in the probe’s positional information. Coregistration also 
improved the target depth detection to 3.5 cm, from multi-location imaging approach.  
Coregistered imaging was further validated in-vivo, although the error in probe’s positional 
information increased to ~0.9 cm (subject to soft tissue deformation and movement). (iii) 
Three-dimensional tomography studies were successfully demonstrated in vitro using 0.45 
cm3 fluorescence targets.  The feasibility of 3D tomography was demonstrated for the first 
time in breast tissues using the hand-held optical imager, wherein a 0.45 cm3 fluorescent 
target (superficially placed) was recovered along with artifacts.  Diffuse optical imaging 
studies were performed in two breast cancer patients with invasive ductal carcinoma.  The 
images showed greater absorption at the tumor cites (as observed from x-ray mammography, 
ultrasound, and/or MRI). In summary, my dissertation demonstrated the potential of a 
hand-held optical imager towards 2D breast tumor detection and 3D breast tomography, 
holding a promise for extensive clinical translational efforts. 
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CHAPTER 1                                                                                 
Introduction 
 
 Clinical imaging of breast tissue holds an essential role in cancer detection, staging1, 
treatment monitoring, and surgical guidance.  Early diagnosis of breast cancer by medical 
imaging technology is integral for reducing the mortality2 and morbidity3 of the disease.  
Breast cancer is the second leading cause of death in women in the U.S. and one out of every 
eight women are diagnosed with the disease each year.[1]  Figure 1.1 shows the mortality rate 
by year per 100,000 women with breast cancer from different regions of the world.  The 
figure shows that the mortality rate due to breast cancer has declined since the early 1990s 
(shaded yellow region), and this is largely due to early diagnosis with improved imaging 
technology. 
 Current screening and diagnostic modalities used in the clinical setting include x-ray 
mammography, breast ultrasound, nuclear imaging, and magnetic resonance imaging (MRI).  
Combinations of these modalities are used complementarily to noninvasively detect the 
presence of lesions and determine if they are benign or malignant.  However, these methods 
are neither comprehensive nor infallible leading to unnecessary biopsies and undetected 
cancers.  X-ray mammography has good resolution, however it requires painful compression 
of the breast tissue, it uses harmful ionizing radiation, and the sensitivity decreases in women 
with denser breast tissue.  Breast ultrasound is nonionizing, portable, and inexpensive, but it 
has poor imaging quality and contrast.  MRI is nonionizing, has good resolution and good 
                                                
1 Determination of the degree to which a cancer has spread 
2 The rate of death due to a disease 
3 The rate of incidence of a disease 
2 
sensitivity in dense breast tissue, however it requires expensive, bulky instrumentation and 
strong magnetic fields.  Nuclear imaging methods, including positron emission 
mammography (PEM) and breast specific gamma imaging (BSGI) provide functional 
information and can detect small tumors, but they require harmful nuclear radiation.   
 
Figure 1.1  Mortality rate by year per 100,000 women with breast cancer. (Adapted from American 
Cancer Society, Breast Cancer Facts and Figures, 2009)  
Currently, x-ray mammography is the gold standard for breast cancer detection.  
There are two types of x-ray mammograms: (i) screening mammograms are performed annually 
in women over age 40 or 50 in order to detect the presence of any suspicious mass; (ii) 
diagnostic mammograms are performed once a mass is detected during the screening process in 
order to try to gain more information of the size and location, and determine if the lesion is 
benign or malignant.  Diagnostic mammograms are typically followed by breast ultrasound 
and then MRI and/or nuclear imaging methods.  These clinical imaging methods are used to
noninvasively determine if a suspicious mass is benign or malignant prior to invasive surgical 
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biopsy.  However, 80% of biopsies performed turn out to be negative, resulting in 
unnecessary physical and psychological trauma for the patient.[2]  Hence, there is a clear 
need for improved breast imaging technology to obviate the number of unnecessary invasive 
biopsies.   
 Diffuse optical imaging using near-infrared (NIR) light is a promising technology 
which has been developed over the past three decades towards applications such as 
functional brain mapping and breast cancer diagnosis.  The method is noninvasive, uses 
nonionizing radiation, requires relatively inexpensive instrumentation, and provides 
functional information from in vivo biological tissues.  Diffuse optical imaging measures the 
endogenous optical property difference between normal and diseased tissue (e.g. cancer).  
External fluorescent contrast agents can be used towards imaging tumors at the molecular 
stage (fluorescence-enhanced diffuse optical imaging).  Diffuse optical imaging has a 
potential role in the clinical setting as a complementary diagnostic tool for breast cancer.  X-
ray mammography has a 10% false negative rate [2] (and increases in women with denser 
breast tissue) which means many cancers go undetected, especially in younger women with 
denser breasts.  Hence, additional imaging tools are required for improved diagnosis.  
 Several research groups are developing diffuse optical imaging as a complementary 
imaging modality towards breast cancer diagnosis.  Most of the optical imaging systems 
require bulky instrumentation and/or compression of the breast tissue.  To overcome these 
limitations, hand-held based optical imaging devices are developed, which are portable and 
patient-comfortable, towards clinical translation of the technology.  However, the hand-held 
devices developed to date have not demonstrated three dimensional (3D) tomography.4    
                                                
4 A method of producing a three-dimensional image of the internal structures of an object by the observation and recording 
of the differences in the effects on the passage of waves of energy impinging on those structures 
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 Currently, a hand-held based optical imaging device has been developed in our 
Optical Imaging Laboratory, which is capable of 3D tomography, and has been tested in 
homogeneous5 tissue phantoms6 [3].  The challenge now is to translate the device to the 
clinical setting in order to perform 3D tomography on human breast tissue.  The overall 
objective of the dissertation is the clinical translation of our hand-held optical imager toward 
bedside imaging and 3D tomography of breast cancer.  The results will demonstrate for the 
first time the feasibility of performing 3D tomography in complex human tissues using a 
hand-held optical imager.  
 In order to facilitate clinical translation of the hand-held optical imager, a systematic 
series of experimental studies was designed and executed to demonstrate and evaluate the 
implementation of (i) two-dimensional (2D) imaging in near-real time (i.e. fast imaging), (ii) 
coregistered imaging7, and (iii) 3D tomography in a clinical setting.  To this end, experiments 
were performed initially in homogeneous tissue phantoms to begin with a simplistic case.  
Subsequent experiments were then performed in vitro8 to better mimic the heterogeneous9 
nature of biological tissues.  The bench-top10 imaging set-up was modified into a pseudo-
bedside imaging set-up, and experiments were performed in vivo11 with healthy human 
subjects to determine the performance on actual breast tissues.  Finally, preliminary studies 
                                                
5 Uniform distribution of scattering properties 
6 A physical model designed to mimic the body or part of the body 
7 The process of accurately positioning the acquired data at the probe location relative to the breast tissue geometry, which 
is necessary to perform 3D tomography (details of our coregistered imaging approach are given in subsequent chapters) 
8 Located outside the organism in a laboratory environment 
9 Non-uniform distribution of scattering properties 
10 Suitable in size or configuration for use on a laboratory workbench 
11 Located within the whole, living organism 
5 
were performed with cancer patients to test the ability of the device to image breast cancer in 
vivo.  The experimental design is summarized in Figure 1.2. 
 
Figure 1.2 Diagram summarizing the systematic experimental study design.  
The dissertation is organized as follows:  Chapter 2 provides background on near-
infrared optical imaging; Chapter 3 gives a review of the hand-held optical imaging devices 
developed by different research groups; Chapters 4 and 5 summarize the recent work 
performed in fluorescence tomography (in phantoms and small animals) and clinical breast 
imaging studies (in human subjects), respectively; Chapter 6 provides the details of the 
instrumentation of the hand-held optical imager and describes the procedures for data 
acquisition, processing, and analysis; Chapter 7 describes the reconstruction method used to 
perform 3D tomography; Chapters 8-14 detail the experimental studies described above and 
summarized in Figure 1.2; Chapter 15 gives an overall discussion of the significant results of 
the studies and Chapter 16 describes ongoing and future work.  A flow diagram of the 
dissertation structure is given in Figure 1.3.   
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 The various studies are performed using both diffuse optical (i.e. using endogenous12 
tissue contrast) and fluorescence-enhanced optical imaging (i.e. using an exogenous13 
contrast agent) towards clinical translation of the hand-held optical imager.  The work 
presented herein will demonstrate the potential role of the hand-held optical imager as a safe 
and patient-comfortable method to provide complementary physiological14, diagnostic and 
prognostic15 information about human breast tissues.    
                                                
12 Originating from inside an organism 
13 Originating from outside an organism 
14 Relating to the biological function of tissue 
15 Predicting the likely outcome or progression of a disease 
7 
 
Figure 1.3:  Flow diagram showing the organization of the dissertation. 
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CHAPTER 2                                                                                                    
Background:  NIR Optical Imaging 
2.1  INTRODUCTION 
Optical imaging is an emerging technique for observing internal functionality of the human 
body.  Three major biomedical applications of optical imaging that have been investigated 
are brain imaging for functional monitoring, breast imaging for cancer diagnosis and 
monitoring response to neoadjuvant chemotherapy16, and muscle imaging for physiology 
monitoring [4].  For these applications, diffusing light fields are used to measure blood 
hemodynamics17 and to detect the presence of tissue inhomogeneities [5].  Biological tissues 
have specific optical properties that become altered in diseased tissue.  These altered 
properties can be discerned by NIR imaging for the application of cancer diagnosis.  This 
chapter will describe tissue characterization using NIR imaging, fluorescence enhanced 
optical imaging, different measurement techniques and configurations used in optical 
imaging, and different types of instrumentation used to perform optical imaging.   
2.2  NIR IMAGING FOR TISSUE CHARACTERIZATION 
When light travels through biological tissue, it becomes scattered and absorbed.  Biological 
tissues are characterized by their absorption coefficient, !a, and scattering coefficient, !s, 
which represent the number of absorption or scattering events per unit length, respectively, 
and are wavelength dependent properties intrinsic to the tissue.  These properties govern 
how the light will propagate within that tissue.  The major biological chromophores (light 
absorbers) are water (H2O), oxy-hemoglobin (HbO2), and deoxy-hemoglobin (Hb).  The 
                                                
16 Preliminary cancer therapy that precedes surgery or a second modality of treatment 
17 The branch of physiology that studies the movement of blood 
9 
major source of scattering is lipids (fatty tissue).  Light is minimally absorbed by the 
chromophores and preferentially scattered at wavelengths in the near-infrared (NIR) region, 
700-900 nanometers (nm) as shown in Figure 2.1.  This region is termed the diagnostic or 
therapeutic window because it is at these wavelengths that light can penetrate deep into the 
tissue before being absorbed.  
Figure 2.1  Absorption coefficient at various wavelengths for water, oxy-hemoglobin, and deoxy-
hemoglobin (adapted from R. Weissleder 2001 [6]). 
NIR light can be used to detect the presence of inhomogeneities (such as a cyst or 
tumor) within biological tissue because the optical properties (!a and !s) differ in normal and 
diseased tissue.  The functional information provided by NIR imaging enables differentiation 
between benign and malignant lesions, whereas modalities such as x-ray mammography and 
computed tomography (CT) only provide anatomical information requiring a needle biopsy
to identify the inhomogeneity. The endogenous contrast between normal and diseased tissue 
can be measured by diffuse optical imaging systems to detect the presence of a tumor.   
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2.3  FLUORESCENCE-ENHANCED OPTICAL IMAGING 
An exogenous contrast agent can be introduced into the tissue to produce a stronger signal 
towards detection of smaller lesions (<0.5 cm diameter).  Indocyanine green (ICG) is a 
fluorescing dye typically used for fluorescence-enhanced optical imaging and tomography 
because it is nontoxic at low concentrations and is approved by the Food and Drug 
Administration (FDA) for use in humans.  Fluorescence occurs when incident light causes a 
fluorescent molecule to excite.  It remains excited for a period of time (the fluorescence 
lifetime, �) and then relaxes to the ground state by emitting a photon of lower energy 
(higher wavelength) than the energy of the incident light.  The principle of fluorescence is 
illustrated using a Jablonski diagram in Figure 2.2.  The fraction of excited fluorescent 
molecules that relax radiatively is known as the quantum efficiency.   
 
 
Figure 2.2  Jablonski diagram showing the principle of fluorescence. 
 
The principle of fluorescence enhanced optical imaging is illustrated in Figure 2.3 for 
continuous-wave based imaging.  When the fluorescent dye is injected into the tissue, it 
tends to accumulate close to the tumor site depending on its specificity.  NIR light excited at 
the tissue surface propagates into the tissue and becomes attenuated due to absorption of 
11
the light by the tissue chromophores.  Upon encountering a fluorescent molecule (or 
fluorophore), the molecule becomes excited (Figure 2.2).  As the molecule relaxes back to 
the ground state, the energy is emitted at a higher wavelength (the fluorescent signal).  The 
fluorescent signal propagates through the tissue becoming further attenuated by absorption.  
The emitted fluorescent light from the fluorophore combined with the original attenuated 
excitation light from the incident source is collected at the tissue surface using NIR sensitive 
detectors and appropriate filters to select the weak fluorescent signal. 
 
Figure 2.3  Principle of fluorescence enhanced optical imaging using continuous-wave based 
measurements. 
2.4  MEASUREMENT TECHNIQUES IN OPTICAL IMAGING 
Different measurements techniques are used in optical imaging which are time-
independent or time-dependent.  The three types of measurement techniques used in optical 
imaging are continuous wave (which is time-independent), frequency-domain photon 
migration, and time-domain photon migration (which are time-dependent).  Figure 2.4 
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shows the basic principle of the three methods.  The continuous wave (CW) technique uses 
light intensity that is constant in time.  The amplitude of the incident light attenuates as it 
passes through tissue and the amount that it attenuates is related to the optical properties of 
that tissue (Figure 2.4A).  CW imaging is relatively simple, fast and inexpensive; however, 
one major drawback is that the absorption (!a) and scattering (!s) properties cannot be 
determined independently since information is collected as a single combined measurement.   
Frequency-domain photon migration (FDPM) uses intensity-modulated light waves that 
experience amplitude modulation decay and phase shift with respect to the incident wave 
(Figure 2.4B).  The amplitude decay measures the absorption properties and the phase shift 
measures the scattering properties enabling each property to be measured independently.  
Time-domain photon migration (TDPM) uses nano- or pico-second laser pulses of incident 
light that broaden and attenuate according to the optical properties as they pass through the 
tissue (Figure 2.4C).  The photon times-of-flight are recorded to acquire a photon 
distribution as a function of time.  TDPM has good temporal resolution and is capable of 
measuring absorption and scattering properties independently.  However, the 
instrumentation is more expensive and complex because it requires detectors with 
picoseconds or better resolution,  and the method requires longer imaging time due to low 
signal-to-noise ratio (SNR) than CW or FDPM.     
 
13
 
Figure 2.4  Diagram of the three measurement techniques for optical imaging: (A) continuous wave, 
(B) time domain photon migration, and (C) frequency domain photon migration  (adapted from 
http://www.medphys.ucl.ac.uk/) 
2.5  MEASURMENT CONFIGURATIONS IN OPTICAL IMAGING 
Imaging systems can be designed for reflection and/or transillumination measurements.  For 
reflection measurements, light that has passed through the tissue is diffusely reflected from 
the same side upon which the incident light was launched.  For transillumination 
measurements, light that has passed though the tissue is diffusely transmitted from the side 
of the tissue opposite from which it was launched. 
Different measurement configurations are used to perform optical imaging which 
determine the type of signal that will be collected from the tissue (reflectance and/or 
transillumination).  The measurement geometries used in breast imaging are typically 
governed by the instrumentation, i.e. bulky instrumentation or hand-held device based 
instrumentation.  Additionally, different combinations of point and area illumination are 
14
used.  These different imaging geometries are described in detail in the following 
subsections. 
Most three-dimensional (3D) optical imaging studies towards breast cancer diagnosis 
employ either compressed tissue based imaging configuration [7-12] (Fig 2.5A) or circular-
based imaging configuration [13-28] (Fig 2.5B).   The compressed tissue based configuration 
is analogous to x-ray mammography, and is disadvantageous due to patient discomfort from 
tissue compression and limited information obtained around the complete breast tissue.  The 
circular-based configuration has minimal patient discomfort, but is limited by the bulky and 
non-portable instrumentation.   The sub-surface based imaging configuration (Fig 2.5C) is a 
relatively new method that requires no tissue compression, and can be designed to mimic a 
portable and flexible imaging probe [27, 29-71].  In recent years, hand-held based optical 
imaging devices employing the sub-surface imaging configuration are developed in an 
attempt to translate the technology to the clinic, with maximum patient comfort and 
portability (compared to the available bulky optical imagers).   A literature review of hand-
held based optical imaging devices developed to date is given in Chapter 3. 
 
Figure 2.5   Different imaging configurations: (A) compressed tissue, (B) circular, and (C) sub-
surface  Adapted from B. Jayachandran, 2007.[27] 
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2.7  IMAGING GEOMETRIES 
2.7.1  Point source vs. area illumination and collection 
Different imaging geometries include the use of point source versus area illumination and 
collection.  In area illumination and collection, the incident laser light from a single source is 
expanded to cover the entire tissue region being imaged at one time.  The light is collected 
from the tissue over the same region by typically using a CCD camera based detector.  This 
method has the advantages of rapid data acquisition and large volume interrogation, but 
requires bulky instrumentation and cannot be made to conform to the geometry of the tissue 
surface.  Point source and detection based imaging uses optical fibers to illuminate and 
collect the light from the tissue surface.  This method has the advantage of placing the fibers 
in direct contact with the tissue surface and can be made into a portable hand-held device 
based imaging system. 
2.7.2  Simultaneous illumination using point sources to approximate area 
illumination 
Point source and detector based imaging systems typically illuminate the source points 
sequentially, via optical fibers.  An alternative approach involves simultaneous illumination 
of multiple source points.  Simultaneous illumination enables rapid data acquisition and 
better approximates a more ideal case of area illumination since a large volume of tissue is 
interrogated in a single measurement.  The hand-held device described herein employs 
simultaneous illumination of six source points in order to facilitate rapid data acquisition and 
larger volume interrogation as in area illumination.  More details will be given in Chapter 6. 
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2.8  INSTRUMENTATION 
Instrumentation for optical imaging is chosen based on the application.  The basic 
components of any optical imaging system are a light source and a detector.  A single source 
and detector pair are used for measuring single-point locations in the tissue which is termed 
optical spectroscopy.  Multiple sources and detectors are required to collect measurements 
over an area of tissue which is termed optical imaging.  The process of collecting 
measurements over an area and reconstructing the spatial optical property maps in 2D or 3D 
is termed optical tomography.   
 
2.8.1  Bulky instrumentation vs. hand-held devices 
Different research groups typically develop or use optical imaging instrumentation either in 
the form of an optical bed using the circular or compressed-tissue imaging configuration, or 
a hand-held probe using the subsurface based imaging configuration.  Several research 
groups have developed optical imaging methods for breast imaging which use a bed upon 
which the subject lies prone while the breast is either suspended in a ring or cup, or 
compressed between two plates.  An example of this type of instrumentation is shown in 
Figure 2.6A.  This type of instrumentation allows for transillumination based imaging and 
control of the tissue geometry for ease in 3D image reconstruction.  However, the 
instrumentation is bulky and non-portable and can be uncomfortable for the subject.  
Additionally, many systems use a matching fluid to compensate for lack of direct contact 
with the tissue.  In order to overcome these limitations, several research groups have 
developed hand-held based optical imaging devices.  Examples of these hand-held devices 
are shown in Figure 2.6B and a complete literature review of the hand-held devices 
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developed to date is given in Chapter 3.  Hand-held devices have the advantages of being 
portable and patient-comfortable, and achieve full contact with various-shaped tissues.  The 
devices developed to date are typically used to collect spectroscopic measurements of tissue 
optical properties and/or to estimate the 2D location of a tumor.  The devices use point 
illumination/detection and reflectance based imaging geometry.  None of the hand-held 
optical devices developed to date have attempted 3D tomography (without the addition of a 
second imaging modality) since they are unable to coregister the image to the tissue 
geometry.  The device described herein is unique in its ability to perform 3D tomographic 
imaging using a hand-held NIR imaging device.   
 
Figure 2.6  Different types of instrumentation used for breast include: (A) bulky optical bed based 
imaging, and (B) hand-held device based imaging. Adapted from S. Erickson, 2009.[29] 
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2.8.1  Sources 
The most common types of sources used in diffuse optical imaging are laser diodes, light 
emitting diodes, halogen lamps, Ti:sapphire lasers, and helium-neon (He-Ne) long coherence 
lasers.  An example of each type of source is shown in Figure 2.7.  Laser diodes (Figure 
2.7A) and light emitting diodes (Figure 2.7B) are semiconductors usually formed by a p-n 
junction powered by an electrical current.  Laser diodes of different NIR wavelengths are 
used according to the measured parameter of interest (e.g. oxyhemoglobin, 
deoxyhemoglobin, water, lipids, etc.).  A halogen lamp (Figure 2.7C) uses a tungsten filament 
combined with halogen gas to produce white light of all wavelengths.  Different filters can 
be used to select particular wavelengths appropriate to the imaging application.  Ti:sapphire 
lasers (Figure 2.7D) are tunable lasers which can emit light in the NIR range between 650-
1100 nm.  A He-Ne laser contains a mixture of helium and neon gas in a small bore capillary 
tube and is usually excited by a direct-current (DC) electrical discharge. 
 
Figure 2.7  Types of sources commonly used in diffuse optical imaging: (A) laser diode 
http://fr.digikey.com/1/3/indexb31.html; (B) light emitting diode http://energyboomer.typepad.com; (C) 
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halogen lamp http://shopzlot.biz/products/abco-halogen-lamp-50w-04423; (D) Ti:sapphire tunable laser  
http://www.dmphotonics.com/DPSS/DPSS_CWlasers_TiSa_pumping.htm; (E) helium-neon He-Ne long 
coherence laser http://www.newport.com 
2.8.2  Detectors 
The most common types of detectors used in diffuse optical imaging are charge-coupled 
device (CCD) cameras, avalanche photodiodes (APD), and photomultiplier tubes (PMT).  
An example of each type of detector is shown in Figure 2.8.  A CCD camera (Figure 2.8A) 
converts optical light signal into electrical amplitude signals using multiple charge-coupled 
devices and reproduces the image of the subject.  An avalanche photodiode (Figure 2.8B) is 
a highly sensitive semiconductor electronic photodetector device that converts light into 
electricity via the photoelectric effect.  Photomultiplier tube detectors (Figure 2.8C) are 
designed to amplify the current of incident light up to 100 million times using multiple 
dynodes in order to detect very low intensity light signals. 
 
Figure 2.8 Types of detectors commonly used in diffuse optical imaging: (A) CCD camera 
http://www.aegis-elec.com/products/hitachi-KP-M3AN.html; (B) avalanche photodiode
http://www.newport.com; (C) photomultiplier tube http://www.prizmatix.com/docs/OptiBlocks.cfm. 
Diffuse optical imaging is an emerging modality which noninvasively measures the 
optical properties (absorption and scattering) of near-infrared light in biological tissues.  
External contrast agents can be used to perform fluorescence-enhanced optical imaging 
toward detection of smaller tumors.  Instrumentation is selected based on the different 
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measurement techniques and imaging configurations for different applications of optical 
imaging in human tissues.  The next three chapters give a review of past work performed by 
different research groups using optical imaging technology for breast tissue imaging. 
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CHAPTER 3                                                                                                      
Past Work:  Hand-held Optical Imaging Devices 
3.1  INTRODUCTION 
Different hand-held based optical devices have been developed by several research groups 
[27,29-71] with differences in the instrumentation, capabilities, and their specific 
applications.  The current review will focus on all the hand-held based devices (termed hand-
held imagers, probes, devices, and imaging systems by various researchers) developed to date 
towards optical imaging of biological tissues using NIR light.  Table 3.1 provides a 
condensed summary of the different NIR hand-held devices developed to date in terms of 
the measurement technique, source and detector type, source wavelengths and input 
intensity, number of sources and detectors, target depth, and the number and type of subject 
studies (see Appendix I for extensive version of the table).  Herein, the different hand-held 
devices are primarily discussed in terms of: (i) the measurement technique employed; (ii) 
imaging methods implemented; and (iii) their specific applications, along with the advantages 
and disadvantages of the different systems available to date.  
3.2  MEASUREMENT TECHNIQUES IN DIFFERENT HAND-HELD 
DEVICES 
 Optical imaging is typically carried out using one of the three measurement 
techniques, namely, continuous wave (CW), frequency domain photon migration (FDPM), 
or time domain photon migration (TDPM).  These measurement techniques are described in 
detail in section 2.4.  Different research groups developing hand-held based optical devices 
employed different measurement techniques based on their specific application and focus of 
research.   
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Table 3.1  Summary of different hand-held devices developed towards optical imaging (extensive 
table provided in Appendix I). 
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3.2  MEASUREMENT TECHNIQUES IN DIFFERENT HAND-HELD 
DEVICES 
Optical imaging is typically carried out using one of the three measurement techniques, 
namely, continuous wave (CW), frequency domain photon migration (FDPM), or time 
domain photon migration (TDPM).  These measurement techniques are described in detail 
in section 2.4.  Different research groups developing hand-held based optical devices 
employed different measurement techniques based on their specific application and focus of 
research.   
 
3.2.1  Continuous Wave (CW) Based Devices  
The CW measurement technique (which measures the attenuated light intensity that remains 
constant with time) has been employed by several of the devices developed for breast 
imaging, although using different sources and detectors.  A CW-based device developed at 
the University of Pennsylvania (Device #3, Table 3.1) employed light emitting diode sources 
(at three wavelengths) and silicon diode detectors [50-51].  Parallely, a different CW-based 
device (Device #7, Table 3.1) was developed by another research group at the University of 
Pennsylvania [60,71], employing a long coherence laser source (4 sources) and fast photon-
counting avalanche photodiodes as detectors (four of them) coupled via detector fibers.  In 
contrast, a hand-held device (termed as a tissue oximeter) developed at the Ohio State 
University (Device #6, Table 3.1) contained embedded laser diode and photodiode modules 
for CW-based NIR imaging [57-58,71]. 
Typically CW-based techniques are preferred over the time-dependent FDPM or 
TDPM measurement techniques, since the instrumentation is simple, inexpensive, and can 
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be made portable towards developing hand-held based imaging devices.  However, the CW 
technique provides limited depth information in comparison to the FDPM and TDPM 
techniques.  This is because the technique only measures the changes in intensity, reflected 
from the combined effect of absorption and scattering (and not individually) [72-75] .  In 
addition, if the CW-based hand-held devices were applied towards fluorescence-enhanced 
optical imaging studies, it would limit the technique from differentiating the changes in 
fluorescence intensity arising from the fluorophore concentration or its decay kinetics (i.e. 
fluorescence lifetime and quantum efficiency). 
3.2.2  Frequency-Domain Photon Migration (FDPM) Based Devices  
 
Most of the hand-held devices developed towards breast imaging employ FDPM technique 
due to the advantage of measuring amplitude and phase shift of the modulated signal 
separately.  The following hand-held devices employ the FDPM measurement technique and 
are described in chronological order of device numbers in Table 3.1.  
�   A multi-wavelength FDPM-based hand-held device (Device #1a, Table 3.1) was 
developed at the University of California, Irvine [33-39].  The device is capable of 
working between 300 kHz to 1 GHz frequencies.  Modulated light source is 
generated using laser diodes and a network analyzer (generates radiofrequency 
signals) and avalanche photodiodes (APD) are used as detectors, since they are 
capable of detecting the collected signals at such high frequency.   A second 
generation of the device (Device #1b, Table 3.1) was developed, which combines 
CW and FDPM methods into a single CW/FD probe [40-46].  The CW component 
was added for broad continuous wavelength coverage resulting in better 
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chromophore identification and improved concentration quantification than that 
achieved using FD alone.   
�   More recently, researchers from the University of California, Irvine miniaturized an 
entire FD imaging instrumentation into a single hand-held device (Device #2, Table 
3.1) [47-49] .  Modulated light source is generated using a signal generator (10 MHz 
to 1GHz) and a laser diode.  A homodyne and heterodyne based imaging version of 
the device were developed and tested on homogeneous phantoms.  The homodyne 
device was simpler, but the accuracy was compromised by noise, while the 
heterodyne device was more complex but the filtering of noise enabled greater 
accuracy [47] .  The homodyne based device used a single frequency at the source 
and detector end, thus contaminating the detected signal with noise from the 
ambient light and harmonic frequency.  Hence, a heterodyne based version of the 
mini-imaging device was developed, wherein two different frequencies were 
employed at the source and detector end (here +45 MHz difference between 
frequencies) in order to generate a new lower-frequency detected signal.  The 
heterodyne approach (along with the use of a sharp crystal filter) filtered the noise 
due to ambient light and harmonic frequency, thus improving the sensitivity of signal 
detection.  This first heterodyne version of the device used one detector for 
amplitude measurements of the 45 MHz heterodyne signal alone, and a second 
detector for the regular phase measurements.  Another version of the above device 
was developed into a full-heterodyne laser breast scanner, which used heterodyne 
technique for both amplitude and phase measurements [49].    The amplitude and 
phase results from a breast phantom using full-heterodyne matched those predicted 
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by diffusion theory better than the results from the homodyne and the first 
heterodyne version of the devices [47].   
�   Two multi-modality based imaging devices (Devices #10a, #10b, #11, Table 3.1) 
were developed at the University of Connecticut that combined FDPM-based optical 
imaging and ultrasound into a single hand-held device [66-71].  The optical part of 
each system used 12 pairs of dual wavelength laser diodes (780 nm and 830 nm) and 
8 photomultiplier tube (PMT) detectors.  The two devices differ in the source-
detector configuration as described in Section 3.3.  
�  A device was developed at the University of Pennsylvania (Device #4, Table 3.1) that 
used two simultaneous light sources, in contrast to the various frequency-domain 
based imaging devices developed by all researchers to date using sequential point 
source illumination.  The device was based on an ac circuit that acquired low 
frequency (3 kHz) measurements at a single wavelength from a pair of anti-phased 
(i.e. out of phase by 1800) light emitting diodes, using a silicon diode detector [53].  
The device collected only amplitude changes, which are independent of frequencies, 
unlike the phase measurements that are optimal at higher frequencies of 100-200 
MHz.  Hence, even a low frequency based device was sufficient to provide an 
optimal signal to noise ratio (SNR) for this device [53], apart from reducing the 
instrumentation costs in comparison to a high frequency based device.  The 
simultaneous anti-phased source illumination caused destructive interference of the 
photon density waves (PDW), which in turn was used to determine the 2-D spatial 
target localization of an absorbing (or fluorescing) target in a 3-D phantom(s) [76-
80]. 
  
 27 
�  A hand-held device was developed at the Huazhong University of Science and 
Technology (Device #5, Table 3.1), which also uses the same principle of 
simultaneous anti-phased source illumination.  The device used two pairs of light 
emitting diodes (LEDs) that produced 3 kHz signals to form a low frequency phased 
array 2D fluorescence system [54].  One pair of LEDs was in-phase and the other 
was out-of-phase to produce two null planes, which in turn indicated the 2D location 
of a fluorescent target.  The device was designed to provide real time detection and 
2D localization of small fluorescent objects within a highly scattering medium.   
 
The advantages of time-dependent (FDPM and TDPM) over time-independent 
(CW) measurement techniques were described in section 2.4.  In addition, FDPM is often 
preferable over TDPM due to improved signal-to-noise ratio (SNR).  Steady-state FDPM 
measurements in terms of amplitude and phase are minimally corrupted by the ambient light, 
since the instrument detects only modulated signals.  Thus the FDPM instrument 
automatically acts as a filter for ambient light rejection, which is not only an advantage for 
FDPM over CW or TDPM techniques, but favored for clinical application in a non light-
proof environment.  Since hand-held optical devices are designed toward clinical translation, 
they typically employ the FDPM technique due to this advantage.   
3.2.3  Time-Domain Photon Migration (TDPM) Based Devices  
Time domain photon migration (TDPM) is not a favorable measurement technique for 
hand-held optical devices due to its expensive and complex instrumentation (as described in 
section 2.4).  To date, only one TDPM-based hand-held device (Device #8, Table 3.1) has 
been developed at Physikalisch-Technische Bundesanstalt in Berlin, Germany [60] for 
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bedside assessment of cerebral perfusion in stroke patients.  The device measured diffuse 
reflectance of 803 and 807 nm light from two picosecond diode lasers with pulse width of 
~100 ps and 60 MHz repetition rate.  Detecting fiber bundles were used to collect the light 
and deliver it to photomultiplier tubes.  The TDPM technique was chosen in this application 
because the measurement of variance in distributions of time of flight of photons can be 
used to monitor changes of absorption in the cortex as opposed to the skin or the skull.  
3.3  IMAGING METHODS OF DIFFERENT HAND-HELD DEVICES  
The hand-held imaging devices employing any one of the three measurement techniques use 
appropriate source-detector configurations to allow spectroscopic, tomographic, or 
interference-based imaging studies. The source-detector configuration governs the type and 
quality of information obtained using the imaging device (as described in section 2.8).  
Spectroscopic and tomographic imaging were described in section 2.8.  In addition, the 
principle of interference can be used toward tumor localization.  This method requires at 
least two sources that simultaneously illuminate in-phase (constructive interference) or out-
of phase (destructive interference), and typically detected using a single detector.  The hand-
held optical devices developed can thus be categorized in terms of the method of imaging as: 
(i) spectroscopic imaging-based, (ii) tomographic imaging-based, and (iii) interference 
imaging-based.  Schematics of the different source-detector configurations employed by the 
hand-held devices using the different imaging methods are shown in Figures 3.1, 3.2, and 3.3 
for spectroscopy-based, tomography-based, and interference-based devices, respectively.   
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3.3.1  Spectroscopic Imaging-based Devices  
Spectroscopic imaging-based devices utilize the simplest source-detector configuration of a 
single source and single detector, in order to obtain spectroscopic information.  The 
spectroscopic imaging-devices developed by a research group at the University of California, 
Irvine used the single source-detector design for characterization of breast tissue [33-46].  
The Device #1a in Figure 3.1 developed by this research group has a single source-detector 
pair to measure photon density wave phase and amplitude from which physiological 
properties of normal and tumor tissue are extracted [33].  The second generation of the same 
device (Device #1b, Figure 3.1) used two source-detector pairs, of which one pair obtained 
FD measurements and the second pair obtained CW measurements [40].  The mini-FDPM 
device developed by researchers at the University of California, Irvine (Device #2, Figure 
3.1) also employed a single source (laser diode) and single detector (APD) that were housed 
within the device in order to make direct contact with the tissue surface [44-49].   
The use of multiple sources and detectors enables measurements from several 
locations and tissue depths and provides more information for the reconstruction of the 
tissue optical  
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Figure 3.1  Schematics of spectroscopic imaging-based devices. (a) Device #1a developed by 
researchers at the University of California, Irvine, which contains a single FD source-detector pair, 
(b) Device #1b developed by the same group, which contains a single FD source-detector pair and a 
single CW source-detector pair, and (c) Device #2 developed by other researchers at the same 
university, which contains a single source and detector embedded within the probe, (d) Device #3 
developed by researchers at the University of Pennsylvania, which contains a single source 
surrounded by 8 detectors, (e) Device #6a developed by researchers at Ohio State University and 
ViOptix, Inc., which contains 8 sources and 8 detectors, (e) Device #7 developed at the University of 
Pennsylvania, which contains 4 sources and 4 detectors, (f) Device #8 developed at Physikalisch-
Technische Bundesanstalt, which contains 2 sources and 4 detectors, (g) Device #9a developed at 
the University of Pennsylvania, which contains 2 sources and 4 detectors, and (h) Device #9b 
developed by the same group, which contains 4 sources and 2 detectors. 
 
properties.  Most of the spectroscopic imaging-based devices developed to date employ 
multiple sources and detectors in their probe design.  The hand-held devices which used 
multiple sources and detectors are described below.  
�   One of the research groups at the University of Pennsylvania [50], developed a device 
for breast imaging (Device #3, Figure 3.1) consisting of a single LED source centered on 
the device that is surrounded by eight silicon diode detectors, each of which were located 
4 cm from the source.  This configuration enables the device to interrogate a larger tissue 
area than the use of a single detector would allow.  Another research group in the same 
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university [58-59] developed a device containing 4 sources lined up parallel to 4 detectors 
(Device #7, Figure 3.1).  The line of sources and line of detectors were separated by 2.5 
cm.    
�   A breast imaging device developed at Ohio State University and ViOptix, Inc. (Device 
#6a, Figure 3.1) contained 8 sources and 8 detectors arranged in a 2.5 cm x 2.5 cm 
matrix [55-59] in order to image even larger areas.  A second generation of the device 
was later developed (Device #6b, Table 3.1) that contained 16 sources and 8 detectors to 
form a 3 ! 3 cm2 matrix [57].  In these devices the photodiode detectors collected the 
light simultaneously at a sampling rate of 100 kHz while the 16 source fibers were 
illuminated sequentially. 
• Several hand-held devices with multiple sources and detectors have also been developed 
towards brain imaging studies.  The device developed at Physikalisch-Technische 
Bundesanstalt in Berlin, Germany (Device #8, Figure 3.1) to measure cerebral perfusion 
in stroke patients contains 2 sources and 4 detectors [60].  One source and two detectors 
are positioned on each hemisphere of the head and four distributions of times of flight 
of photons were measured simultaneously at the 4 detector positions.  Two other 
devices were developed at the University of Pennsylvania to monitor radiation therapy in 
patients with head and neck tumors [61].  One device contains 2 sources and 4 detectors 
with layout as shown in Figure 3.1 (Device #9a) and the second device contains 4 
sources and 2 detectors (Device #9b, Figure 3.1).  Both devices use NIR spectroscopic 
tools, but the former device is used to measure tumor blood flow before and during 
radiation therapy (method termed as diffuse correlation spectroscopy), and the latter 
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device is used for quantification of the concentration of tissue chromophores in the head 
and neck regions (method termed as diffuse reflectance spectroscopy).  
3.3.2  Tomographic Imaging-based Devices  
The tomography imaging-based devices employ multiple sources and detectors in order to 
obtain 2D surface images as well as employ the measurements towards tomographic 
reconstructions.  One group from the University of Connecticut developed hand-held NIR 
devices with multiple source-detector configurations combined with an ultrasound array [62-
71] as shown in Figure 3.2 (Devices #10a, #10b and #11).  The use of multiple sources and 
detectors enabled area imaging using the NIR component, and a priori information from the 
ultrasound component enabled 3D tomography, thus determining the target location. 
 
 
Figure 3.2 Schematics of tomographic imaging-based devices. (a) Device #10a  developed by 
researchers at the University of Pennsylvania and University of Connecticut, which contains a central 
ultrasound component surrounded by 12 sources and 4 detectors, (b) Device #10b developed at the 
University of Connecticut, which contains an additional 4 detectors, and (c) Device #11 developed 
by the same group, which contains an ultrasound component with 12 sources and 8 detectors. 
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3.3.3  Interference Imaging-based Devices  
All of the devices containing multiple sources are sequentially illuminated during imaging 
studies.  In contrast, the interference imaging-based devices are designed and developed to 
perform simultaneous illumination of multiple sources for tumor location studies.  The 
interference imaging-based device developed at the University of Pennsylvania [53] for 
breast  
 
 
Figure 3.3  Schematics of interference imaging-based devices. (a) Device #4 developed at the 
University of Pennsylvania, which contains a detector centered between two anti-phase sources for 
phase cancellation technique, (b) Device #5 developed by researchers at the Huazhong University of 
Science and Technology, which contains a detector centered between a pair of in-phase sources and a 
pair of anti-phase which also uses the phase cancellation technique. 
 
imaging employed two 800 nm LED sources that are illuminated simultaneously, but anti-
phase (i.e. out-of-phase) with respect to each other (Device #4, Figure 3.3).  A single silicon 
diode detector was placed mid-way (and in the same plane) between two sources, in order to 
detect and locate breast tumors based on the principles of destructive interference signals (as 
described in Section 3.3).  A different breast imaging device developed at the Huazhong 
University of Science and Technology (Device #5, Figure 3.3) employed two pairs of 
simultaneous light sources, wherein one pair was in-phase (to generate constructive 
interference pattern of the PDW) and the second pair was anti-phase (to generate destructive 
interference pattern of the PDW).  The emitted optical signals were detected using a single 
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fiber located at the center of the four sources in the probe that was connected to a 
photomultiplier tube (PMT) [54].  The in-phase and anti-phase sources interfere to create a 
null plane which was used to locate a target within the turbid medium.  The target location 
was determined by the constructive or destructive interference pattern of the photon density 
waves (PDWs) in the presence of a tumor.  This is a different approach towards real time 
localization of absorbing fluorescent objects within a highly scattering medium (in turn 
applicable for breast cancer localization).  
3.4  CLINICAL APPLICATIONS OF DIFFERENT HAND-HELD DEVICES  
The selection of measurement technique and source-detector layout is influenced by the 
application to which the hand-held optical imaging device will be used.  Hand-held devices 
for NIR spectroscopy/imaging are used for several different applications related to the 
breast tissue (primarily), including measurement of normal and abnormal tissue physiological 
properties, tumor localization, and monitoring tumor changes during neoadjuvant 
chemotherapy treatment. 
3.4.1  Measurement of Normal and Abnormal Tissue Physiological Properties  
NIR spectroscopy has been used to show that the optical properties of normal breast tissue 
vary under different circumstances.  Studies were conducted at the University of California, 
Irvine using the single source-detector device to demonstrate the differences in tissue 
physiological properties in pre- and post-menopausal subjects [35,40], as well as during 
different time periods of the menstrual cycle [38].  The results showed the ability of the NIR 
device to demonstrate wavelength-dependent differences in absorption and scattering 
properties between pre- and post-menopausal normal breast tissues as well as differences in 
the same breast tissue during different time periods in the menstrual cycle.  It was also 
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shown that the tissue properties vary both amongst different normal subjects, and also with 
respect to the different locations within the same breast of a normal subject [39].   
One of the primary objectives of NIR spectroscopic imaging is to detect the 
presence of a tumor, based on the differences in the optical properties of normal versus 
diseased (tumor-bearing) tissue.  Several hand-held devices have been developed toward 
detection of tumors within breast tissue: 
�  Device #1a in Table 3.1 was used to obtain measurements from normal and tumor-
containing human breast tissue [33].  Measurements were performed on two human 
subjects using a FDPM-based device, wherein one subject had fibroadenoma with 
ductal hyperplasia and the other had a benign fluid-filled cyst.  The FDPM-based 
device was able to measure changes in absorption and scattering due to the presence 
of a small (1 cm diameter) lesion in the human breast.  The data demonstrated 
differences in the concentrations of oxy- and deoxy-hemoglobin, and water in the 
normal versus tumor-bearing breast.  A second detector was added to the above 
probe for a clinical study involving four human subjects with palpable lesions [34].  
The second detector enabled two different source-detector distances (1.3 and 2.5 
cm) to be applied with each measurement, which provided information from 
different tissue depths.  The results showed the differences in tissue optical 
properties between tumor and normal tissue, as well as between different types of 
lesions.   
�   The combined continuous wave and frequency-domain (CW/FD) based device 
(Device #1b, Table 3.1) developed at the University of California, Irvine was used to 
measure tissue properties in human subjects.  The CW/FD based device was 
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compared to a system that used only FD (Device #1a, Table 3.1) in a study involving 
a total of 31 normal and abnormal human subjects [41].  The FD component used 
only a few discrete wavelengths within the range of 650-1000 nm, whereas the CW 
component measured continuously across the entire range.  The added bandwidth of 
imaged frequencies due to the CW measurements resulted in better chromophore 
identification and improved concentration quantification than using FD component 
alone.  Another study was performed using the CW/FD based device in order to 
identify functional contrast in normal and abnormal breast tissue within a statistically 
relevant population of human subjects [45].  The spectra from tumor and normal 
tissue measured with the CW/FD based device were compared in 57 patients.  The 
results showed differences in the optical properties of the tissue based on subject 
age, tumor size, and tumor pathology.  Optical measurements obtained towards 
differentiating normal from diseased tissues were from lesions as small as 1 cm, 
whose locations were determined a priori from standard x-ray mammography.  
�   The full-heterodyne hand-held broadband breast scanning device developed at the 
University of California, Irvine (Device #2, Table 3.1) was tested on breast and 
muscle phantoms [47] and an abnormal human subject [49].  The device was used to 
extract the optical properties (absorption and scattering coefficients) from 
phantom(s) and human tissue(s).  Based on the measured differences in the 
absorption coefficients between the diseased (i.e. tumor) and normal breast tissue, 
the device detected the presence of a 6.36 ! 4.09 cm2 lesion in-vivo, located at a tissue 
depth of 0.5 cm.  The lesion size detected was relatively large compared to those 
detected by other hand-held devices, yet this device is relatively simple, compact, and 
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an inexpensive design that is capable of extracting optical properties within a tissue 
volume [49].    
�   The multi-detector hand-held device developed at the University of Pennsylvania 
(Device #3, Table 3.1) was used in an extensive study to show the differences in the 
biochemical and physiological properties of breast tissue containing growing cancers, 
compared to corresponding normal tissue in the contralateral breast [50].  The use of 
multiple detectors increases the area and volume that can be interrogated with each 
scan, apart from increasing the overall data acquisition rates.  Also, a source-detector 
separation of 4 cm has a significant probability of detecting a target at a depth of 4 
cm or more [50].  In a study involving 116 subjects recruited over six years, CW 
measurements were obtained on both the normal and tumor-bearing breast tissues of 
human subjects.  The smallest lesion detected was 0.8 cm and the greatest tissue 
depth reached was 4 cm.  The results demonstrated the ability of the device to detect 
the presence of lesions based on measured values of angiogenesis and 
hypermetabolism.  The difference in these values between the normal and the tumor 
bearing breast indicated the presence of cancer.  All the subjects involved in the 
above study were patients undergoing biopsy, and hence the lesion location was 
known a priori using a different imaging modality.  
�   The hand-held device (termed as tissue oximeter by the researchers) designed by Xu, 
et al (Device #6, Table 3.1) was used for real time imaging of tissue oxygen saturation 
and hemoglobin concentrations [55-57].  Simulation experiments and sensitivity 
analysis were performed with respect to tumor size, tumor depth, tumor lateral 
location, and optical contrast [55].  The maximum measurement depth was 1.5 cm 
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with absorption sensitivity of 0.1 cm.  The device was used in a study in conjunction 
with ultrasound to image an abnormal breast in a human subject [56].  The results 
from combining NIR spectroscopy and ultrasound modalities demonstrated 3D 
tomographic imaging (towards 3D target localization) of functional parameters of a 
breast lesion and the surrounding normal tissue.  3D reconstruction was performed 
after the added information of a second imaging modality (ultrasound).  The actual 
lesion size imaged for this study was 0.58 ! 0.41 ! 0.51 cm3.  In another study, the 
same device was used (without ultrasound) to test the effect of compression on 
human calf muscle and human breast tissue in vivo [57].  The homogeneous optical 
property in terms of absorption coefficients was determined for these tissues, using 
analytical solution of the diffusion equation in semi-infinite/infinite medium along 
with the 2D and 3D experimental images.   
�  A hand-held device (Device #7, Table 3.1) was designed to measure blood flow 
heterogeneity [58-59] in order to show that blood flow in a breast containing a 
palpable tumor is different than that in a normal breast.  The device was used to 
obtain measurements from a 2.0 cm diameter lesion located at a depth of 1.0 cm.  
The results showed that blood flow was greater in the tumor region than in the 
normal tissue. 
3.4.2  Tumor Localization and Characterization  
Several hand-held devices have been designed not only to detect the presence of a tumor, 
but also to determine the 2D location of the lesion within a breast using NIR optical 
imaging. 
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�   The ac circuit based device developed at the University of Pennsylvania (Device #4, 
Table 3.1) was used in phantom(s) and in-vivo human studies as well [53].  As 
described in Section 3.2, the device worked by phase cancellation from the two light 
sources.  The device was scanned across the breast or phantom and when the 
presence of a target was detected, a change in sound or light on the device indicated 
the 2D location of the lesion.  The device was able to detect the presence and 2D 
location of phantom targets as small as 1.0 cm3, which were located up to a depth of 
5 cm.   
�  The only hand-held device that was used for fluorescence measurements has been 
developed at the Huazhong University of Science and Technology (Device #5, Table 
3.1).   A study was performed with a phantom containing a 1.0 cm3 target with 0.8 
!M ICG, located at a depth of 0.8 cm [54].  The device uses the phase cancellation 
technique (as described in Section 3.2) with a combination of constructive and 
destructive interference patterns in order to locate the fluorescent target. 
These hand-held devices demonstrate the ability to indicate the 2D location of a target from 
surface measurements based on phase cancellation of PDWs.  They have the advantage of 
being simple and compact and give 2D target locations even prior to any tomographic 
imaging.   
 One major goal of optical imaging is to not only localize a lesion, but also to 
differentiate if the lesion is benign or malignant.  Conventional imaging techniques such as 
x-ray mammography and breast ultrasound have limited ability to differentiate benign and 
malignant lesions leading to large numbers of benign biopsies [67].  Optical imaging using a 
single wavelength can measure optical absorption, which is related to tumor vasculature.  
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When multiple wavelengths are used, oxyhemoglobin and deoxyhemoglobin can be 
measured and give information regarding tumor malignancy [69].     
Several versions of a multi-modal hand-held device (Devices #10a, #10b, #11, Table 
3.1) have been developed at the University of Connecticut [62-71] which combine NIR 
optical imaging and ultrasound into a single hand-held device.  The optical information using 
multiple wavelengths can better determine the tumor malignancy [67,69] and the ultrasound 
component provides a priori information which enables tumor localization by 3D 
reconstruction [65].  The device was used to image and differentiate benign and malignant 
lesions in human subjects.  The lesions were successfully reconstructed using the a priori 
information from the ultrasound component and it was found that malignant lesions had a 
much higher maximum total hemoglobin concentration due to increased angiogenesis 
[67,69].  
3.4.3  Monitoring Tumor Changes during Neoadjuvant Chemotherapy  
Another important application of optical hand-held devices is to monitor the progression of 
a tumor over time as chemotherapy treatment is administered.  Neoadjuvant chemotherapy 
treatment is administered to a cancer patient prior to surgery in an attempt to decrease the 
size of the tumor.  Several studies have been conducted toward this application. 
�   The CW/FD based device developed at the University of California, Irvine (Device 
#1b, Table 3.1) was used in several studies conducted in order to monitor tumor 
response to neoadjuvant chemotherapy in patients [42-43,46].  The tumor locations 
were known a priori from mammography, ultrasound, or palpation.  The device was 
used to measure the physiological characteristics of the tumor prior to 
chemotherapy.  This was followed by monitoring the changes in tissue optical 
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properties over several months, due to changes in the tumor with neoadjuvant 
chemotherapy treatment.    
�  In a different study, NIR spectroscopic imaging using the same CW/FD device was 
performed along with MRI in order to monitor the response to neoadjuvant 
chemotherapy in a human subject [43].  The initial lesion size was 3.8 ! 4.3 ! 4.3 cm3 
before treatment and 3.0 ! 2.4 ! 2.3 cm3 after treatment. The NIR spectroscopy 
measurements provided functional information in terms of absolute hemoglobin 
concentrations and tumor hemoglobin oxygen saturation, while the MRI provided 
anatomical information.   The final images were a combination of the functional 
information from NIR spectroscopy and the structural information from MRI.   
�   Researchers from the University of Connecticut used their multi-modal hand-held 
device (Device #11, Table 3.1) to image heterogeneous hemoglobin distributions in 
large cancers, which are used to monitor tumor vascular responses to neoadjuvant 
chemotherapy [70].  Tumors ranging from 2.5 to 4 cm were monitored in six 
patients.  The studies showed that after several cycles of neoadjuvant chemotherapy 
the measured values of total hemoglobin concentration and spatial extension were 
much smaller in comparison to those prior to chemotherapy. 
Most of the applications using the different hand-held devices were involved with the breast 
tissue and hence described in detail above.  In addition, there has been applications of hand-
held based NIR devices towards cerebral perfusion in stroke patients (Device #8, Figure 
3.1), and monitoring radiation therapy in patients with head and neck tumors (Devices #9a, 
9b, Figure 3.1). 
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3.5  DISCUSSION AND CONCLUSION 
Many hand-held based NIR devices have been developed for optical spectroscopy and 
imaging applications.  Apart from being non-invasive and non-ionizing, the advantages of 
hand-held optical imaging devices are that they are also portable, relatively inexpensive, and 
patient-comfortable because they do not require tissue compression.  However, optical 
measurements can be easily contaminated by motion artifacts caused by patient or operator 
as well as relative motion of the probe and soft tissue during contact imaging, similar to 1D 
ultrasound probes scanned in 2D to perform 3D imaging.  Careful operation procedure and 
operator training are required to obtain good quality images using hand-held based optical 
devices over using bulky optical systems employing compression plates or circular geometry.   
The optimal design of a hand-held device is determined by the parameter(s) to be 
measured and the specific applications it is implemented towards.  The hand-held devices 
developed to date primarily use CW and/or FDPM measurement techniques.  FDPM has 
the added advantage over CW of collecting both amplitude and phase information separately 
and thus provides improved optical contrast and greater depth information [77].  The hand-
held devices also differ in the source-detector configuration, which is primarily governed by 
the desired applications they are developed towards.  A single source and detector design has 
been used for spectroscopic measurements of physiological properties.  Dual sources 
illuminated simultaneously and out-of-phase have been used for target location by detection 
of phase cancellation.  Multiple sources and detectors have been configured towards imaging 
a given area of the tissue.       
The overall goal of any hand-held based optical device is to accelerate the clinical 
translation of the technology, with maximum patient comfort and portability (compared to 
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the many bulky optical imagers available).  However, all of the hand-held optical devices 
available to date have only flat probe heads, which limit them from contouring to tissue 
curvatures with good surface contact.  The flat probe head design also limits the devices to 
collecting only diffuse reflectance measurements, and not transilluminated measurements.  
Independent of the measurement technique (CW, FDPM, or TDPM) employed, reflectance-
based measurements provide limited depth information and depth recovery of tumors in 
comparison to transillumination-based measurements [3] (wherein the light is allowed to 
propagate through tissue depths and NIR signals are collected on opposite surfaces with 
respect to the illuminating surface).     
In addition, most of the applications of these hand-held based optical devices are 
limited to spectroscopic measurements of physiological properties and 2D target localization 
(without tomographic analysis).  To date, these hand-held optical devices (or imagers) have 
not been successful in demonstrating 3D tomographic imaging of tissue phantoms or real 
tissues using NIR imaging alone (with or without fluorescence), since the source and 
detector points are not co-registered onto the tissue contours.  In order to successfully 
reconstruct a lesion size and location in three dimensions, a priori information from another 
imaging modality (e.g. ultrasound) was required [65-70]. 
The hand-held optical imager developed in our laboratory is unique from other 
devices in that it is capable of performing 3D tomography (using NIR imaging alone) via 
implementation of self-coregistration facilities.  The features and instrumentation of the 
device are described in detail in Chapter 6.  
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CHAPTER 4                                                                                                       
Past Work:  Fluorescence Tomography Experimental Studies 
4.1  INTRODUCTION 
Fluorescence-enhanced diffuse optical tomography (FDOT) has been explored by many 
research groups in the past three decades.[3,81-133]  This chapter gives a review of the 
recent literature from 2008 to the present.  A literature review of image reconstruction using 
experimental data from fluorescence tomography (FT) studies up to the year 2007 is 
provided in Appendix B.  Table 4.1 provides a summary of the experimental research 
performed in fluorescence tomography from 2008 to the present.  The work performed by 
different research groups is summarized here in terms of (i) efforts to improve the 
reconstruction algorithm for fluorescence tomography, (ii) efforts to develop and/or 
improve instrumentation for fluorescence tomography, and (iii) efforts to improve 
experimental methods of fluorescence tomography.  
4.2  RECONSTRUCTION ALGORITHM FOR FLUORESCENCE 
TOMOGRAPHY 
Reconstruction of fluorescent optical data is mathematically challenging due to the ill-
posed18 nature of the inversion problem.  Several research groups are currently working to 
improve the computational aspect of fluorescence tomography.   
 
 
 
 
                                                
18 Having more than one solution. 
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Table 4.1   Summary of the experimental research performed in fluorescence tomography 
from 2008 to the present 
 
 Phantom / Animal Measure
ment 
Method 
Instrumentation 2D 
or 
3D 
  
Reference Backgroun
d 
Target Contrast Source Detector Forward 
Method 
Inverse 
Method 
Agent Ratio (geometry) (geometry) 
(Davis, et 
al, 2008) 
[121] 
DPBS, 1% 
intralipid, 
ICG, & 
India ink 
Plastic 
cylinder 
R=1 cm   
ICG 3.3:1 CW (w/ 
MRI) 
690 nm laser 
diode (point) 
CCD (point) 3D Diff. 
Approx. 
Laplacian 
& 
Jacobian 
(Kepshire, 
et al, 2008) 
[115] 
Water, 2% 
India ink, 
5% Tween-
20, 1% 
intralipid 
Cylinder 
R=4 mm 
Pp-IX 3.5:1 - 
10:1 
CW 635 nm laser 
diode (area) 
CCD (area) 2D  Diff. 
Approx. 
FluoroFAS
T 
(software 
package) 
(Ge, et al, 
2008) 
[3] 
1% Liposyn 
(10x10x6.5 
cm) 
Plastic 
sphere 
R=0.475 
cm 
ICG 1:0 FDPM 785 nm laser 
diode (point) 
ICCD 
(point) 
3D FEM AEKF 
(Mohajerani
, et al, 
2009) 
[122] 
Nu/Nu mice   4T-1 
murine 
breast 
adenocarci
noma cells 
ProSen
se 
in-vivo CW -- -- 3D Diff. 
Approx. 
MSE & 
coincidenc
e mask 
(Davis, et 
al, 2009) 
[123] 
Liquid 
(water, 1% 
intralipid)          
Solid 
(gelatin, 
TiO2, blood) 
2 small 
heterogenei
ties 
LuTex 2.5:1, 
3:1 
CW 690 nm laser 
diode (point) 
CCD (point) 2D FEM diffusion-
based 
optimizatio
n 
(Ziegler, et 
al, 2009) 
[124] 
rectangular 
cuvette 
(25x25x6 
cm3) 
delrin twin 
cones 
Omocy
anine 
5:1 TDPM Ti:sapphire 
laser (point) 
GaAs-PMT 
(point) 
3D Diff. 
Approx. 
Rytov 
approx. 
(Deliolanis, 
et al, 2009) 
[125] 
Nude mice Lewis lung 
carcinoma 
cells 
mCherr
y 
fluores
cent 
protein 
in-vivo CW 593 nm, 750 
nm laser 
diode (area) 
CCD (area) 3D none ART 
(Kepshire, 
et al, 2009) 
[126] 
Phantom 
from ART, 
Inc. 
Sphere 
R=4 mm 
Pp-IX 1:0 CW 
(noncont
act) 
635 nm laser 
diode (point) 
4 PMTs 
(point) 
2D none NIRFAST 
(Ge, et al, 
2009) 
[127] 
1% Liposyn 
(10x10x6.5 
cm) 
R=0.29-
0.475 cm 
ICG 5:1 - 
1:0 
FDPM 785 nm laser 
diode (point) 
ICCD 
(point) 
3D FEM AEKF 
(Lin, et al, 
2010) 
[128] 
Agarose 
powder, 
India ink, 
intralipid 
(25 mm 
diameter) 
Glass tube 
R=1.2 mm 
ICG 1:1-
25:1 
CW (w/ 
DOT & 
XCT) 
785 nm, 830 
nm laser 
(point) 
CCD (area) 2D Coupled 
Diff. Eq. 
Laplacian  
(Hyde, et al, 
2010) 
[129] 
Transgenic 
mice 
Amyloid-
beta 
plaques 
Oxazin
e 
derivati
ve 
probe 
in-vivo CW 650 nm laser 
diode (area) 
CCD (area) 3D Diff. 
Approx. 
Tikhonov 
w/ 
structural 
priors 
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(Schultz, et 
al, 2010) 
[130] 
Euthenized 
nude mice 
Artificial 
brain lesion 
Alexa 
750 
fluoroc
hrome 
in-vivo CW (w/ 
XCT) 
670 nm, 750 
nm laser 
diodes 
(point) 
CCD (area) 3D Diff. 
Approx. 
Tikhonov, 
Laplace 
prior, 
diagonal 
weighting 
prior 
(Liu, et al, 
2010) 
[131] 
Cylinder 
phantom 
R=1.5 cm 
(1% 
intralipid) 
2 glass 
tubes 
R=0.15 & 
0.3 cm 
ICG 1:0 CW Halogen 
lamp (area) 
CCD (area) 3D Coupled 
Diff. Eq. 
ART 
(Baritaux, et 
al, 2010) 
[132] 
Cylinder 
R=12.5 mm 
(India ink, 
titanium 
oxide) 
Cylinder 
R=2 mm 
Alexa 
Fluor 
680 
1:0 CW 655 nm laser 
diode (area) 
CCD (area) 2D Diff. 
Approx. 
Lp 
regularizat
ion 
(Biswal, et 
al, 2010) 
[133] 
Intralipid 
solution & 
SCID/Ncr 
mice 
Glass tube 
R=0.5 cm; 
MDA231luc 
cells 
Cy7 5:1 - 
50:1 
FDPM 690 nm laser 
diode (point) 
PMT (point) 3D none Born 
approxima
tion 
 
A research group from the University of Berlin used an algebraic reconstruction 
technique (ART) method to analyze DOT data and incorporated a noise-weighted back 
projection method.[124]  This method has the advantages of:  (i) allowing high cutoff 
frequencies to be chosen due to the algorithm’s avoidance of significant distortions of the 
reconstructed image, and (ii) the ART algorithm uses a normalized image vector which 
improves the separation of absorption and scattering by rescaling to a dimensionless image 
vector with comparable size of the norm of both images. The algorithm was tested with 
experimental data from a breast phantom using measured time-domain diffuse reflectance 
and transmittance of excitation and fluorescence radiation.  Images were collected with a 
fluorescent target embedded in the phantom with compressed-tissue geometry using three 
different source-detector geometries: (i) projection-shadow geometry; (ii) slab fan-beam 
geometry; (iii) slab reflection and transmission geometry.  The results showed that collecting 
reflectance data at the excitation and fluorescent wavelength in addition to the transmitted 
data greatly improved the depth resolution.  They concluded that scanning time-domain 
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fluorescence mammography will be improved by the use of both reflectance and 
transmittance measurements from both sides of the compressed breast. 
 A group from Georgia Institute of Technology developed a reconstruction approach 
that uses a mean-square error algorithm and accounts for what they term as “tunneled light”, 
i.e. the portion of light that passes through parts of the tissue which have lower absorption 
and hence has higher intensity than the portion of light that passes through the other parts 
of the tissue.[122]  The reconstruction approach uses the strong spatial correlation between 
the excitation and emission images to estimate the tunneled components and gain a resulting 
image containing mostly signal due to the fluorescence.  The resulting image is further 
refined using a coincidence mask (i.e. a map of the ‘hot spots’ that occur in both emission 
and excitation images).  The algorithm was tested on experimental data from in vivo studies 
performed on a human colon adenocarcinoma xenograft tumor model.  The results showed 
much stronger fluorescent signal from deeper tissues using this method.  They concluded 
that identification, estimation, and correction of signal from tunneled light can improve 
image reconstruction in fluorescence tomography.   
 The research group from Harvard Medical School presented a Tikhonov based 
method for reconstruction of multimodal FMT-XCT or FMT-MRI images which uses 
information from within the data to get data-driven priors rather than the typical user-
defined priors.[129]  The first step compensates for the resolution differences between XCT 
(high resolution) and FMT (low resolution) by labeling each FMT voxel as a linear mixture 
of the different tissue types identified in the high-resolution image.  The segment labels were 
used to construct a low dimensional inverse problem that gives a single intensity value for 
each anatomic area, and the values were used as parameters to define a spatially varying 
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regularization term for the full resolution FMT problem.  The algorithm was tested on 
experimental data collected from APP23 transgenic mice exhibiting amyloid-� plaques in 
the cortical region.  The results showed that the method of using data driven priors 
generated improved reconstruction of the fluorescence in the cortical region. 
 A research group from Tsinghua University developed a method that uses principal 
component analysis (PCA) on a time-series of FDOT images in order to detect and visualize 
organs with different kinetics.[131]  PCA is a method used to extract relevant features of a 
correlation matrix based on principal components, which express different kinetic behavior 
with high inter-correlations.  PCA was performed on 6 frames from tomographic images 
(with zero mean) from dynamic FDOT images at the same slice.  The principal component 
elements were used as weight factors to generate images containing different colors to 
represent regions with different kinetic behavior.  The method was tested on simulated 
mouse data and experimental data from phantom studies.  The results using the PCA 
method showed images that illustrated organs and functional structures that had different 
kinetic patterns.  They concluded that the PCA method (i) provides a non-invasive method 
for measuring changes in organ function, (ii) enhances the resolution and specificity of 
FDOT through emphasis of differences in kinetic behavior, (iii) provides additional 
anatomical information without the use of multiple modalities, and (iv) is not subject to 
model-based restrictions since it is independent of any kinetic model. 
 A research group from the Swiss Federal Institute of Technology developed a 
reconstruction approach that uses what they term as Lp regularization (p ! 1) to reconstruct 
fluorescence data using a matrix-free strategy in order to reduce computational costs.[132]  
They tested the sparsifying effect of using L1 regularization and compared it to L2 
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regularization (Tikhonov method).  2D reconstructions were performed using experimental 
phantom data.  The results showed that the method improved the computation time and 
memory requirements since it does not require calculation of a system matrix, and the 
reconstructions obtained using the L1-regularization displayed fewer artifacts and improved 
localization than those using a linear algorithm.   
 A research group from the University of Connecticut developed a Born 
approximation based reconstruction approach  which separately estimates the structural 
parameters of a target such as target center (depth and spatial x and y locations) and size, as 
well as reconstructs the functional information using only optical based measurements.[133]  
The method was tested on data from phantoms and mice injected with VEGF/Cy7 (an 
angiogenesis tracer).  The results showed the ability to reconstruct fluorescent targets with 
less than 25 nM of contrast agent up to 2 cm deep in both homogeneous and heterogeneous 
backgrounds. 
4.3  INSTRUMENTATION FOR FLUORESCENCE TOMOGRAPHY 
One major challenge of fluorescence tomography from an instrument perspective is poor 
spatial resolution due to the highly scattering nature of biological tissue.  Several research 
groups are currently developing instrumentation designed to improve the imaging ability of 
fluorescence tomography by combining the method with spatial prior information from 
other methods such as x-ray CT.   
The research group from Dartmouth College developed a multi-channel spectrally 
resolved fluorescence optical tomography system within a clinical MRI for imaging of 
molecular targets in small animals.[121]  The fiber-optic based NIR system was composed of 
16 fiber bundles which each contain six detection fibers and one source fiber used to obtain 
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transmission and emission NIR spectra.  The emission light was spectrally fitted to separate 
the fluorescent signal from the background improving the accuracy and sensitivity of images 
with small concentration of fluorophores.  The tissue morphology acquired from MRI was 
used as an imaging guide for the optical reconstruction.  Results from phantom and small 
animal studies demonstrated the capability to image low fluorescent contrast (3.3:1) in 70 
mm diameter tissue volumes using the spatial prior information from the MR images.   
  Another group from Dartmouth College designed a small animal imaging system 
which couples fluorescence tomography (FT) and x-ray microcomputed tomography 
(microCT).[126]  The information from microCT was used as spatial prior information and 
overlays the FT image on the microCT image.  The FT system uses a rotating gantry with a 
single source and and a fan-beam of detectors which rotate around the surface of the object 
for non-contact excitation and detection.  Results from phantom studies demonstrated the 
ability of the system: (i) to allow maximum sensitivity in optical tomography with single 
photon counting, (ii) use a noncontact imaging configuration to accompany microCT, (iii) 
obtain fluorescence and transmission data in parallel, (iv) require only several minutes total 
for imaging time, and (v) perform imaging with multiple detectors in parallel.   
 A research group from the University of California, Irvine developed a unique, fully 
integrated tri-modality gantry-based system that combines FT, DOT, and x-ray CT (XCT).  
XCT was used to provide anatomical prior information and DOT was used to provide 
functional prior information of the heterogeneous optical background for the FT 
reconstructed images.[128]  The optical system used point source (3 optical fibers) and area 
detection configuration for transmission based imaging.  Results using the DOT prior 
information only demonstrated accurate localization of a fluorescent target within a 
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heterogeneous phantom background; however, the concentration of the fluorophore was 
recovered with 70% error.  Results using both the DOT and XCT prior information 
recovered the fluorophore with only 8% error. 
 A research group from the Technical University Munich designed a hybrid small 
animal imaging system which combines fluorescence tomography and x-ray computed 
tomography.[130]  The 360º-projection free-space FT system uses point source (two optical 
fibers) and area detection configuration for transmission based imaging.  Structural priors 
from the XCT images were incorporated into the optical reconstruction to allow improved 
imaging performance.  Results demonstrated the ability of the system to reconstruct an 
artificial brain lesion within a euthanized nude mouse.   
 Most of the instrumentation for fluorescence tomography studies has been focused 
toward small animal imaging (especially multimodality imaging).  In our Optical Imaging 
Laboratory we have developed a hand-held probe based optical imaging system and 
demonstrated 3D fluorescence tomography in clinically relevant sized tissue phantoms.[3]   
Extensive phantom studies demonstrated the ability of the device to reconstruct a 
fluorescent target (0.45 cm3) up to a depth of 2.5 cm under perfect uptake conditions.[127]  
A 1.0 cm deep fluorescent target was recovered under a target to background contrast as low 
as 25:1.  The sensitivity and specificity of the device was estimated at 43% and 95%, 
respectively, based on phantom studies.  In vivo fluorescence tomography performed in 
human subjects using the hand-held optical imager is demonstrated in Chapter 13 below.   
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4.4  EXPERIMENTAL METHODS OF FLUORESCENCE TOMOGRAPHY 
 
Fluorescence tomography imaging methods face several challenges such as strong excitation 
light leakage which masks the weak fluorescent signal, limited depth recovery when using 
reflectance-based measurements, and limited spatial resolution.  Several research groups have 
performed studies designed to improve the results obtained from fluorescence tomography 
by optimizing the experimental imaging methods.   
A research group from Dartmouth College performed a study to optimize 
fluorescence tomography for sub-surface imaging of protoporphirin IX.[115]   Phantom 
experiments were performed using a noncontact based imaging system to compare 
fluorescence remittance imaging (FRI) and sub-surface fluorescence diffuse optical 
tomography (FDOT) with the contrast agent protoporphirin IX.  They found that 
tomographic imaging was able to produce a better contrast ratio, while simple planar 
fluorescence imaging produced better signal to noise ratio.  They concluded that an optimal 
system for localizing embedded fluorescent regions should combine fluorescence reflectance 
imaging and sub-surface tomography in order to increase sensitivity and improve depth 
detection. 
 The same group performed another study to investigate the influence of tissue 
optical properties on the shape of near-infrared (NIR) fluorescence emission spectra 
propagating through centimeters of tissue-mimicking material.[123]  Experimental studies 
were performed using liquid and gelatin-based phantoms and Lutetium Texaphyrin (LuTex) 
contrast agent.  The NIRFAST model platform was used to calculate spectrally resolved 
emission spectra at discrete wavelengths and compared to experimentally measured spectra.  
The phantom results showed spectral distortion resulting in emission peak shifts of up to 60 
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nm in wavelength which is analogous to beam hardening and softening in x-ray tomography 
which causes image artifacts.  They concluded that spectrally resolved detection strategies 
should be implemented in order to account for these effects and reduce error. 
 A group from Harvard University tested the ability of a small animal imaging system 
to perform complete-angle projection (360º) fluorescence tomography  in vivo in mouse lung 
and brain tumors.[125]  In both tumor models, the fluorescence was positively identified 
close to the tumor location with noncontact FT in all imaging experiments.  They also 
applied fluorescence dataset normalization in order to correct for dynamic range variation in 
the resulting illumination through the tissue and inhomogeneity.   
4.5  CONCLUSION 
Fluorescence tomography is a promising technique for noninvasive functional imaging.  
However, there are several challenges that are currently being addressed by researchers.  The 
challenges include strong excitation light leakage which masks the weak fluorescent signal, 
poor spatial resolution due to high scattering of the light in biological tissues, and 
mathematical complexity of image reconstruction due to the ill-posed nature of the inversion 
problem.  This chapter reviewed the current (2008-present) efforts of different research 
groups to improve the experimental methods, reconstruction algorithm, and instrumentation 
used in performing fluorescence tomography. 
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CHAPTER 5                                                                                                         
Past Work:  Clinical Diffuse Optical Imaging in Human Subjects 
 
Testing of diffuse optical imaging technology in human tissues is integral for translation of 
the technology into the clinical setting.  In the past decade, several research groups have 
evaluated the performance of diffuse optical imaging in human breast tissue using different 
methods and instrumentation.[134-152]  A systematic review of diffuse optical imaging of 
the healthy and diseased breast was performed by Leff, et al in 2008.[134]    This chapter 
summarizes the major findings by Leff et al and then describes significant clinical studies 
performed in 2008-2010.   
 Leff et al systematically reviewed clinical studies involving close to 2,000 females 
who underwent diffuse optical imaging of healthy and diseased breast tissue.  The review 
focused on summarizing the studies to determine the ability of diffuse optical imaging to (i) 
provide information on the tissue composition of healthy breast tissue, (ii) detect breast 
lesions/abnormalities, and (iii) differentiate benign from malignant disease. 
 Several articles reported the use of diffuse optical methods for measuring the optical 
properties of healthy breast tissue, namely the absorption coefficient (!a) and reduced 
scattering coefficient19 (!s’).  A summary of the experimentally determined absorption and 
scattering properties at near-infrared wavelengths is given in Table 5.1.  The global averages 
(highlighted in pink in Table 5.1) determined the absorption coefficient (!a) to be 0.04 ± 0.02 
cm-1 at wavelengths between 600 and 800 nm and 0.05 ± 0.03 cm-1 at wavelengths between 
800 and 900 nm.  The global average reduced scattering coefficient (!s’) was determined to 
be 10 ± 5 cm-1 at wavelengths between 600 and 700 nm and 8 ± 4 cm-1 at wavelengths 
                                                
19 The effective scattering coefficient which accounts for the anisotropy factor (cosine of the angle of scattering). 
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between 700 and 900 nm.  The remarkable consistency in absorption and scattering 
properties between studies using various methods and instrumentation supports the ability 
of diffuse optical methods in providing information on the composition of healthy breast 
tissue. 
Table 5.1:  Summary of optical properties of healthy breast tissue from the 
literature.  Adapted from Leff, 2008 [134] 
 
Several research studies were reported which involved optical imaging of breast 
tissue containing a lesion or abnormality (either benign or malignant).  In a total of 212 
cases, 179 lesions were detectable by different diffuse optical methods.  This data suggests a 
lesion detection rate of 85% for optical mammography based approaches.  In order to detect 
the presence of abnormal tissue by diffuse optical methods, there must be a detectable
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difference in the tissue optical properties of healthy and abnormal tissue.  Several studies 
focused on comparing total hemoglobin concentration (HbT) and oxygen saturation (SO2) in 
healthy and abnormal tissue.  The results showed that healthy breast tissue had an average 
HbT of 21 ± 6 !M/l and average SO2 of 68 ± 5%.  The average HbT and SO2 of 
fibroadenoma was 54 ± 13 !M/l and 69 ± 3% respectively.  The average HbT and SO2 of 
malignant disease was 65 ± 34 !M/l and 66 ± 24% respectively.  The findings show that 
there is significant difference in the HbT of healthy and abnormal breast tissue, while there 
is no obvious difference in SO2 between healthy and abnormal breast tissue.  The review 
pointed out that only one study reported on the sensitivity and specificity for detecting 
malignancy using spectroscopic information.  Chance et al used a multiwavelength hand-held 
device to acquire data over six years from 166 patients with 44 confirmed malignancies.  
They reported the ability to distinguish cancerous from noncancerous breast tissue with a 
sensitivity of 96% and specificity of 93%.  Overall, the results reported from different 
research groups demonstrate potential of using diffuse optical methods to differentiate 
healthy and abnormal breast tissue. 
 Several research groups reported studies to distinguish benign and malignant breast 
lesions based on diffuse optical measurements of blood volume, saturation, or both.  Several 
of the studies showed that the maximum and average HbT were significantly higher in 
malignant lesions than benign lesions.  However, the results were from a relatively small pool 
of data and more extensive trials will be required to demonstrate conclusive results. 
 Overall, the reports summarized by Leff et al suggest that diffuse optical studies of 
healthy breast tissue show the breast to be nonuniform, and the composition of healthy 
breast tissue is modified due to physiological changes during the life of the female.  Diffuse 
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optical methods seem capable of distinguishing lesions from healthy tissue and demonstrated 
detection of 85% of lesions in breast tissue.  Results suggest that diffuse optical methods 
have potential to distinguish benign and malignant lesions, but further studies and 
improvements in the technology are needed.   
 A summary of reported studies in clinical imaging of breast tissue using diffuse 
optical methods between the years 2008 and 2010 is given in Table 5.2.   
Table 5.2:  Summary of clinical diffuse optical imaging studies between 2008 and 2010. 
   Measurement 
Geometry 
  Measurem
ent 
Technique 
Measurem
ent 
Parameter 
   
Refere
nce 
Instrum
entation 
Met
hod 
Point/Ar
ea 
Reflect/     
Trans 
Source Dete
ctor 
Subject Sens
. 
Spec
. 
                        
You, 
et. al., 
2010 
[146] 
Hand-
held 
imager 
(NIR & 
US) 
DO
T & 
US 
Point -- 
Subsurf
ace 
Reflection   Laser 
diode (785, 
830 nm) 
APD FDPM THC 198 
patients 
(benign & 
malignant) 
83.9
% 
66.7
% 
Solim
an, et. 
al., 
2010 
[147] 
Optical 
bed w/ 
parallel 
plates & 
matchin
g fluid 
DO
S 
Point -- 
Compre
ssed 
Transillumi
nation 
Laser 
diodes 
(690, 730, 
780, 830 
nm) 
PMT TDPM HbO2, Hb, 
%water, 
SP 
10 breast 
cancer 
patients  
-- -- 
Choe, 
et. al., 
2010 
[148] 
Optical 
bed w/ 
parallel 
plates & 
matchin
g fluid 
DO
T 
Point -- 
Compre
ssed 
Transillumi
nation 
Laser 
diodes 
(650, 690, 
750, 786, 
830, 905 
nm) 
CCD 
came
ra 
FDPM & 
CW 
HbO2, Hb, 
THC, SC 
47 patients 
(benign & 
malignant) 
98% 90% 
Jiang, 
et. al., 
2009 
[149] 
Optical 
bed w/ 
ring 
DO
S 
Point -- 
Circular 
Reflection 
& 
transillumin
ation 
Laser 
diodes 
(660-850 
nm) 
-- FDPM   HbT, SO2, 
%water, 
SP 
16 cancer 
patients 
-- -- 
Kukret
i, et. 
al., 
2010 
[150] 
Hand-
held 
imager  
DO
S 
Point -- 
Subsurf
ace 
Reflection   Laser 
diodes 
(660, 690, 
780, 808, 
830 nm)  & 
tungsten-
halogen 
lamp 
APD FDPM & 
CW 
specific 
tumor 
component
s (STC) 
60 subjects 
w/ 22 
malignant, 
18 benign, 
21 control  
91% 94% 
Stahel
, et. 
al., 
2009 
[151] 
Hand-
held 
imager  
DO
S 
Point -- 
Subsurf
ace 
Reflection   Laser 
diodes 
(690, 730, 
750, 808, 
870, 920, 
970 nm) 
APD FDPM HbO2, Hb, 
%water, 
SP 
20 healthy 
subjects 
-- -- 
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van de 
Ven, 
et. al., 
2009 
[152] 
Optical 
bed 
FD
OT 
Point -- 
Circular 
Transillumi
nation  
lasers 
(690, 730, 
780, 830 
nm) 
 CW Omocyanin
e (external 
contrast 
agent) 
12 cancer 
patients 
-- -- 
  
 Stahel et al performed a study to compare the optical properties of breast tissue 
between females who use oral contraceptives to regulate their menstrual cycles and those 
who had spontaneous menstrual cycles.[151] The study was performed using a 
multiwavelength frequency-domain hand-held optical imager containing a single source and 
detector fiber pair.  The results of blood volume and oxygenation measurements showed 
that the breast perfusion, water content, and scattering power in females using oral 
contraceptives was nearly constant during the menstrual cycle and tended to vary in females 
with spontaneous menstrual cycles, while oxygen saturation tended to remain stable in both 
groups.  This study further confirms the ability of diffuse optical methods to be used to gain 
information about healthy breast tissue. 
 Three groups reported studies using diffuse optical methods to distinguish benign 
and malignant breast lesions.  Choe et al used an optical bed with parallel-plate imaging 
geometry to measure oxy-, deoxy-, and total hemoglobin concentration, along with blood 
oxygen saturation and tissue scattering in 47 subjects with 51 lesions.[148]  95% of the 
malignant lesions were invasive ductal carcinoma; of the non-malignant lesions, 40% were 
fibroadenoma, 30% were cysts, 30% were lobular carcinoma in situ, and 10% were fibrocystic 
disease.  The results showed higher total hemoglobin concentration (THC) and scattering in 
malignant lesions than in the surrounding tissue.  Cysts showed lower scattering than the 
background.  Fibroadenomas showed weak contrast in THC and scattering.  The tumor-to-
normal ratios of all parameters were close to unity in the benign lesions, whereas they were 
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significantly different from unity in the malignant cases.  Kukreti et al used data collected 
with a combined FD-CW hand-held optical imager with dual source and detector pairs.[150]  
They used data from 22 malignant and 18 benign lesions to retrospectively determine if 
benign and malignant lesions could be distinguished using near-infrared spectroscopy.  
Results showed a sensitivity of 91% and specificity of 94%.  You et al used a combined near-
infrared and ultrasound based hand-held imager to measure THC in 198 females with 214 
lesions (96 benign and 118 malignant).[146]  The average THC in benign lesions was 125.5 ± 
83.4 !M/l while in malignant lesions it increased to 222.2 ± 87.2 !M/l.  Using a cutoff of 
140 !M/l they were able to detect malignant lesions with a sensitivity of 83% and specificity 
of 66.7%.  The results from these three studies show continued promise of the ability of 
diffuse optical methods to distinguish benign and malignant lesions which has potential to 
reduce the number of surgical biopsies in women with breast lesions. 
 An additional aspect where diffuse optical methods have been applied for breast 
imaging is to monitor the response to neoadjuvant chemotherapy.  Jiang et al performed a 
study to evaluate two methods used to summarize diffuse optical data by region of interest 
analysis to compare complete and incomplete response to neoadjuvant chemotherapy in 
patients with locally advanced breast cancer.[149]  In seven cases of subject data, diffuse 
optical spectroscopy (DOS) measurements of total hemoglobin concentration, blood oxygen 
saturation, water fraction, optical scattering amplitude, and scattering power were analyzed 
using both fixed- and variable-size region of interest (ROI).  Results showed that only the 
measurements of total hemoglobin demonstrated significant difference in the complete and 
incomplete response outcomes.  Soliman et al used diffuse optical methods to measure tissue 
concentration of deoxyhemoglobin (Hb), oxyhemoglobin (HBO2), percent water (%water), 
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and scattering power (SP) in ten patients undergoing neoadjuvant chemotherapy for locally 
advanced breast cancer.[147]  The results showed significant difference in all four parameters 
between responders and nonresponders to the the therapy.  The studies performed by these 
two groups demonstrate the potential role of diffuse optical imaging in monitoring response 
to neoadjuvant chemotherapy in breast cancer patients. 
 External contrast agents can be used in order to improve the detection and 
characterization of breast lesions by diffuse optical methods, especially for smaller-size 
tumors.  Van de Ven et al performed a study to evaluate a novel fluorescent imaging agent, 
Omocianine, in 11 women suspected of breast cancer.[152]  Four different dosage levels 
were used, the smallest and medium doses were each used in three cases and the two highest 
doses were used in five cases.  The results showed the ability to detect two out of three 
tumors using the lowest dose and three out of three tumors using the medium dose.  None 
of the five tumors were detected using the two highest doses.  These results demonstrate the 
potential of using Omocianine as a fluorescent contrast agent to detect lesions using low 
doses of the agent. 
 Diffuse optical imaging of breast tissues has been explored by several research 
groups in the clinical setting using various methods and instrumentation.  Studies show the 
potential of diffuse optical methods to gain information in healthy breast tissue, distinguish 
abnormal tissue from healthy background tissue, distinguish benign and malignant tumors, 
and monitor response to neoadjuvant chemotherapy.  Additionally, use of external contrast 
agents can improve imaging ability of diffuse optical methods by increasing the contrast.   
 Clinical trial in human subjects is an essential and defining stage in the development 
of new imaging technology.  Hand-held optical imagers provide a promising avenue toward 
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rapid translation of the optical imaging technology to the clinical setting.  The overall 
objective of the dissertation is toward the clinical translation of our hand-held optical imager, 
which is unique in its ability to perform 3D tomography.  Various studies were performed in 
tissue phantoms, in vitro, and in vivo toward this objective.  The next chapter describes the 
instrumentation and data analysis procedures for the studies performed toward clinical 
translation of the hand-held optical imager developed in our Optical Imaging Laboratory. 
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CHAPTER 6                                                                                    
Instrumentation and Data Analysis 
6.1  INTRODUCTION 
A hand-held optical imaging device has been designed and developed in our Optical Imaging 
Laboratory with the following unique features: (i) flexibility to image different tissue 
curvatures (0o - 45o) via a geometrically adaptive probe head; (ii) ability to simultaneously 
illuminate (at 6 point locations) and collect NIR signals (at 165 point locations) towards 
rapid data acquisition; (iii) portability and comfort from the hand-held design with maximal 
patient comfort [3]; and (iv) coregistration facilities to enable 3D tomographic imaging in 
complex tissue geometries [153].   
 Previously, experiments were performed to demonstrate 3D fluorescence 
tomography using the hand-held based optical device in slab tissue phantoms [3].  In order 
to perform 3D tomography, the image collected with the hand-held device must be 
coregistered to the geometry of the phantom being imaged.  For the past studies, the images 
collected using the probe were manually coregistered to the simple slab phantom geometry 
at the known location on the phantom surface.  In the current research, automated 
coregistration capabilities are implemented to facilitate translation of the device towards 
clinical studies in order to perform 3D tomography in curved (in vivo) tissue geometries.  
Experimental studies are performed using the hand-held based optical imaging system on 
tissue phantoms, in vitro, and in vivo with human subjects.  This chapter describes the 
instrumentation used to collect continuous-wave and frequency-domain based 
measurements (Section 6.2), the principle of continuous-wave and frequency-domain based 
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optical imaging (Section 6.3), the experimental protocol for data acquisition in phantom and 
in vitro studies (Section 6.4), and the automated coregistered imaging process (Section 6.5). 
6.2  OPTICAL IMAGING SYSTEM 
The three major components of the imaging system are the hand-held probe, the laser diode 
source, and the intensified charge-coupled device (ICCD) detector.  The instrumentation is 
developed such that it can acquire both continuous wave (CW) based and frequency-domain 
photon migration (FDPM) based optical measurements as required.   
 The hand-held probe head is designed with unique features in that it is flexible to 
contour to different tissue curvatures, it has a large imaging area (4 x 9 cm2) for large volume 
interrogation, and it uses simultaneous illumination and detection for rapid data acquisition.  
The hand-held probe head is shown in Figure 6.1.  The six red dots show the location of six 
source fibers and the black dots are the 165 detector fibers.  The probe is divided into three 
sections and each of the side sections is capable of curving up to 45°.   
 
 
Figure 6.1  The actual hand-held probe face showing the source-detector configuration.  The large 
red dots represent the six source fiber locations and all other small holes are the 165 detector fiber 
locations. 
 
 At the source end, a single 785-nm laser diode source (530 mW, HPD1005-9MM, 
Intense Ltd., North Brunswick, NJ) is split into six illuminating fibers using a custom-built 
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collimator-diffuser package.  The laser source is coupled to the handheld probe as shown in 
Figure 6.2.  For FDPM measurements, the source end is modulated using a frequency 
synthesizer (HP 8656B, Hayward, CA) and RF amplifier (ENI500L, ENI Inc., Rochester, 
NY) as shown in Figure 6.3.   
 
Figure 6.2  Hand-held probe based optical imaging system showing the hand-held probe is fiber-
optically coupled to the laser source and ICCD camera (left).  The probe face is flexible to contour to 
different tissue curvatures (right).   
 
 At the detector end, a gain modulated image intensifier (FS9910, ITT Night Vision, 
VA) is optically coupled to the CCD camera (PI-SCX 7495-0002, Roper Scientific, Trenton, 
NJ).  For FDPM measurements, the image intensifier is modulated using a frequency 
synthesizer (PTS 310, Programmed Test Sources Inc., Littleton, MA) and RF amplifier 
(ENI503L, ENI Inc., Rochester, NY) as shown in Figure 6.3.  The two frequency 
synthesizers at the source and detector end are phase locked and operated at the same 
frequency (100 MHz).  The output intensity from the ICCD camera is sensitive to the phase 
delay and upon introducing a phase shift from 0 to 2�, phase-sensitive images are collected 
from which measurements can be extracted in terms of amplitude (AC) and phase (�) of the 
modulated signal.  
65
 
Figure 6.3 Schematic of the instrumentation for the hand-held optical imager.  The CW based 
imaging system is shown in white and the additional components for FDPM based imaging are 
highlighted in blue. 
The CCD camera acquires steady-state phase sensitive images at 32 phase delays 
between 0 and 2�.  The exposure time for the CCD camera is 0.2 seconds (s) for a single 
image (in all experiments) and each collected image represents the average signal from 5 
repetitions.  The exposure time was kept small enough to allow rapid image acquisition and 
using more than 5 repetitions was previously determined not to improve the result.[154]  
The image is acquired in 1024 " 1024 pixels and is hardware binned to 128 " 128 pixels for 
improved signal to noise ratio and faster imaging time.  The raw image is post-processed in 
MATLAB software developed in house to get the DC values (for CW imaging) at each 
detector location on the probe and displayed as a 2D contour plot.  For FDPM imaging, the 
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amplitude (AC) and phase (�) information is extracted using fast Fourier transforms (FFT), 
and the final image is presented as a 2D surface contour plot of the AC or phase values at 
each of the 165 detector points of the probe. 
 When operated in continuous wave mode (Figure 6.3, white portion), the laser light 
is emitted at a constant intensity and travels to the tissue via optical fibers connected at the 
probe face.  The light passes from the probe into the phantom or tissue and becomes 
attenuated due to the effect of the absorption and scattering properties of the medium.  The 
reflected light is collected at the tissue surface by the optical fibers in the probe and carried 
to the detector.  Different types of filters are used depending on the type of study.  For 
absorption based studies a neutral density filter is used to uniformly attenuate the collected 
signal.  For fluorescence based studies two band pass interference filters of blocking OD 4 
and 6 (HRF-830.0, blocking OD 6 and F-830.0, blocking OD 4, CVILaser, Albuquerque, 
NM) are used to select the weak 830nm fluorescent signal and reject the 785 nm excitation 
signal.  The filtered signal reaches the image intensifier at the photocathode and is converted 
into electrons.  The electrical signal is amplified at the micro-channel plate (MCP) according 
to the manual gain setting on the power supply of the image intensifier.  The amplified signal 
then encounters the phosphor screen where it is converted back to a light signal and imaged 
onto the CCD camera.  The raw image is a 1024 " 1024 distribution of intensity signal from 
each of the 165 detector fibers in the bundle.  The 1024 " 1024 image is hardware-binned to 
128 " 128 to reduce noise and processing time.  Post-processing MATLAB software 
developed in house is then used to back calculate the location of each detection point on the 
hand-held probe face and interpolated to generate a 2D surface contour plot.  Frequency-
domain based optical imaging involves the use of a modulated laser signal.  In our hand-held 
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based optical imaging system, the incident light is continuously produced and the intensity is 
sinusoidally modulated via a frequency synthesizer at 100 MHz.  As the intensity-modulated 
light passes from the hand-held probe into the tissue, the intensity of the signal becomes 
attenuated and the phase of the modulation altered according to the optical properties of the 
tissue.  The attenuated and phase-shifted signal is then collected from the tissue surface and 
the detected signal is modulated at the same frequency.  The fast Fourier transform is used 
to extract the intensity and phase information to generate separate 2D contour plots which 
in turn provide information about the optical properties within the tissue. 
6.3.  ACQUISITION OF OPTICAL DATA WITH THE HAND-HELD IMAGER 
Two-dimensional (2D) diffuse optical and fluorescence-enhanced imaging was performed, 
using the hand-held device operated in the CW-mode, on tissue phantoms, and in vitro.  
Spherical acrylic targets (of different sizes) filled with 0.02-0.08% India ink as an absorbing 
contrast agent (for diffuse optical studies) or 1 !M ICG fluorescent contrast agent (for 
fluorescence-enhanced studies) were used to mimic a tumor in experiments with tissue 
phantoms, in vitro, and healthy human subjects.    The probe was placed in full contact with 
the phantom or tissue surface as shown in Figure 6.4 and CW images of the absorption or 
fluorescent intensity were acquired in close to real-time (~2 sec delay).  The raw intensity 
images at the ICCD camera end were acquired in 1-sec (0.2 sec exposure time " 5 
repetitions).  These images were post-processed (~1 sec) using in-house developed Matlab 
codes (Section 6.4) in order to acquire the final 2D surface contour plots of fluorescence 
intensity distribution of the imaged surface.  The entire data acquisition and post-processing 
was automated such that close to real-time (~2 sec delay) imaging is possible.  For 
frequency-domain imaging, phase-sensitive images were collected with a ~2-minute imaging 
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time.  The 2D surface contour plots of fluorescence intensity signal may or may not 
differentiate the target from the tissue phantom background, based on the target and 
background optical properties.   
 
 
Figure 6.4  Experimental set-up for tissue phantom, in vitro, and in vivo studies: (A) empty phantom 
showing target inclusion and placement of probe, (B) tissue slab phantom with 1% Liposyn solution 
for uniform scattering in the background, and (C) in vitro slab phantom with heterogeneous scattering 
in the background.  
 
6.4.  ELIMINATION OF EXCITATION LIGHT LEAKAGE (SUBTRACTION 
BASED POST-PROCESSING) 
During fluorescence optical imaging, the output signal at the tissue surface is a mixture of 
fluorescence signal and the attenuated incident NIR (i.e. excitation) signal.  This fluorescence 
signal is filtered from the strong excitation signal (3-4 orders of magnitude higher) using 
appropriate optical (bandpass) filters and imaged by the detector.  However, the filters are 
not capable of 100% rejection of the excitation light, causing excitation leakage and 
contamination of the fluorescent signal. Hence, a second-level of post-processing is carried 
out to subtract a background non-fluorescing image from the final fluorescence image plots 
for each experimental case, in order to account for the excitation leakage.  Initially, optical 
measurements were acquired prior to placing the fluorescent target in the phantom, in an 
attempt to represent the excitation leakage (or background noise).  These (background noise) 
measurements were subtracted from the fluorescence optical measurements obtained from 
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experimental cases that included fluorescent targets, in order to effectively eliminate the 
signal from the excitation source light.  In the clinical setting involving actual diseased tissues 
(unlike the simulated fluorescent targets in the current study), this could be accomplished by 
acquiring image(s) of the tissue before and after the contrast agent (e.g. ICG) injection.  The 
non-fluorescent image(s) acquired prior to ICG injection will in turn be subtracted from the 
fluorescent images acquired after ICG injection, in order to account for the background 
noise.  Another method is to collect an image from both breasts and subtract the image of 
the ipsilateral (tumor-containing) breast from the image of the contralateral (non-tumor-
containing) breast.  This was the method applied in the human subject studies with breast 
cancer patients (Chapter 14). 
A single image acquisition consists of collecting an image with target (~ 2 sec), 
collecting a background image (~ 2 sec) and subtracting the two images (~ 1 sec).  The 
subtracted 2D optical images are generated rapidly (< 5 sec), making the entire process a fast 
2D surface imaging technique.   
6.5.  AUTOMATED COREGISTERED IMAGING PROCESS 
In order to perform 3D tomography using a hand-held optical imager, it is necessary to 
coregister the 2D image at the appropriate location on the tissue geometry.  For the past 
tomography studies with cubical tissue phantoms, the images were manually coregistered at 
the known locations on the simple cubicle geometries. In order to perform 3D tomography 
in human tissue with varied complex geometries, it is necessary to track the probe location in 
real time and automatically coregister the image at the tissue location.  To this end, 
coregistered imaging facilities developed by a master’s student in our lab have been 
implemented with our hand-held based optical imaging device.   
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 Coregistered imaging involves the alignment of two or more images (planar or 
volumetric) in a single coordinate space.  Herein, an intramodality20 coregistration method 
(similar to 3D ultrasound imaging) is used to acquire 3D coregistered surface images from 
2D surface data collected using the hand-held device.  These 3D surface images will in turn 
be used towards 3D tomographic analysis.  In coregistered imaging, the position and 
orientation of the probe is tracked with respect to the tissue or phantom surface being 
imaged.  This tracked 3D positional information is then used to accurately position the 
acquired optical images onto the tissue geometry.   
Tracking of the probe position is achieved using an acoustic-based 3D tracker 
(Logitech Inc., Fremont, CA) which consists of a transmitter (positioned ~2 feet above the 
hand-held probe), receiver (implemented onto the probe head), and a processing unit.  The 
position and orientation of the receiver (probe head) is tracked in real-time in reference to 
the transmitter.  The probe’s position is acquired by the computer with six degrees of 
freedom (x, y, z, pitch, yaw, and roll21) using MATLAB software developed in house and 
interfaced to the processing unit tracking software.  The tracked probe’s position and 
orientation are displayed on the computer screen as position coordinates angles of rotation.  
Coregistered imaging of tissue/phantoms is implemented as a three-stage process 
(see Figure 6.5).   
Stage 1:  The special 3D location of the probe is determined and the probe’s position and 
orientation is tracked in real-time with respect to a discretized mesh of the phantom or tissue 
geometry (steps 1-4 in Figure 6.5).  
                                                
20 Two types of coregistration techniques that exist include intermodality and intramodality.  Intermodality coregistration 
combines images of different modalities (e.g. CT/MRI, SPECT/MRI, optical/MRI, etc.), whereas intramodality 
coregistration combines images from the same modality (e.g. 3D ultrasound imaging). 
21 Pitch, yaw, and roll refer to the tracked object’s rotational orientation in reference to the x-, y-, and z-axis respectively. 
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Figure 6.5 Flowchart of the coregistered imaging process, implemented as automated coregistration 
software during optical imaging studies. 
 
 
Stage 2: The hand-held probe based imaging system is used to acquire raw data, i.e. 
optical signals of intensity (step 5 of Figure 6.5).   The raw data is post-processed (step 6 of 
Figure 6.5) using MATLAB software developed in house as described in section 4.1 to 
generate and display the image as a 2D surface contour plot (step 7 of Figure 6.5).  The 
average time to acquire the raw data and display the post-processed images (2D contour 
plots) is ~2 sec (0.2 sec exposure time for each of the 5 repeated measurements, and ~1 sec 
for data post-processing to obtain 2D surface contour plots). 
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Stage 3:  Image coregistration is performed using tracking/coregistration interfacing 
software developed in house in MATLAB/LabVIEW.  The optical data from the 2D surface 
contour plot is coregistered onto the 3D discretized phantom at the probe location using the 
positional information of the entire probe head (i.e. all source and detector point locations) 
during each scan.  The entire coregistered imaging process is described in detail in reference 
[153]. 
The current version of the coregistration software is designed to work with 
phantoms with known position/orientation, and does not take into account any motion of 
the phantom or tissue being imaged.  In the future, this can be remedied by adding tracking 
abilities to the phantom (or subject) being imaged, thereby allowing location and orientation 
of the phantom/tissue to be automatically known and updated in real-time.  The use of 
additional trackers is currently being implemented by a master’s student in our laboratory.  
6.6.  CONCLUSION 
A CW and FDPM based hand-held optical imaging system has been developed in our 
laboratory for coregistered imaging and 3D tomography of breast tissue.  This chapter 
detailed the instrumentation and data analysis procedure for the experimental studies to 
perform fast 2D imaging.  The next chapter will describe the AEKF based reconstruction 
algorithm used to perform diffuse optical and fluorescence-enhanced diffuse optical 
tomography using our hand-held based optical imaging device. 
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CHAPTER 7                                                                                          
Fluorescence-enhanced Diffuse Optical Tomography 
7.1  INTRODUCTION 
Three dimensional (3D) optical tomography is used to reconstruct the 3D volume and 
location of the tumor within the tissue.  Measurements collected at the surface of the tissue 
are used to mathematically reconstruct the optical property distribution at discrete points 
within the tissue volume.  The optical properties of interest in biological tissue are 
absorption and scattering.  There are two types of mathematical problems addressed in 
tomography: the forward problem and the inverse problem.  The forward problem is used to 
simulate light propagation in tissue of known optical property distribution.  The inverse 
problem is used to reconstruct the optical properties within the tissue given a set of 
experimentally measured values (fluence) at the tissue surface.  In each mathematical 
formulation, the tissue volume is discretized and the optical properties are calculated at each 
discrete location.  This chapter will describe the mathematical model of light propagation in 
tissue, the forward and inverse problems, and the AEKF reconstruction algorithm used to 
perform 3D tomography. 
7.2  LIGHT PROPAGATION IN BIOLOGICAL TISSUES 
The propagation of light through a highly scattering medium is often modeled using the 
diffusion approximation of the radiative transport equation.  The coupled diffusion 
equations for the case of fluorescence-enhanced imaging in the frequency domain are [104] 
                        [ ] )r-r( s!
"
µ S
c
iD x
x
axxx =#$
%
&
'
(
)
++#*•*+                                                 (1) 
  
 74 
                       [ ] xmaxm
m
ammm i
q
c
iD !"#
$
%&
'
(
=!"
#
$
%
&
'
++!)•)( * +,
µ
+
µ
1
1                              (2) 
 
where the subscripts x and m are used to represent the excitation and emission wavelengths 
of light respectively.  In these equations, � is used to represent the amplitude of the fluence 
signal  "a and "s represent the absorption and scattering coefficients, q and � are the 
quantum efficiency and fluorescent lifetime of the fluorophore, c is the velocity of light, � is 
the modulation frequency, and r is the positional vector.  D is the diffusion coefficient given 
by: 
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where g is the anisotropy factor.  The partial current boundary condition is applied which 
assumes that once a photon leaves the tissue it does not return.  It is expressed by 
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where � is the index-mismatch parameter, which is a function of the effective refractive 
index, and n is the normal to the surface. 
 The diffusion approximation of the radiative transport equation is applied in the 
forward and inverse problems to model light propagation in tissue and to reconstruct the 
internal distribution of tissue optical properties using surface measurements. 
7.3  FORWARD PROBLEM 
The forward problem in optical imaging is used to predict light transport in biological tissue 
during simulations.  The problem is stated as follows:  Given a distribution of light sources 
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on the boundary of an object and a distribution of tissue parameters within the object, find 
the resulting measurements that would occur at the surface.  Figure 7.1 illustrates the 
forward and inverse problems.   In the forward problem (left), the parameters !a and !s’ are 
known within the tissue and the propagation of light to the boundaries is predicted.  In 
biomedical optical imaging, the forward problem is typically solved using the diffusion 
approximation to the radiative transport equation described in section 7.2.  The diffusion 
equation is solved numerically using a finite difference or finite element based approach.  
For the studies described herein, a Galerkin based finite element approach was used to solve 
the forward problem. 
 
 
Figure 7.1  Illustration of the forward and inverse problem in optical tomography.  In the forward 
problem, the optical property distribution is known and used to predict the measurements that would 
occur at the surface of the tissue.  In the inverse problem, the measurements obtained experimentally 
at the surface are used to reconstruct the unknown optical property distribution within the tissue. 
 
7.4  INVERSE PROBLEM 
The inverse problem in optical imaging is to reconstruct the unknown optical properties 
within a tissue given a set of measurements at the boundary.  The problem is stated as 
follows:  Given a distribution of light sources and a distribution of measurements on the 
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surface, calculate the tissue parameter distribution within the tissue.  The inverse problem is 
illustrated in Figure 7.1 (right) where a set of measurements of fluence (�i) is collected at the 
boundary, and the unknown internal properties of the given tissue are mathematically 
reconstructed (in this case, !a and !s’).  In the case of the inverse problem, the number of 
unknowns is much greater than the total number of surface measurements acquired and the 
problem is to solve an underdetermined system of linear equations.  The solutions are non-
unique and inconsistent making the problem ‘ill-posed’ 
7.5  APPROXIMATE EXTENDED KALMAN FILTER (AEKF) BASED 
RECONSTRUCTION ALGORITHM 
Optical tomography has been performed using different algorithms such as Algebraic 
Reconstruction Techniques (ART) [125], NIRFAST [126], and Born approximation [133].  
For the tomography studies performed herein, a Bayesian reconstruction technique was used 
which is an approximate extended Kalman filter (AEKF).[104]  The Kalman filter is a linear 
state Bayesian estimator that is used in process control in order to estimate a state 
recursively, using the previous observations.  The filter yields estimates of true measurement 
values and the corresponding calculated values by the following process: (i) predict a value, 
(ii) estimate the uncertainty of the predicted value, (iii) compute a weighted average of the 
predicted value and the measured value.  The estimator determines the mean value of the 
conditional probability function of the unknown parameters using given measurements, 
assuming that the state variables and observations are normally distributed random variables.  
This Bayesian estimator was chosen due to the following advantages:  (i) the updates in each 
iteration are weighted and the matrix inversion is regularized using measurement error 
(between repeated measurements) and model error (which results from simplifications of the 
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diffusion approximation), and (ii) the parameter error values are estimated separately from 
the parameter value itself and used to damp and regularize the inversions.  The method of 
the AEKF algorithm is given by the following pseudocode[104]: 
 
iterate 
1: x = f(y) 
for i = 1 to # source illuminations 
2: y
xJ
!
!
= ii
 
3: ( )
1!
""++""= TT JPJQRJPK iiiiii  
4:  ( )iiii xzKy !"=#  
5:  PJKPP !!"# ii  
end 
6:  
!"+#
i
iyyy
 
until convergence 
 
where the definitions of each term is given in Table 7.1. 
Table 7.1.  Definitions of terms used in AEKF pseudocode. 
x distribution of  predicted measurements
z corresponding experimental measurements
y unknown parameter (updated recursively)
J Jacobian matrix
K gain matrix
Q model error covariance
R measurement error covariance
P parameter error covariance
f forward solver
 
 
The parameter x represents the distributed predictions of the referenced measurements (the 
logarithm of AC and the phase shift for the case of frequency-domain measurements), which 
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are generated by the forward simulator f.  The parameter y represents the vector of current 
estimates of the unknown optical property, which is an inverse pseudo-� transform of the 
optical absorption coefficient !axi (in the case of fluorescence imaging, it is the absorption 
coefficient due to the fluorophore, !axf).  The measurement error covariance was assumed 
uncorrelated, and repeated observations (in this case, five) at each detector location were 
used to experimentally determine the variance for each source-detector pair.  The model 
error covariance Q is difficult to estimate for unknown domains, and was empirically chosen 
to be one-fourth the mean of the measurement error variance.  The discrepancies between 
measurements and predictions (z - x) are weighted by a gain matrix K in order to update the 
uncertain parameters y and the parameter error covariance P.  The gain matrix K is used to 
update the unknown optical parameter y and the parameter error covariance P.  An initial 
variance estimate was set (typically 0.01, however 0.1 was used for some in vitro cases due to 
inhomogeneous background) and the parameter error was assumed uncorrelated with the 
initial estimate.   
 A flow diagram of the AEKF based reconstruction algorithm used herein is 
illustrated in Figure 7.2.  In fluorescence studies the reconstructed parameter is the 
absorption coefficient at the excitation wavelength (!axf).  The algorithm starts with an initial 
guess of uniform distribution (herein, arbitrarily set to 0.003 cm-1), and uses the experimental 
data from the hand-held probe along with simulated measurements using the forward model 
(diffusion approximation) to get an updated distribution of the parameter of interest (!axf).  
Each updated distribution is then used in the algorithm until the convergence criteria is met 
and the reconstruction is complete.  The AEKF algorithm is carried out recursively, i.e  each 
set of measurements is used to continuously update the unknown parameter y and the 
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parameter error covariance P, without storing the set of measurements from each loop. This 
recursive AEKF algorithm is carried out iteratively until the reconstructions converge.  The 
convergence criteria was met when the root mean square output error RMSE was less than 
1%, or the total number of iterations exceeded 50. 
The AEKF reconstruction algorithm was developed for frequency-domain based 
fluorescence tomography.  Modifications were made to the algorithm during the various 
tomography studies presented herein to adapt for continuous-wave based measurements, 
multiple-scan studies, and in vivo studies.  The modification details will be given in the 
materials and methods for each tomography study appropriately. 
 
Figure 7.2  Flow diagram of the AEKF based reconstruction algorithm. 
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7.6 CONCLUSION 
This chapter detailed the reconstruction approach used in the tomography studies performed 
herein.  The diffusion approximation of the radiative transport equation is used to model 
light propagation in biological tissue (forward problem).  An approximate extended Kalman 
filter (AEKF) based reconstruction algorithm is used to reconstruct the unknown optical 
property distribution within tissue given experimental measurements at the tissue surface 
(inverse problem).  The next chapters detail the experimental studies performed toward the 
goals of fast 2D imaging, coregistration, and 3D tomography in tissue phantoms, in vitro, and 
in vivo with human subjects. 
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CHAPTER 8                                                                                                  
Study I:  2D Imaging in Tissue Phantoms and In Vitro in Near-Real 
Time 
8.1 INTRODUCTION 
Real-time imaging is a useful tool for on-site cancer diagnosis in the clinical setting.  Prior to 
performing 3D tomography studies using our hand-held optical imager, studies were 
performed to determine the ability of the device to detect a target via 2D imaging in near 
real-time.  This chapter describes experimental studies that were performed in tissue 
phantoms and in vitro designed to detect the presence and estimate the 2D location of a 
fluorescent target using continuous wave based imaging. 
8.2  MATERIALS AND METHODS 
Fast 2D imaging was facilitated by the use of simultaneous multiple-point illumination and 
collection and CW based measurements.  Studies were performed using slab tissue phantoms 
composed of 10"10"10 cm3 acrylic cubes filled with 650 ml of 1% Liposyn solution 
(Liposyn II, 20%, Henry Schein, Melville, NJ) in order to mimic the optical properties of a 
typical breast tissue.  The fluorescent target was placed at different depths (1.5-2.5 cm) from 
the imaging surface and real-time as well as fast (subtracted) images of fluorescence intensity 
were acquired.  The different experimental cases are summarized in Table 8.1. 
 Prior to in vivo studies with human subjects, experiments were performed using in 
vitro phantoms, which were composed of minced chicken breast combined with 1% Liposyn 
solution, in order to introduce a non-uniform scattering background.  The in vitro mixture of 
minced chicken breast (480 ml) and 1% Liposyn (260 ml) was placed inside a 10"10"10 cm3 
acrylic cube.  Real-time as well as fast (subtracted) images of fluorescence intensity were 
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acquired under different experimental conditions using either a 0.23 cc or 0.45 cc fluorescent 
target located at various depths between 1-2 cm (see Table 8.1).   
Table 8.1  Summary of experimental cases for slab tissue phantom and in vitro studies. 
 
8.3  RESULTS 
8.3.1 Tissue Phantom Studies 
Real-time images using the slab phantom with uniform scattering in the background are 
shown in Figure 8.1 as 2D surface contour plots of the fluorescence intensity data with a 
target placed at different depths (1.5-2.5 cm) from the imaging surface.  The non-uniform 
intensity distribution in Figure 8.1 is possibly due to the residual excitation leakage around 
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the six source fibers (after the implementation of the subtraction technique).  Additionally, 
the input laser source signal is not evenly distributed amongst the six source fibers, possibly 
causing a variation or non-uniformity in the output fluorescence intensity distribution.   
 
Figure 8.1  Near real-time images of fluorescence intensity obtained as 2D surface contour plots, 
acquired from slab phantoms (with uniform background scattering). The fluorescent target was 
placed at different locations and depths: (A) target location: (x,y,z) = (2.0, 2.7. 1.5), and (B) target 
location (x,y,z) = (2.0, 2.7, 2.0) and (C) target location: (x,y,z) = (3.0, 2.2, 2.5).  The black hollow 
circle in each sub-plot is the true target location. 
 
 The images show the feasibility of performing (close to) real-time 2D imaging using 
the hand-held device in tissue phantoms.  The actual target location in the images is 
indicated in the figures by the black open circle in the x-y plane for different target depths in 
the ‘z’ direction.  The fast 2D image estimates the 2D target location (instantly) in the x-y 
plane.  This information can then be further used towards 3D tomography (in the future) in 
order to determine the tumor volume, location, and depth [3].  
 From these plots, it is obvious that the real-time images are capable of differentiating 
the target from the background when the 0.45 cc target was 1.5 cm deep.  At greater tissue 
depths, the target was not distinctly differentiable due to the strong excitation leakage from 
the background.  Upon applying the subtraction technique (as described in Section 6.4), the 
target is clearly differentiable from the background in all the experimental cases (see Figure 
8.2).  These subtracted images also have potential to obtain 3D target localization via 
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tomographic imaging, as long as the probe’s location on the tissue surface is coregistered 
with respect to the surface fluorescence images.   
 
Figure 8.2  Fast subtracted images of fluorescence intensity obtained as 2D surface contour plots, 
acquired from slab phantoms (with uniform background scattering).  The 0.45 cc fluorescent target 
was placed at different locations and depths: (A) target location: (x,y,z) = (2.0, 2.7. 1.5), and (B) target 
location (x,y,z) = (2.0, 2.7, 2.0) and (C) target location: (x,y,z) = (3.0, 2.2, 2.5).  The black hollow 
circle in each sub-plot is the true target location. 
 
8.3.2 In Vitro  Studies 
The results for the in vitro phantom experiments are shown in Figures 8.3 (real-time images) 
and 8.4 (fast subtracted images) for different target depths (1-2 cm) under T:B contrast ratio 
of 1:0.  The true target location in the images is given as x,y,z coordinates where ‘x’ is the 
lateral position, ‘y’ is the height and ‘z’ is the depth (distance from the imaging surface) 
which vary among the images.  Due to heterogeneous scattering of the background 
phantom, only the subtracted images were capable of clearly differentiating the target from 
the background for targets deeper than 1.0 cm.  These studies show the ability of the hand-
held device to perform fast 2D surface imaging and target localization within a non-uniform 
scattering tissue-mimicking background.    
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Figure 8.3  Near-real time images of fluorescence intensity obtained as 2D surface contour plots, 
acquired from in-vitro slab phantoms (with non-uniform background scattering). The 0.45 cc 
fluorescent target was located at a depth of (A) 1.0 cm, and (B) 1.5 cm, from the imaging surface.  
The black hollow circle in each sub-plot is the true target location.   
 
 
 
Figure 8.4  Fast subtracted images of fluorescence intensity obtained as 2D surface contour plots, 
acquired from in-vitro slab phantoms (with non-uniform background scattering).  Images were 
collected for different target sizes and depths.  Images (A)-(C) contain a target size of 0.45 cc at 
depths of 1.0, 1.5, and 2.0 cm respectively.  Images (D)-(F) contain a target size of 0.23 cc at depths 
of 1.0, 1.5, and 2.0 cm respectively.  The black hollow circle in each sub-plot is the true target 
location. 
 
 
8.4  DISCUSSION 
The fluorescence imaging studies described here demonstrate for the first time the 
acquisition of fast 2D surface images (in < 5 sec) of a fluorescent target in uniform tissue 
phantoms and in vitro using a hand-held based optical imaging device.  The subtracted images 
have a potential to clearly differentiate target(s) from the background (under various 
experimental conditions), demonstrating the potential to translate the technology towards 
on-site breast imaging in a clinical environment.  Additional experiments were performed 
with the target located at greater depths in the tissue phantoms, but the target was not 
detected at a depth of 2.5 cm.  At 2.5 cm deep, the detected signal from the target is close to 
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the noise floor, and hence not differentiable from the background.  A multi-location 
scanning approach is currently developed for differentiating deeply located or small volume 
targets from homogenous or heterogeneous background (details in Chapter 9).  In short, this 
approach will incorporate the use of coregistered images obtained at multiple locations on 
the tissue surface, such that the targets can be differentiated from artifacts22 as well as the 
background [80].  When comparing Figures 8.2 and 8.4, it can be seen that the images from 
the in vitro phantom contain more noise than those from the uniform tissue phantom.  This 
can possibly be attributed to the heterogeneous distribution of scattering properties or 
shifting of the chicken breast as the target is removed (which can cause a change in the signal 
distribution when the background image is collected).  Experiments were also performed 
using the in vitro phantoms with a T:B contrast ratio of 100:1.  However, the noise from the 
background signal dominated the image and a target was not detected even after subtracting 
the excitation background signal.  Upon applying our multi-location scanning approach, the 
targets were differentiable under imperfect uptake conditions (i.e. T:B = 100:1).  In addition 
to fast 2D imaging, the hand-held device described here has demonstrated 3D tomography 
of fluorescent targets with tissue phantoms using frequency-domain based measurements in 
order to estimate the 3D location and volume of the target within the tissue. [3].  Additional 
efforts involve the implementation of fast and automated coregistration facilities in order to 
enable precise 2D target localization (instantaneously) as well as 3D tomography studies in 
vitro as well as in vivo (Chapter 10 and 13, respectively). 
                                                
22 Any signal that occurs in the image which is not from the target or tumor. 
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8.5  SUMMARY AND CONCLUSION 
Preclinical testing of a hand-held optical imager was performed to demonstrate the ability of 
the device to perform fast 2D imaging toward tumor detection in near real-time.  
Experimental studies show the ability of the device to detect and estimate the 2D location of 
a 0.45 cm3 fluorescent target up to 2.5 cm deep in a tissue phantom with homogeneous 
background and fluorescent targets of 0.23 or 0.45 cm3 volume up to 2.0 cm deep in vitro 
with heterogeneous background (more like a true tissue case). The goal of these studies was 
to determine if it was possible to detect a signal from the target using only fast 2D imaging.  
Target localization can be performed subsequently using 2D or 3D tomography.  The results 
presented herein demonstrate the potential of the device toward target detection and 
estimation of 2D target location even prior to 3D tomographic analysis. 
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CHAPTER 9                                                                                                       
Study II: Coregistered Imaging towards Improved Target Depth 
Detection (using Multiple-scan Coregistered Imaging) 
9.1  INTRODUCTION 
The feasibility of 2D target detection and 3D tomographic analysis using this hand-held 
optical imager has been demonstrated from tissue phantom and in vitro fluorescence imaging 
studies.  During these studies, a single scan in the region of interest was acquired to detect 
and recover the embedded target(s) tomographically (using manually coregistered optical 
images).  However, it was observed that as the target depth was increased and/or its volume 
decreased, the target was not detectable from 2D images, nor was it recovered from 3D 
tomography studies.  Experimental studies using single fast 2D images showed the ability to 
detect a target (0.45 cm3) up to 2.5 cm deep in tissue phantoms and up to 2.0 cm deep in vitro 
(details in section 8.3).  Herein, an alternate imaging approach of using multiple-scans from 
various locations of the tissue surface is developed (using automatically coregistered optical 
images) and its feasibility to detect deeper targets is assessed [155]. 
In the current work, the recently developed multi-scan imaging approach is 
extensively assessed to determine the target detection limits of our hand-held optical imager.  
Studies were performed using the liquid tissue phantoms in order to determine the extent of 
improvement upon the previous studies using single-scan.  Studies were also extended to in 
vitro tissue models in order to assess the performance of the device in a non-uniform (or 
heterogeneous) scattering background, in order to better mimic human tissue.  
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9.2  MATERIALS AND METHODS 
9.2.1 Phantom and In Vitro Studies 
Experimental studies were performed initially using the simple case of the uniform liquid 
tissue phantom and were then extended to more realistic in vitro models.  Phantom 
experiments were performed using tissue phantoms composed of 1% Liposyn (800 mL) in a 
10"10"10 cm3 acrylic cube.  Acrylic sphere targets of sizes 0.23 - 0.45 cm3 filled with 1 !M 
indocyanine green (ICG) were placed at different depths (2.5-4.0 cm) from the imaging 
surface to represent a tumor.  Experiments were performed increasing the depth by 0.5 cm 
until the target was no longer detected.  The experimental set-up is shown in Figure 9.1.  The 
probe was placed in full contact with the phantom surface and multiple scans (2D 
coregistered images) were collected using the method described in section 2.5 below.   
 
Figure 9.1  Experimental set-up for phantom studies.  (A) A spherical target filled with 1 !M 
indocyanine green is enclosed within the cubical phantom to represent a tumor.  (B) The phantom is 
composed of a 1% Liposyn solution to mimic the optical properties of human breast tissue.  
To represent the heterogeneous nature of human tissue, studies were also performed 
in vitro using minced chicken breast (480 mL) combined with 1% Liposyn (260 mL) in a 
10"10"10 cm3 acrylic cube in order to introduce a background of non-uniform scattering.   
The 0.45 cm3 fluorescent target was placed at different depths between 2.0-4.0 cm, until the 
target was no longer detected.  The experiments were performed for the perfect uptake case 
  
 90 
with tumor-to-background ratio (T:B) of 1:0 and imperfect uptake case with T:B of ~100:1.  
Table 9.1 summarizes the different experimental studies performed in which a target was 
detected.  For each image collected, a subtraction-based post-processing technique was used 
to eliminate excitation light leakage (as described in Section 6.4). 
 
Table 9.1  Summary of experimental studies in which a target was detected in tissue phantoms and in 
vitro.  The cases where the deepest target was detected for phantom or in vitro, and perfect or 
imperfect uptake are highlighted in red. 
 
Experimental 
Case 
Experiment 
# 
Target     
Volume 
(cm3) 
Target 
Depth 
(cm) 
 
T:B 
 
 
 
Tissue 
Phantom 
1 0.45 3.0 1:0 
2 0.45 3.5 1:0 
3 0.23 2.5 1:0 
4 0.23 3.0 1:0 
5 0.23 3.5 1:0 
6 0.45 2.5 100:1 
7 0.45 3.0 100:1 
8 0.23 2.0 100:1 
9 0.23 2.5 100:1 
10 0.23 3.0 100:1 
 
 
In Vitro 
11 0.45 2.5 1:0 
12 0.45 3.0 1:0 
13 0.45 3.5 1:0 
14 0.45 2.0 100:1 
15 0.45 2.5 100:1 
 
 
 
9.2.2  Validation of Coregistered Imaging in Phantoms 
In order to quantitatively determine the accuracy of the tracked position and coregistered 
image compared to the true location on the phantom, the probe was placed at five different 
reference points of known locations (moving 0.5 cm vertically) and five measured values 
were recorded from the tracking software at each position.  The average, standard deviation, 
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and discrepancy of these measured values for each position are given in Table 9.2.  It can be 
seen from the standard deviation of the measured values that the tracked probe position 
fluctuates between 0.013-0.094 cm.  The average total distance off represents the accuracy of 
the tracked position compared to the true location.  The average total distance off is ~0.19 
cm.  The deviation and discrepancy of the measured values can be attributed to 
instrumentation error such as fluctuation in the tracked position of the probe.  Currently, 
efforts are made to overcome these limitations and improve the stability of the tracking 
system (Chapter 16). 
Table 9.2  Average and standard deviation of x,y,z coordinates as displayed in tracking software and 
total distance off  between true and measured values.  Values are in units of centimeters and each 
measured value represents an average of 5 measurements while probe was at each of the 5 positions. 
9.2.3 Multiple Scan Technique 
The multiple scan technique involves collecting a series of scans at different probe positions 
and coregistering each image to its appropriate location.  A scan is defined as a 2D surface 
contour plot of fluorescence intensity data collected from a CW image (the mean of 5 
repeated images at the same location) using the ICCD based detection system.  Each image 
is immediately coregistered to the discretized phantom mesh.  By scanning at multiple 
locations, the weak fluorescence signal from the target (which appears at the same location 
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on the tissue geometry during each scan) can possibly dominate the strong excitation light 
leakage (which tends to appear at different locations on the tissue geometry during each 
scan).   
 Different combinations of image positions were used to determine the optimal 
multi-scan method.   Initially 4-5 scans were collected moving the probe 0.5 cm in the 
vertical direction between each scan.  For the same experimental case, 9 scans were collected 
moving the probe in 0.25 cm increments in the vertical direction.  Additionally, repeated 
scans were collected at each probe location.  It was determined that collecting 2-3 repeated 
scans (i.e. 2-3 " 5 repeated images or 10-15 repeated images) at each probe location for 4-5 
positions 0.5 cm apart resulted in better target detectability with fewer artifacts than 
collecting single scans (i.e. 1 " 5 repeated images) at each probe location for 9 positions 0.25 
cm apart.  This can possibly be attributed to two reasons: (i) the inaccuracy (from instability) 
of the positional tracking system (described in section 2.3) has greater impact at smaller 
positional increments (e.g. 0.25 cm), leading to increased artifacts; and (ii) the variability in 
the instrument’s response is minimized by increasing the number of repeated scans (or 
images) at the same location.   The number of repeated scans (or images) can be increased 
for the case where the probe locations were 0.25 cm apart.  However, this further increases 
the overall imaging time and hence was not attempted.  In the future, for an in vivo case, 
multiple images can be collected and summed from arbitrary probe positions and the 
number of scans can be optimized to minimize the overall imaging time and number of 
artifacts.  The position will be known since the image is immediately coregistered at its 
location.  
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9.3  RESULTS 
 
Figure 9.2 shows four single images (2D contour plots of fluorescence intensity) for 
experimental case # 12 where a 0.45 cm3 fluorescent target was placed 3.0 cm deep in vitro 
under perfect uptake condition (T:B=1:0).  Multiple scans were collected as described in 
section 2.5.  In each image, the true target location is indicated by a black open circle.  The 
images show that the target is not detected in a single scan, and only random distributions of 
artifacts (high intensity signals that appear in the image which do not originate from the 
target) are visible.   
 
 
 
Figure 9.2  Coregistered images from single scans (2D contour plots of fluorescence intensity data) 
at four probe positions for experimental case #12 (a 0.45 cm3 fluorescent target placed 3.0 cm deep, 
x-dimension in-vitro phantom under T:B=1:0).  In each image, the white dotted line represents the 
probe position with respect to the phantom and the black open circle represents the true target 
location. 
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Upon summation of eight scans, the fluorescent signal is detected at the target location 
(Figure 9.3).  This can be attributed to the random distribution of artifacts that appear in 
different locations for each single scan, while the signal from the target remains in the same 
location relative to its coregistered position on the phantom.  Upon summation of the 
coregistered images, the random signals from the artifacts tend to diminish compared to the 
consistent signal from the target, which tends to intensify. 
 
Figure 9.3  Summated image of multiple scans shown in Figure 9.2 (experimental case #12).  The 
summed image represents summation of 8 single scans, where 2 scans were collected at each of the 4 
probe positions shown in Figure 9.3,  The black open circle represents the true target location. 
 
 
Figure 9.4 shows the result for summated multi-scan images for experimental cases 
5, 10, 13, and 15 (Table 9.1, bold).  Case 5 represents a 0.23 cm3 target placed 3.5 cm deep in 
the tissue phantom under perfect uptake conditions (T:B=1:0).   The target was detected 
close to the true location and no artifacts were present.  Case 10 represents a 0.23 cm3 target 
placed 3.0 cm deep in the tissue phantom under imperfect uptake condition (T:B=100:1).  
The target was detected at the true location with some diffused signal around it.  Case 13 
represents a 0.45 cm3 target placed 3.5 cm deep in vitro under perfect uptake conditions 
(T:B=1:0).    The target was detected at the true location with artifacts also visible far from 
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the target location.  These artifacts can be attributable to the heterogeneous nature of the in 
vitro phantom.   
 
 
 
Figure 9.4  Summed images of multiple coregistered scans from the four best experimental cases 
listed in Table 1.  The black open circle indicates the true target location for each case. 
 
 
Case 15 represents a 0.45 cm3 target placed 2.5 cm deep in-vitro under imperfect uptake 
conditions (T:B=100:1).  The target was detected close to the true location along with 
minimal artifacts around it.   
The initial experiments designed to detect deeper targets consisted of performing a single 
scan at 4-5 positions moving the probe 0.5 cm in the vertical (z) direction.  For deeper 
targets (>3.0 cm), heterogeneous (in vitro) phantoms, and/or imperfect uptake cases, the 
target was not detected upon summation of four or five scans.   However, it was observed 
that when multiple repeated scans were collected at the same location for each probe 
position, the targets were detectable.  In other words, increasing the number of repeated 
scans is as important as increasing the number of scan locations towards deep target 
detection under heterogeneous and/or imperfect uptake conditions.   
The results presented here demonstrate that deeper and smaller targets can be detected using 
the multiple-scan approach than using a single-scan alone.  The impact of these results 
extend beyond target detection in 2D in that the information can be used as a priori 
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information to aid 3D reconstruction using a single frequency-domain image (or scan) 
towards deeper target recovery (future work). 
9.4  DISCUSSION 
The prime hypothesis for the current study is that a single scan (of a large area, 4 x 9 cm2) 
can fail in detecting deeper targets during a near real-time optical imaging study.  Upon 
scanning at multiple locations on the surface of a tissue geometry, the possibility to detect 
deeper targets and differentiating them from artifacts tends to improve upon summing all 
these multiple scans.  The detection limits of our hand-held optical imager, the first of its 
kind that can scan large areas in near real-time, has been 2.5 cm for a 0.45 cm3 target under 
T:B=1:0 from the past studies (Chapter 8) involving a single scan from the region of interest 
on the tissue geometry.  In the current study, it was clearly observed that upon summation of 
the intensity signals from multiple scans of the tissue surface, targets of smaller volume and 
as deep as 3.5 cm were detectable.  However, artifacts start appearing when the target depth 
is increased, the target volume is decreased, and/or heterogeneity of the background 
increased.  The reasons for these artifacts are two-fold: (i) The uneven source strength 
distribution of the 6 simultaneous sources affects the ability to detect the target depending 
on the proximity of the target to the stronger sources.  As multiple scans are collected the 
strong source may move away from the target resulting in a more diffused signal which 
produces a greater number of artifacts upon subtraction of the background.  (ii) The 
positional information of the hand-held probe is not accurately coregistered due to the 
instability of the motion tracking device, which can lead to misalignment of the target signal 
in the multiple images.  As a result, some signals which originated from the target can be 
mistaken as artifacts due to their improper location in the image.  Currently, work is carried 
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out to homogenize the source strength distribution by altering the instrumentation set-up at 
the source end, and also developing alternate motion tracking approaches that are stable and 
more accurate in comparison to the current device.   
 Researchers in the past have demonstrated detection of targets as deep as 5 cm using 
their hand-held optical devices [50].  However, the detection was typically a point location 
that was spectroscopically obtained from the tissue surface.  In addition, the specificity of 
getting a negative result (not detecting any target) in the absence of the target (i.e. in the 
surrounding tissues) is not described.  In other words, unlike the current hand-held optical 
imager that can produce 2D images over large areas in near real-time, the other hand-held 
imagers have a limited imaging area (mostly point-based imaging) and typically produce only 
spectroscopic measurements from a few sources/detectors.   
 The advantage of the current hand-held imager’s optical data is that it can be applied 
towards 3D tomography studies, since the positional location of the optical data with respect 
to the 3D tissue geometry is coregistered during imaging studies.  Hence, the 
implementation of the multi-scan imaging approach and using the summated images towards 
immediate 2D deep target detection and future 3D tomographic analysis is feasible.  
Although the present study is focused on fluorescence-enhanced optical imaging, the multi-
scan summation and imaging approach is applicable for absorption-based diffuse optical 
imaging studies as well. 
 In the area of fluorescence tomographic imaging, Sevick’s research group was one of 
the first groups to demonstrate 3D fluorescence optical tomography in clinically relevant 
sized tissue phantoms, using large bulky optical imaging instrumentation [24].  Fluorescent 
targets of 1 cm3 volume were recovered at a depth up to 2.8 cm under perfect uptake 
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conditions.  The first in vivo 3D fluorescence optical tomography of breast cancer in human 
subjects was demonstrated by Corlu et. al. where tumors were recovered in vivo up to 2.0 cm 
deep in human breast tissue [110].  From our past 3D tomography studies using the hand-
held imager on large tissue phantoms, 0.45 cm3 targets as deep as 2.5 cm were recovered in 
uniform tissue phantoms under perfect uptake conditions [3].   
In a recent in vivo study using a simulated fluorescent target, a single scan using our 
hand-held optical imager was able to detect a 0.23 cm3 target ~ 2.5 cm deep in human breast 
tissue (Chapter 11).  These studies demonstrate the potential that upon using multiple scans 
and applying the summation approach, deeper and smaller targets can become detectable 
from the tissue surface.  In addition, these summated images can also assist in 
tomographically recovering deeper targets beyond what is demonstrated to date in the area 
of fluorescence optical tomography.  However, the developed hand-held optical imager is 
limited to reflectance based imaging, which tends to limit the recovery of the target’s true 
depth during 3D tomography.  Currently, research is carried out to develop alternate imaging 
approaches using the hand-held device such that trans-illumination measurements can also 
be acquired in an attempt to improve the target depth recovery (during 3D tomography). 
9.5  CONCLUSION 
Herein we have demonstrated improved detection limits via application of a multiple-scan 
technique.  The multi-scan imaging approach is facilitated by the use of fast 2D coregistered 
imaging in CW mode.  Previous results using single-scan imaging showed that the greatest 
target depth detected was 2.5 cm and 1.5 cm for a 0.45 cm3 target in a (liquid) tissue 
phantom under perfect and imperfect uptake conditions, respectively.  By using the multi-
scan technique, this depth was improved to 3.5 cm for a smaller target (0.23 cm3) under the 
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T:B=1:0 condition.  Under imperfect uptake conditions (T:B=100:1), the detectable target 
depth was increased from 1.5 cm to 3.0 cm.  Since these results were promising, studies were 
extended to in vitro models, which better represent the non-uniformity of human tissue.  
From these in vitro studies the target was detected at depths of 3.5 cm and 2.5 cm for perfect 
(1:0) and imperfect uptake (100:1) cases, respectively.  These studies demonstrate that 
summation of multiple coregistered images can be used towards deeper target detection than 
is capable from single scans alone.  In a clinical setting, this technique can be used to acquire 
multiple images quickly in order to detect the presence of a tumor, determine its 2D location 
within the tissue, and also perform 3D tomography studies (as a follow-up).  Thus, the hand-
held optical imager has potential for fast 2D imaging and 3D tomography in the clinical 
setting for breast cancer diagnosis.   
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CHAPTER 10                                                                                                     
Study III: 3D Tomography Studies in Tissue Phantoms and In Vitro  
10.1  INTRODUCTION 
Parallel to the coregistered imaging studies described in Chapter 9, 3D tomography studies 
were carried out in tissue phantoms and in vitro with simple geometries using manual 
coregisteration.  This chapter describes FDPM tomography studies using a single image and 
CW tomography studies using multiple summated images towards recovery of targets at 
greater depths.  
10.2  MATERIALS AND METHODS 
10.2.1  FDPM Based Reconstructions In Vitro 
Three-dimensional fluorescence tomography studies were performed from FDPM 
measurements collected using the hand-held device with in vitro phantoms.  The phantoms 
were composed of minced chicken breast (480 mL) and 1% Liposyn (260 mL) for a total 
volume of 800 mL within a 10x10x10 cm3 acrylic cube.  A 0.45 cc acrylic sphere target was 
filled with 1 !M ICG and placed at different locations and depths within the phantom.  A 
FDPM image was collected with the target followed by a background image with the target 
removed to use to subtract the excitation signal.  In all cases the laser power was set to 217 
mA, the frequency synthesizer was set to 2.7 dB, and the exposure time was 200 msec.  The 
gain setting on the image intensifier was adjusted for each data set and held constant 
between images with and without a target.  The optical properties of the phantom (!ax, !sx’, 
!am, and !sm’) were measured at both the excitation (‘x’) and emission (‘m’) wavelengths (785 
and 830 nm, respectively) using a single pixel homodyne FDPM optical property 
measurement system.  Multiple repetitions (5-10) of the optical property measurements were 
101 
collected and averaged for each in vitro phantom.  The phantom was stirred between each 
measurement in order to acquire values that are an average representation of the mixture as a 
whole.  An example optical property measurement set including mean and standard 
deviation of the optical properties at each wavelength is shown in Table 10.1.  The table 
shows large standard deviations due to the heterogeneous nature of the phantom material, 
and hence ten measurements were collected and averaged for each wavelength.  The output 
intensity of the six source points at the probe face were measured using a digital optical 
power meter (PM121 w/ S121 sensor, 500nW-500mW, Thorlabs, NJ) and average values 
were used as input parameters in the reconstruction algorithm.  The initial guess of the 
reconstructed parameter (!axf) was arbitrarily set to a uniform distribution of 0.003 cm
-1 and 
an initial p-value of 0.01 was used in all cases.  Table 10.2 provides a summary of the 
experiment parameters for various experimental cases including the average measured source 
intensities, the gain setting on the image intensifier, the actual target location in cm, the 
actual target volume, the measured optical property values of the phantom at the excitation 
and emission wavelengths, the target to background ratio (T:B), the recovered target location 
in cm, the recovered !axf values in cm
-1, the recovered target volume, the number of 
iterations executed before convergence, and the breakpoint (cutoff value selected on the first 
breakpoint of a histogram plot of the recovered !axf values).  The total distance off between 
the true and recovered target locations was calculated using the following equation: 
                  (1)
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Table 10.1  Sample optical property measurements of the in vitro phantom.  All optical property 
values are in units of cm-1.  
 
The results from two example cases (highlighted in yellow in Table 10.2) are given in Section 
10.3.1.  
10.2.2  CW Based Reconstructions using Summed Multiple-scan Data 
Three-dimensional (3D) reconstructions were performed using the CW based data from all 
the multiple-scan experimental cases detailed in Chapter 9 (summarized in Table 9.1).  For 
the CW based reconstructions, the modulation was set to zero in the reconstruction 
algorithm for continuous amplitude.  Each experimental set encompassed a series of 8 scans, 
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2 repetitions at 4 different probe locations moving vertically in 0.5 cm increments (see 
Section 9.2.2 for more details on the multiple-scan acquisition).  The 2D images of the 
summed multiple-scan data were presented in Section 9.3.  Herein, 3D reconstructions were 
performed using two methods: (i) individual reconstructions were performed using the data 
from each single scan and the recovered !axf values were then summed; (ii) the initial raw 
data from the 8 scans was summed together into a single data set which was then used to 
perform 3D reconstructions.  A separate mesh was generated to input in the reconstruction 
algorithm for the different data sets, with different nodes assigned to the source and detector 
coordinates according to the coregistered location of the probe with respect to the phantom. 
10.3  RESULTS AND DISCUSSION 
10.3.1  FDPM Based Reconstructions In Vitro  
Figure 10.1 shows the result for experimental case #26 (Table 10.2) with a target located 2.0 
cm deep from the imaging surface under perfect uptake conditions.  The 2D contour plot 
represents the subtracted fluorescence intensity data collected in the frequency domain and 
the three isosurface contour plots show three different views of the 3D reconstruction of the 
target.  These plots show a recovered target; however the absorption coefficient values of 
the fluorophores (labeled as V1 in Figure 10.1) are low (close to the initial distribution of 
0.003).  The total distance off between the true and recovered target location was 1.9 cm.  
This large value is mostly attributable to the z-coordinate which represents the depth of the 
target from the imaging surface.  
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Table 10.2  Summary of the experiment parameters for two sample experimental cases including the 
average measured source intensities, the gain setting on the image intensifier, the actual target 
location in cm, the actual target volume, the measured optical property values of the phantom at the 
excitation and emission wavelengths, the target to background ratio (T:B), the recovered target 
location in cm, the recovered !axf values in cm-1, the recovered target volume, the number of 
iterations executed before convergence, and the breakpoint (cutoff value selected on the first 
breakpoint of a histogram plot of the recovered !axf values).  A full table of all experimental cases 
performed is given in Appendix C. 
 
The true z-coordinate was 2 cm, while the recovered z-coordinate was only 0.2 cm (Table 
10.2).  The limited depth recovery is due to the physics of reflectance based measurements 
and has been reported by other research groups in the literature.[23,105,114] 
Figure 10.2 shows the 3D reconstruction result for experimental case #27 (Table 
10.2) with a target located 2.5 cm deep under perfect uptake conditions.  The 2D contour 
plot shows the presence of more artifacts at this deeper target location; however the 
isosurface plots of the 3D reconstructions show that the target was recovered at this depth.  
Similar to the previous result, the recovered absorption coefficient values of the 
fluorophores (labeled as V1 in Figure 10.2) are low (close to the initial distribution of 0.003), 
the reconstructed location was close to the true location in the x-y plane, and the recovered 
depth is shallow compared to the true depth.  The total distance off between the true and 
recovered target location was 2.0 cm, which is mostly attributable to the depth (z-
coordinate). 
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Figure 10.1.  Reconstruction of 2.0 cm deep target within heterogeneous in vitro phantom under 
perfect uptake case.  (A) 2D image collected using hand-held device, (B) 3D view of isosurface plot 
of reconstructed target, (C) three views of reconstructed target (solid open circle represents true 
target location; dotted line encircles recovered target).  The term V1 in the legend represents the scale 
for the recovered !axf values in cm-1. 
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Figure 10.2  Reconstruction of 2.5 cm deep target within heterogeneous in vitro phantom under 
perfect uptake case.  (A) 2D image collected using hand-held device, (B) 3D view of isosurface plot 
of reconstructed target, (C) three views of reconstructed target (solid open circle represents true 
target location; dotted line encircles recovered target).  The term V1 in the legend represents the scale 
for the recovered !axf values in cm-1. 
10.3.2  3D CW Based Reconstructions using Summed Multiple-scan Data 
Figure 10.3 shows an initial result from the heterogeneous in vitro phantom with the target 
located at 2.5 cm depth from the imaging surface under imperfect (100:1) uptake.   
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Figure 10.3  3D reconstruction using summed coregistered data.  (A) 2D contour plot of summed 
images collected using hand-held probe.  (B) Coregistered image of summed data with phantom 
mesh.  (C) Isosurface plot of 3D reconstruction.  (D)  Contour slices showing intensity data of 3D 
reconstruction.  The true target location is indicated by a black circle (A-B) or a dark red sphere (C-
D). 
Figure 10.3A shows the 2D contour plot of fluorescence intensity of the summed image 
with the true target location indicated by the black open circle.  Figure 10.3B shows the 
coregistered image of the summed data.  Figure 10.3C and 10.3D shows the isosurface and 
contour slices of the 3D reconstruction respectively.  From the contour slices it can be seen 
that a high signal is reconstructed in the region where the target is located and the 
reconstructed location is closer to the true depth than previous reconstructions using single-
scan FDPM data.  There is also noise signal reconstructed close to the imaging surface.  This 
is a result of reflectance-based measurements and in future the first centimeter can be cut off 
during deep target imaging.   
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 These preliminary results demonstrated the potential for deeper target recovery upon 
3D fluorescence reconstructions using summed multiscan coregistered images.  In previous 
reconstructions using a single image, the target was recovered shallower than the true depth 
(~ 1 cm deep).  This is due to the use of reflectance based measurements and the same result 
was found by other researchers as well.[23,105,114]  Figure 10.3D shows that the 
reconstructed signal from the 3.0 cm deep target is located at a depth greater than 2 cm.  In 
the case of deep target imaging, the first cm of the image can be cut off to minimize this 
noise.   
 Sample results from four of the experimental cases that were reconstructed are 
presented herein and the details are summarized in Table 10.3.  Figure 10.4 shows the 
reconstruction results (shown as contour slices) from experimental case A where the 8 single 
scans were reconstructed individually.  The true target location is indicated by a grey sphere.  
It can be seen that the 3.0 cm deep target was not recovered upon 3D reconstruction using 
single scans. 
 
Table 10.3  Summary of selected experimental cases for summated image reconstructions. 
Experimental Case 
Target 
Volume 
Target 
Depth T:B 
Target 
(x,y,z) 
Tissue 
Phantom 
A 0.45 cm3 3.0 cm 100:1 (4.5, 2.5, 3.0) 
B 0.23 cm3 2.0 cm 100:1 (6.0, 2.5, 2.0) 
In Vitro C 0.45 cm
3 3.0 cm 1:0 (4.5, 2.5, 3.0) 
D 0.45 cm3 3.5 cm 1:0 (4.5, 2.5, 3.5) 
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Figure 10.4  Individual 3D reconstructions (shown as contour slices) of the 8 single scans from 
experimental case A in Table 10.3.  The grey sphere represents the true target location. 
Figure 10.5 shows results for the first method of CW based summated multiple-scan 
reconstructions where the recovered !axf values from the individual reconstructed scans were 
summed together.  The results show contour slice plots for the four experimental cases 
summarized in Table 10.3.  In each case, the plots in the left column represent the 
summation of four scans from four probe locations (i.e. scans 1,3,5,7) and the plots in the 
right column represent the summation of the repeated set of four scans at the same probe 
locations (i.e. scans 2,4,6,8). 
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Figure 10.5  Results for the first method of CW based summated multiple-scan reconstruction 
(shown as contour slices) where the recovered !axf values from the individual reconstructed scans 
were summed together.  The true target location in each plot is indicated by a grey sphere.  
Plots B1, C1, and C2 in Figure 10.5 show recovered signal close to the true target location 
without surrounding artifacts.  However, there is no discernible target recovered in the other 
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five plots.  Hence, it cannot be concluded that a target is recoverable using this method of 
summation towards 3D tomography. 
 The results from the second reconstruction method where the 2D image containing 
the summed raw data from the entire set of eight scans was used in the 3D reconstruction 
are given in Figure 10.6.  Figure 10.6A shows the result for a 0.45 cm3 target with 1 !M ICG 
placed 3.0 cm deep in a tissue phantom under imperfect uptake (T:B=100:1).  Figure 10.6B 
shows the result for a smaller target (0.23 cm3) with 1 !M ICG placed 2.0 cm deep in a tissue 
phantom under imperfect uptake (T:B=100:1).  Both cases show a region of higher signal 
close to the true target location (indicated by the yellow dotted circles).  In each case, the 
recovered signal is located vertically higher than the true target location, and there are many 
surrounding artifacts.  Figure 10.6C shows the result for a 0.45 cm3 target with 1 !M ICG 
placed 3.0 cm deep in vitro under perfect uptake (T:B=1:0).  Figure 10.6D shows the result 
for a 0.45 cm3 target with 1 !M ICG placed 3.5 cm deep in vitro under perfect uptake 
(T:B=1:0).  In both cases, there is no significant signal recovered close to the true target 
location.   
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Figure 10.6:  Results for 3D reconstructions performed using multiple summated coregistered 
images.  Details of each experimental case are given in Table 10.3.  The yellow dotted circles indicate 
possible recovered signal from the fluorescent targets.  The true target locations are indicated by grey 
spheres circled in black for emphasis. 
Overall, the results did not show that reconstruction of summated images enables 
deeper target recovery.  This could be due to several factors.  The summed images were 
treated as a single image at the initial probe location with six source locations and 165 
detector locations.  An alternate approach would be to incorporate additional source and 
detector positions at the additional probe locations.  However, this would misrepresent the 
experimental procedure by treating the sequentially collected scans as though they were 
collected simultaneously with additional sources and detectors.  A parallel study was 
performed where the individual data sets were reconstructed prior to summation and then 
the recovered !axf values were summed.  However, the results did not show reconstruction 
of the deeper targets upon summation.  This was likely due to the high amount of noise and 
lack of signal at the true target location in each of the individual reconstructed images.  In 
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the future, some filtration techniques might be applied to reduce the noise in the images 
possibly enabling reconstruction of the targets using the summated images. 
10.4  SUMMARY AND CONCLUSION 
Studies were performed to demonstrate 3D tomography in tissue phantoms and in vitro to 
recover a fluorescent target within a heterogeneous scattering background.  FDPM based 
reconstructions were performed in vitro and fluorescent targets were recovered up to a depth 
of 2.5 cm.   CW based multiple-scan reconstructions were performed in tissue phantoms and 
in vitro toward deeper target recovery using two methods: (i) summation of the recovered !axf 
values from the individually reconstructed single scans; (ii) performing 3D reconstruction 
using the summed raw data from the entire set of scans.    The results from the CW based 
multiple-scan reconstructions did not conclusively show the reconstruction of deeper targets 
upon using the summated images.  Possible filtration techniques can be applied in the future 
to reduce the noise in the summed images. 
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CHAPTER 11                                                                                                  
Study IV :  2D Imaging In Vivo  with Healthy Human Subjects in Near-
Real Time towards Target Detection 
11.1  INTRODUCTION 
Thus far, fast 2D imaging, coregistered imaging, and 3D tomography have been 
demonstrated in tissue phantoms and in vitro.  Herein, in vivo studies are performed on 
healthy human subjects to demonstrate the feasibility of using the hand-held device to image 
a fluorescent target with a background of real human breast tissue.[156]   
11.2  MATERIALS AND METHODS 
All human subject studies were approved by the Florida International University 
Institutional Review Board.  Healthy female volunteers age 21 and above were recruited for 
the studies.  A spherical fluorescent target was used to simulate a tumor (the same target 
used in phantom and in vitro studies) and was placed underneath the flap of the breast tissue 
(i.e. between breast tissue and chest wall, underneath the tissue) as shown in Figure 11.1.  
Table 11.1 gives a summary of the in vivo experimental cases performed.   
 
Figure 11.1  Schematic showing the location of an absorbing target placed superficially underneath 
the breast tissue and the location of the probe during imaging. 
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Table 11.1  Summary of experimental cases performed for in vivo fast 2D imaging studies. 
 
In the first study, a 0.23 cc sphere with 1 !M ICG was placed under the right breast 
in the 4 o’clock position.  The flat probe face was placed against the breast tissue (centered 
at the 6 o’clock location) with gentle compression to achieve full contact with the tissue and 
a near-real time CW fluorescent intensity image was acquired (around the target region).  The
depth of the target within the tissue was approximately 2.5 cm as measured with a Vernier 
caliper.  The experiment set-up for in vivo human subject studies is shown in Figure 11.1 
(with mannequin for demonstration only). 
 
Figure 11.2  Experimental set-up for in vivo studies with human subject (mannequin shown here for 
demonstration only).  The hand-held probe is placed in full contact with the breast tissue.  The raw 
image and the 2D contour plot are displayed on the computer screen. 
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 A second study was performed using a single target with the probe in the maximum 
curved position (i.e. 45° curvature of the two side plates of the 3-plate based probe face).  
The images collected with the probe in the curved position possibly include trans-illuminated 
measurements in addition to reflectance based measurements.  This study was performed to 
demonstrate the feasibility of using the probe in its curved position, such that it can contour 
along the tissue and also provide fluorescent images that can aid in target detection.   Herein, 
a 0.45 cc fluorescent target containing 1 !M ICG was placed under the right breast in the 8 
o’clock position.  A real-time as well as fast (subtracted) image of fluorescence intensity was 
acquired.    
 A third study was performed to demonstrate the feasibility of imaging multiple 
targets within real human breast tissue.  Two targets were placed under the fold of the left 
breast tissue, with a 0.23 cc target at the 6 o’clock position, and a 0.45 cc target was placed at 
the eight o’clock position of the same breast.  A real-time as well as fast (subtracted) image 
of fluorescence intensity was acquired by applying gentle compression on the left breast 
tissue.   
 During the studies, the probe was placed visually over the breast tissue and centered 
with respect to the nipple region.  For future in vivo studies with human subjects, a more 
systematic protocol is currently being developed.  The method uses a clear plastic sheet with 
holes placed on a grid at premeasured locations.  The plastic will be placed over the tissue 
and a pen will be used to mark the probe locations on the tissue.  The grid is shown in figure 
11.2.   
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Figure 11.3  Systematic grid developed for future imaging studies.  The positions are measured with 
reference to the center (nipple) region which is indicated by the red dotted circle.   
The positions are measured and numbered from the nipple region and the number of 
locations used will be determined by the volume of tissue to be imaged.  For the first set of 
images, the probe will be centered over the marks in the middle region with the bottom of 
the probe aligned with each mark.  For the second set the probe will be centered over the 
marks in the outer region, and for the third set the probe will be centered over the marks in 
the inner region.  The positions are labeled with U or L to indicate “upper” and “lower” 
region, respectively, and O, M, or I to indicate “outer”, “middle”, or “inner” region, 
respectively.  The entire set will be repeated on the other breast at the corresponding 
locations.  For the studies described here, the probe location in all cases roughly corresponds 
to the LM4 location in Figure 11.2. 
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11.3  RESULTS 
 
 Figure 30 shows the fast 2D subtracted images of fluorescence intensity obtained in 
vivo (from a normal human subject using a simulated target) with the probe in the flat 
position (Figure 30A) and in the curved position (Figure 30B).  These subtracted image 
results demonstrate the feasibility of fast 2D surface imaging and 2D target localization in a 
clinical environment.  The real-time (non-subtracted) images of fluorescence intensity were 
unable to differentiate the target from the heterogeneous background, and hence only the 
fast 2D subtracted images are shown in Figure 11.3. 
 
Figure 11.4  Fast subtracted images of fluorescence intensity obtained as 2D surface contour 
plots, acquired in vivo from a human subject using a spherical fluorescent target, for two 
experimental cases: (A) the probe was in the flat position and a 0.23 cc target was placed at the 4 
o’clock position, and (B) the probe was in the curved position and a 0.45 cc target was placed at 
8 o’clock position.  The images acquired using the probe in the curved position are illustrated as 
projected as a flat 2D image, in order to be consistent with the images presented in case (A) (i.e. 
using the probe in flat position).  
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Figure 11.5  Fast subtracted image of fluorescence intensity obtained as 2D surface contour plot, 
acquired in vivo from a human subject using two spherical fluorescent targets (0.23 and 0.45cc). 
 
 
 The 2D subtracted images of fluorescent intensity from multiple simulated targets in 
a human subject are shown in Figure 11.4.  The 0.23 cc target is detected in the center of the 
image and the 0.45 cc target is detected towards the left side in the image, which are very 
close to the true locations of these targets.  This study demonstrates the potential to image 
and localize multiple fluorescent targets (of different sizes) within human breast tissue.    
11.4  DISCUSSION AND CONCLUSION 
The fluorescence imaging studies described here demonstrate for the first time the 
acquisition of fast 2D surface images (in < 5 sec) of a fluorescent target in vivo using a hand-
held based optical imaging device.  The subtracted images have a potential to clearly 
differentiate target(s) from the background of human breast tissue at a depth of ~2.5 cm 
either with the probe in the flat position using gentle compression or with the probe in the 
curved position to contour around the tissue curvature.  The results demonstrate the 
potential to translate the technology towards on-site breast imaging in a clinical environment.  
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CHAPTER 12                                                                                                   
Study V: Coregistered Imaging In Vivo  with Healthy Subjects 
12.1  INTRODUCTION 
In order to perform 3D tomography in complex geometries such as human breast tissues, it 
is necessary to accurately coregister the image to the tissue geometry.  In the phantom 
studies described above, the simple cubical geometries were generated manually using 
Gambit software.  In the case of human subjects, the geometry shape and volume varies for 
each subject and thus must be acquired individually.  This chapter describes the process of 
acquiring the breast tissue geometry for each human subject, generating the surface mesh of 
the tissue geometry, and demonstrating coregistered imaging on normal human subjects.  
12.2  MATERIALS AND METHODS 
12.2.1  Initial coregistered imaging approach (motorized 3D scanner & sitting 
position) 
 
A commercially available hand-held 3D scanner (Polhemus, Inc.) was employed to acquire 
the breast tissue geometry.  Use of the scanner on human subjects was approved by the FIU 
Institutional Review Board.  A motorized system was implemented with scanner to 
automatically acquire the scan without requiring an operator to hold the scanner.  This 
method was designed to enable the scanning procedure to be independent of the operator as 
well as to allow more privacy for the subject since the scanner would be operated by 
computer from outside a curtained room.  The automated scanning system set-up is shown 
in Figure 12.1A where the subject was seated in an upright position during the scan 
(mannequin is shown for demonstration only).  Each scan was composed of a series of four 
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sweeps of the scanner which would cover both sides of the breast tissue as well as part of 
the chest wall and ribcage area.  The acquired geometry was displayed by the  
 
Figure 12.1  Initial set-up for acquiring 3D breast tissue geometry for coregistered imaging. 
Polhemus software (Figure 12.1B) and then exported as a .MAT file and discretized using 
MATLAB software developed in house to generate the surface mesh geometry to be loaded 
into the coregistration software (Figure12.1C).  The automated coregistered imaging process 
using MATLAB/LabVIEW software developed in house was detailed in Chapter 6. 
12.2.2  Validation of coregistered imaging in human subjects  
Automated coregistered imaging has been demonstrated in phantoms which have rigid 
structure and simple geometry.  Translation of this procedure to human tissue is a much 
more complex case since human tissue is not rigid and has irregular shapes.  Prior to in vivo 
studies on human subjects, it is necessary to validate the automated coregistered imaging 
process on actual human tissue. 
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Coregistered imaging in human breast tissue is validated by the following procedure.  
In step one the breast tissue geometry is acquired by using a 3D scanner to scan the breast 
tissue (Figure 12.2A).  In step two, the 3D geometry is transformed into a discretized surface 
mesh (Figure 12.2B).  In step three, an initial reference point is automatically inserted into 
the mesh at the center region of the tissue which is marked correspondingly at the same 
location on the subject (Figure 12.2C).  Four additional reference points are generated 
automatically and the x-y-z positions are given quantitatively relative to the initial reference 
point (Figure 12.2D).   
 
Figure 12.2  Automated input of reference points within any 3D scanned geometry. 
In step four, the locations of the additional reference points are measured on the subject and 
marked with surgical tape (Figure 12.3A).  In step five the probe is positioned such that the 
origin is located at the initial reference point on the subject (Figure 12.3B-C) and the 
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coregistration software is initialized (Figure 12.3D).  In step six, the probe is moved to other 
positions marked by the additional reference points and the coordinates of the probe 
location given in the tracking software are compared to the known coordinates of the 
reference points marked on the subject to validate that the image is coregistered onto the 
true location of the tissue.   
 
Figure 12.3  Placement of reference points on the subject and initialization of coregistration 
software. 
In order to quantitatively determine the accuracy of the tracked position and 
coregistered image compared to the true location on the tissue, the probe was placed at the 
four different reference points of known coordinates and ten measured values were recorded 
from the tracking software at each position.  The average, standard deviation, and 
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discrepancy of these measured values for each position are given in Table 12.1.  The average 
measured value and standard deviation represent the precision of the tracking software.   
 
Table 12.1  Average and standard deviation of x,y,z coordinates as displayed in tracking software and 
total distance off  between true and measured values.  Values are in units of centimeters and each 
measured value represents an average of 10 measurements while probe was at each of the 4 
positions. 
 
 
It can be seen from the standard deviation of the measured values that the tracked probe 
position fluctuates between 0.1-0.4 cm.  The average total distance off represents the 
accuracy of the tracked position compared to the true location.  The average total distance 
off is 0.99 cm.  The deviation and discrepancy of the measured values can be attributed to 
several factors:  (i) The inherent fluctuation within the tracking instrumentation;  (ii) Slight 
movements of the operator while holding the hand-held probe in position;  (iii) Small errors 
in the measuring and placement of the physical reference points marked on the human 
subject.  In future, efforts will be made to overcome these limitations and improve the 
accuracy of the tracking coordinates. 
 A study was performed with a normal human subject to demonstrate self-
coregistered imaging on actual human tissue.  Figure 12.4 shows the front panel for the 
coregistration software and the image of the meshed tissue geometry with the reference 
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points (probe position is not shown here).  Once the reference points are added to the mesh, 
a text file is generated and saved which contains the x,y,z coordinates of the reference points 
and the relative distance of each reference point from the initial reference point which is 
used to place the markers at the corresponding location on the subject. 
 
 
Figure 12.4  Screen capture of coregistration software showing meshed geometry of breast tissue 
with reference points (probe location inactive in this view). 
 
 The probe was placed at the initial reference point location and the coregistration 
software was initialized.  Figure 12.5 shows the tracked probe position at the initial point 
(the origin) and at two additional reference points as it was moved to the corresponding 
Distance in cm of each 
r fer ce point from 
initial reference point 
Image of meshed 
geometry with 
reference points 
xyz locations of 
reference points 
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positions marked on the subject.  Images are shown in profile view from the subject’s left 
side. 
 
 
Figure 12.5  Images from coregistration showing probe position tracked in real-time at different 
reference locations. 
 
 In order to perform coregistered imaging, a 0.45 cc spherical target filled with 2 !M 
ICG was placed underneath the flap of the breast tissue (as described in section 11.2) in the 
center.  The probe was placed in full contact with the tissue without applying pressure and 
an image was collected.  The target was then removed while keeping the probe in the same 
position and a background image was collected.  The background image was subtracted from 
the target image and the subtracted image was coregistered to the meshed geometry of the 
breast tissue at the probe location.  The resulting coregistered image is shown in Figure 12.6.   
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Figure 12.6  Coregistered image of simulated target behind human breast tissue.  White dotted line 
represents the probe position. 
 
 
 This initial study demonstrates the ability to track and coregister an image to the 
location within the tissue geometry.  Some limitations include slight movements of the 
subject which are not measured or accounted for in the tracking software and could affect 
the accuracy of the coregistered position, and slight conformation of the tissue upon contact 
by the hand-held probe face.  These limitations were addressed by modifying the imaging 
set-up as described in the next section. 
12.2.3.  Modification of coregistered imaging in v ivo  to improve accuracy (hand-held 
3D scanning and imaging in supine position) 
 
The initial set-up for coregistered imaging in vivo with human subjects had several limitations 
which resulted in inaccuracy of tracking and coregistration at the true probe location.  The 
following limitations and proposed solutions were presented: 
(1)  Limitation #1:  Movement of subject during imaging process which is not 
accounted for in coregistration software.   
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Proposed Solution:  A chair will be acquired for the human studies, which has the 
ability to recline to a 45-90 degree angle to prevent subject from leaning.  Once 
positioned in the chair in a relaxed posture, the subject will be scanned with the 3D 
scanner and then they will remain in same position to be imaged with the hand-held 
probe.                                                                                              
(2) Limitation #2:  Deformation of the breast tissue upon contact with the hand-held 
probe causing the geometry of the tissue to be changed from the 3D scanned 
geometry. 
Proposed Solution:  When the subject is lying at a 45-90 degree reclined positioned, 
the breast tissue will naturally flatten against the chest wall.  Additionally, surgical 
tape will be used to tape the breast tissue in a flattened conformation similar to the 
procedure used during ultrasound-guided biopsy.  This will enable the probe to be in 
contact with the tissue with minimal deformation since the tissue will remain 
generally flat. 
(3)  Limitation #3:  Operator error in measurement and placement of markers on the 
subject at the reference points. 
Proposed Solution:  An optically clear plastic covering can be placed over the breast 
tissue.  The coronal-view coordinates of the reference points can be more accurately 
marked on the plastic before it is placed over the tissue surface at the appropriate 
position. 
The following steps were implemented in the modified experimental study set-up in 
order to address the limitations listed above: 
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Solution for Limitation #1:  A massage chair capable of reclining 45-90º with arm rests was 
acquired for the imaging studies (Figure 12.7).  The subjects rested in supine position on the 
chair with the back reclined at 45º and arms resting at the sides or on the armrests.  This 
position was chosen such that it would be reclined enough to minimize movement of the 
subject (as opposed to the upright position with no armrests in the initial set-up which 
allowed movement of the subject) as well as maintain line-of-sight between the probe and 
the tracker which would be inhibited if the chair was reclined to greater angles.  In order to 
acquire the 3D geometry with the subject in the reclined position, the Fastscan was taken 
back as a hand-held scanner and used to scan the tissue by hand (the motorized system will 
be used in future applications described in Chapter 16).   
 
Figure 12.7  Modified human subject imaging set-up.  Subject lies supine in recliner chair (45º) 
during acquisition of tissue geometry with 3D scanner and imaging using handheld imager. 
Solution for Limitation #2:  The reclined position of the subject also helped to overcome 
limitation #2 since the position caused the breast tissue to flatten against the chest wall 
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resulting in minimal conformation of the tissue by the probe during imaging.  However, the 
amount of tissue curvature and deformation depended on the volume and density of the 
tissue, thus the amount of deformation varied among subjects.  (This issue will be addressed 
in future by use of a custom-built garment described in Chapter 16). 
Solution for Limitation #3:  For the initial studies with normal human subjects, the 
subjects were recruited by advertisement and hence the size and shape of the tissues imaged 
varied greatly.  Hence, it was not feasible at that stage to use a prepared plastic with the 
reference points marked.  Instead, a more accurate approach of choosing reference points 
was implemented in which the center (nipple) was used as the initial reference point and 
other reference points were measured and marked at specific distances from the center using 
the ‘clock’ notation.  This method treats the breast as the face of a clock and locations are 
determined by their respective location on the clock (Figure 12.8 left) and the distance from 
the nipple is measured in centimeters (Figure 12.8 right).  This method is typically used in 
the clinical setting during breast ultrasound imaging. 
 
Figure 12.8  ‘Clock’ method for referencing locations on the breast tissue.  The relative section of 
the tissue is determined by the position on the ‘clock’ (shown on left side) and the distance from the 
nipple is measured in centimeters (shown on right side).  
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The imaging process using the modified set-up is shown in Figure 12.9, where the 
imaging room is closed off from the instrumentation room by a curtain and only the probe is 
visible in the room.  The probe was placed against the breast tissue while the location was 
recorded by the acoustic tracker and the images were automatically coregistered at the probe 
location relative to the tissue geometry.  The resulting images were immediately displayed on 
a monitor in the imaging room that was linked to the computer operated from the 
instrumentation room. 
 
Figure 12.9  Modified imaging set-up.  The subject lies in supine position in recliner chair while 
breast tissue is imaged using hand-held optical imager.  Mannequin shown for demonstration only. 
12.2.4  Experimental Study I: Automated Coregistered Imaging using Initial Imaging 
Set-up 
Experiments were performed using the initial coregistered imaging approach where 
the subject was seated upright at a 90º angle.  A 0.45 cm3 spherical target filled with 1 
!M ICG was placed underneath the flap of the breast tissue as illustrated in Figure 
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11.1.  Images were collected with the target at 3 different locations corresponding to 
the 4 o’clock, 6 o’clock, and 8 o’clock positions.  In each case, the probe was centered 
over the target location and placed in full contact with the breast tissue.  CW images 
were collected with the target in place and background images were collected (with 
the target removed) for subtraction based post-processing.  The post-processed 
images were automatically coregistered during live imaging at the probe location with 
respect to the tissue. 
12.2.4  Experimental Study II Automated Coregistered Imaging using the Modified 
Imaging Set-up  
 
Experimental studies were performed with healthy human subjects using the 
modified coregistered imaging set-up.  The subject lay in the supine position in the 
recliner chair at a 45º angle.  The chest region including both breast tissues and the 
ribcage was scanned by hand using the 3D scanner.  Figure 12.10 shows the 3D scanned 
geometry of a normal human subject using the modified set-up where the subject was lying 
in supine position in a recliner chair at a 45º angle.  The reclined position caused the tissue to 
flatten against the ribcage in order to minimize deformation of the tissue during imaging.  A 
default image was used in this study since the purpose of the study was to demonstrate 
coregistered imaging using the modified approach and not to detect a target.  The probe was 
placed in contact with the breast tissue and the default image was coregistered to the tissue 
geometry at the probe location. 
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Figure 12.10  Geometry acquired using the modified imaging set-up with a healthy subject lying 
supine in recliner chair with 45º angle.  The white dotted line represents the probe location during 
imaging. (A) Frontal view. (B) Side view. 
12.2.5  Experimental Study III Manual Coregistered Imaging using the Modified 
Imaging Set-up
Absorption based coregistered imaging studies were performed using a target 
containing India ink as an absorbing contrast agent.  Manual coregistered imaging was 
performed since the instability of the acoustic based tracker had increased in time to 
the point where it was no longer usable for coregistration purposes.  For these studies, 
the probe position was measured on the breast tissue and marked using surgical tape.  The 
image was then manually coregistered at the measured position using post-processing 
coregistration software.  Two experiments were performed using 0.45 cm3 spherical targets 
filled with different concentrations of India ink (0.08% and 0.02%) placed underneath the 
flap of the breast tissue at the 6 o’clock location.  
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12.3.  RESULTS 
12.3.1  Experimental Study I: Automated Coregistered Imaging using Initial Imaging 
Set-up 
 
Figure 12.11 shows results for coregistered imaging studies with healthy subjects using the 
initial set-up.  Figure 12.11A shows the position of the probe and the discretized geometry 
relative to the subject.  Figure 12.11B shows the resulting coregistered image for case #1 
where a 0.45 cm3 target was placed at the 6 o’clock position.  A zoomed image of the same 
result is shown in Figure 12.11C.  Figures 12.11D and 12.11E show zoomed images of the 
results for cases #2 (0.45 cm3 target at the 8 o’clock position) and #3 (0.23 cm3 target at the 
4 o’clock position) respectively.  In each case, the probe was placed such that the strongest 
source was close to the target location and subtraction based postprocessing was applied to 
eliminate excitation leakage (as described in Section 6.4 above).  The results show that a 
0.23-0.45 cm3 fluorescent target was detected through ~2.5 cm of human breast tissue and 
coregistered to the appropriate location on the tissue geometry. 
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Figure 12.11  Coregistered images of fluorescence intensity data collected from a normal subject with 
an ICG-filled target using the initial set-up (subject seated in upright position).  (A) Location of 
probe and image relative to the subject.  (B) Case #1 image:  0.45 cm3 target at the 6 o’clock position.  
(C) Zoomed image of Case #1.  (D) Case #2 image:  0.45 cm3 target at the 4 o’clock position.  (E) 
Case #3 image: 0.23 cm3 target at the 8 o’clock position.  All targets contain 1 !M indocyanine green. 
12.3.2  Experimental Study II Automated Coregistered Imaging using the Modified 
Imaging Set-up 
Figure 12.12 shows automated coregistered images from a normal human subject 
using the modified imaging set-up with the acoustic tracker.  The geometry was rotated to a 
45º angle over the y-axis in the coregistration software to correspond to the 45º reclined 
position of the subject.  The probe location was coregistered to the tissue at two different 
locations: the first location was centered over the breast tissue with the bottom of the probe 
positioned 2 cm beneath the nipple region (Figure 12.12A-C) and the second location was 
above the breast in the chest wall region with the bottom of the probe positioned 3 cm 
above the nipple region (Figure 12.12D-F).  
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Figure 12.12  Automated coregistered images in a healthy subject (no target) using the modified 
imaging set-up.  (A) Probe position #1.  (B) Frontal view of coregistered image at probe position #1.  
(C) Side view of coregistered image at probe position #1.  (D) Probe position #2.  (E) Frontal view 
of coregistered image at probe position #2.  (F) Side view of coregistered image at probe position 
#2.  
12.3.3  Experimental Study III Manual Coregistered Imaging using the Modified 
Imaging Set-up 
Figure 12.13 shows results from absorption-based studies in a normal subject with a 0.45 
cm3 target filled with 0.08% India ink located at the 6 o’ clock position.    Figure 12.13A 
shows the location of the probe relative to the subject.  Figure 12.13B shows the probe 
location placed manually in the post-process coregistration software, and Figure 12.13C 
shows the resulting coregistered image.  It can be seen that the target is detected as a lower 
intensity (blue) signal indicating higher absorption at the location of the target.  A 
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background image was also collected (without target) and subtracted to eliminate 
background noise. 
 
Figure 12.13  Manually coregistered images from a healthy subject with 0.45 cm3 target with 
0.08% India ink placed under the breast tissue at the 6 o’clock position. 
Figure 12.14 shows the results for the case of the lower concentration target (0.02% India 
ink) placed at the 6 o’ clock position.  Figure 12.14A shows the location of the probe relative 
to the subject.  Figure 12.14B shows the probe location placed manually in the post-process 
coregistration software, and Figure 12.14C shows the resulting coregistered image.  The 
resulting contrast is lower due to the lower concentration of the absorbing agent, but the 
lower signal (blue) from the target can be seen at the target location in the 2D image (Figure 
12.14B) and the coregistered image (Figure 12.14C). 
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Figure 12.14  Manually coregistered images from a healthy subject with 0.45 cm3 target with 0.02% 
India ink placed under the breast tissue at the 6 o’clock position. 
12.4  DISCUSSION 
The modified imaging set-up was designed to overcome the limitations of the initial set-
up and improve the accuracy of automated coregistered imaging using the acoustic 
tracker.  However, during implementation of the modified set-up, there were some 
difficulties encountered.  The acoustic based tracker operates most effectively when the 
transmitter is placed level with the floor and the receiver is parallel to it.  When the 
subject was reclined at a 45º angle, the tracker lost line of sight on many areas of the 
tissue.  To overcome this issue, the transmitter was mounted at a 45º angle above the 
subject’s head to enable it to be parallel with the receiver on the probe as it was placed on 
the breast tissue.  However, with this set-up, the tracker would lose line of sight when the 
receiver was blocked by the subject’s head.  In addition, the tracker experienced 
significant fluctuations and losing/gaining of line-of-sight even when the probe was held 
at a constant location.  This demonstrates that the accuracy of the tracker is poor even 
apart from any error on the part of the operator or movement of the subject or tissue.  
  
 139 
Hence, it was determined that an alternate method of automated tracking must be 
pursued.  We are currently developing an optical based automated tracking method that 
will have much greater accuracy than the acoustic tracker (described in Chapter 16).  
Once the alternate tracking method is implemented, quantitative studies will be 
performed to determine the improvement in the accuracy of coregistered imaging in 
human subjects due to improvements in the imaging set-up and stability of the tracker. 
 Images can be manually coregistered to the tissue geometry if the probe location 
is accurately measured relative to the tissue.  The MATLAB software (developed in-
house) that was used to generate the discretized mesh of the scanned geometry was 
modified to automatically find the initial reference point (at the nipple region) and lock it 
to the origin in the coregsitration software.  The imaging locations were measured in 
centimeters and marked on the tissue for accurate positioning of the probe with reference 
to the origin (nipple).  The images were collected with the hand-held imager at the 
predetermined locations and manually coregistered using post-process coregistration 
software.  This method is valid as long as the tissue is relatively flat against the chest wall 
making the imaging surface close to planar.  For tissues with greater curvature, it would 
be more difficult to manually coregister with accuracy due to rotation of the probe with 
respect to the origin.  For efficient real-time tracking and imaging, a more accurate 
tracking system will be implemented. 
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12.5  SUMMARY AND CONCLUSION 
An automated coregistered imaging approach was implemented and validated in vivo on 
human breast tissue.  A 3D scanner was used to acquire the breast tissue geometry from 
each individual subject and an acoustic based tracking system was used to track the probe 
location in real-time.  The initial imaging set-up had several limitations which led to 
inaccuracy in the coregistered imaging.  The set-up was modified to overcome these 
limitations; however, the tracking system was unstable.  Results demonstrate the ability 
to detect an absorbing target through breast tissue of a healthy human subject and images 
were manually coregistered at the measured probe locations.  These studies demonstrate 
that manual coregistered imaging can be performed in human subjects under simple 
conditions and automated coregistered imaging is feasible.  The coregistered images will 
be used to perform 3D tomography in human breast tissue as described in the following 
chapter. 
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CHAPTER 13                                                                                                  
Study VI:  3D Tomography in v ivo  with a Healthy Human Subject 
13.1  INTRODUCTION 
Previous tomography studies performed using our hand-held optical imager involved 
phantoms with simple geometries and structured 3D mesh, and the experimental image data 
was manually coregistered at the known probe location with respect to the phantom.  The 
major challenge in performing 3D tomography in human tissue as opposed to simple 
phantoms is to generate the discretized volume geometry (or mesh) for the human breast 
tissue.  For simple cubicle phantoms, the geometry and mesh were generated within a single 
software (Gambit) and the same mesh was used for each phantom reconstruction.  In the 
case of human subject studies, the various breast tissue geometries must be acquired for each 
subject and discretized into tetrahedral volume mesh.  This chapter describes the procedure 
developed herein for acquiring a tetrahedral volume mesh of the various breast tissues of 
different human subjects and extracting the experimental information corresponding to each 
coregistered data set, which is needed to input into the reconstruction algorithm to perform 
3D reconstructions. 3D fluorescence tomography is performed using a coregistered image 
from a healthy human subject with a superficially placed target.  The results presented herein 
demonstrate for the first time the feasibility of performing 3D tomography in human breast 
tissue in vivo using a hand-held optical imager. 
13.2  MATERIALS AND METHODS 
13.2.1  Procedure for 3D Mesh Acquisition and Reconstruction In Vivo 
A commercially available 3D surface scanner was employed to scan the breast tissue of each 
subject.  The subject was seated upright in a 90 degree position and the motorized system 
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was used to scan both sides of the breast tissue, chestwall, and ribcage.  The resulting surface 
scan is shown in Figure 13.1 (left).  The scanner software was used to cut the surface 
geometry to extract only the left breast in order to reduce computation time when 
performing the reconstruction.  
 
Figure 13.1  Scanned surface geometry of breast tissue.  The imaged section was cut from the full 
geometry and used in the reconstruction. 
The acquired surface scan was then imported into a software (GiD) and a volume was 
generated from the surface scan.  Meshing softwares are typically designed such that a 
geometry is both generated and meshed within that same software.  However, our 
application presented a unique complication in that we required an externally acquired 
complex geometry to be imported into the software and used to generate a 3D volume and 
mesh.  After many trials and much troubleshooting it was determined that the method to 
acquire the mesh was to import the scanned surface into GiD and use the software to 
generate a volume.  The volume generated in the GiD software is shown in Figure 13.2.  The 
generated volume was then imported into Gambit which was used to generate the 
tetrahedral volume mesh.   
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Figure 13.2  Volume geometry of scanned breast tissue. 
After acquiring the tetrahedral volume mesh from Gambit, there were several steps 
required to prepare the mesh for importing into the reconstruction algorithm.  The first step 
was to determine the coordinates of the optical data image (collected by the hand-held 
device) with respect to the volume mesh (since the original coregistered image used only a 
surface mesh to reduce the imaging time and the coordinates are different in the volume 
mesh generated for reconstruction).  A post-processing version of the coregistered imaging 
software was used to coregister the image to the new volume mesh using the positional 
information stored from the original surface coregistered image acquired during live imaging.  
A code was developed in MATLAB to then extract the coordinates and intensity data for use 
in the reconstruction algorithm.   
Another piece needed for the reconstruction algorithm was the coordinates of the 
sources and detectors relative to the volume mesh.  In the case of cubical phantoms, the 
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coordinates on the simple geometry were manually entered since the 0.5 cm spaced grid of 
detectors aligned perfectly with the 0.25 cm spaced grid of the cubical mesh.  In the case of 
human breast tissue, the mesh is unstructured and the probe location is not perfectly aligned 
with the mesh coordinates.  Hence, a method was developed to determine the source and 
detector coordinates of any random probe position on the various unstructured volume 
meshes.  A grid was generated corresponding to the source and detector locations of the 
hand-held probe image.  The source locations in the grid were assigned a high value and the 
detector locations were assigned a low value.  The grid was then coregistered to the volume 
mesh using the same positional information from the original surface coregistered image.  A 
code was developed in MATLAB to extract the coordinate locations of the sources and 
detectors from the volume coregistered image according to the relative intensity values.   
 Since at this point the coordinates now correspond to the coordinate system in the 
coregistration software (which is different from the original coordinate system assigned by 
the Gambit software), the volume mesh from the coregistration software was exported to be 
used in the reconstruction algorithm.  However, a complication existed in the mesh exported 
from the coregistration software.  The coregistration software assigned nodes and elements 
of the mesh using a different method than the Gambit software.  In the Gambit software, 
the nodes are assigned first and then connected to form the elements, resulting in more 
elements than nodes.  The coregistration software (using the MATLAB ‘patch’ function) 
first generates the elements and then assigns the node numbers individually within each 
element (Figure 13.3).  Hence, adjacent elements assign multiple numbers to the same node.   
This resulted in a very large number of nodes compared to elements which greatly and 
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unnecessarily increases the computational time, and the mesh was incompatible with the 
reconstruction algorithm.   
 
Figure 13.3  Illustration of the two methods of assigning node numbers.  (A) The mesh generated by 
MATLAB and exported from the coregistration software assigns the elements first and then gives 
each node in the element number assignments independent of the adjacent elements resulting in 
multiple numbers assigned to the same node.  (B) The preferred method is where the node numbers 
are assigned first and then elements are constructed among those nodes such that each node is 
shared by multiple elements and only assigned a single number resulting in much fewer nodes than 
elements.   
To overcome this complication, a code was developed in MATLAB to eliminate the 
repeated nodes and reassign the node numbers within the elements correspondingly.  
Additionally, a code was generated in MATLAB to reassign the node numbers 
corresponding to the source and detector locations and the image intensity data according to 
the corrected numbers.  The final mesh and all the extracted information were then 
imported into the reconstruction algorithm to perform 3D tomography. 
The entire procedure developed herein for acquiring the tetrahedral volume mesh, extracting 
the experimental information, and performing 3D tomography in vivo in order to reconstruct 
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a target within the breast tissue geometry of a human subject is outlined in the following ten 
major steps:   
Step 1:  Acquire the coregistered image of optical intensity data from the breast tissue 
(detailed in Chapter 12 above).   
Step 2:  Use the 3D surface geometry from the Fastscan to generate a 3D volume.  
The 3D surface geometry that was scanned from the breast tissue was imported in IGES 
format into the GiD software which was used to generate a 3D volume from the surface.  
Figure 13.1 shows the volume geometry generated in the GiD software.   
Step 3:  Generate a 3D tetrahedral volume mesh and corresponding triangular surface 
(or boundary) mesh for the volume breast geometry.  The 3D volume from the GiD 
software was loaded into Gambit software which was used to generate the unstructured 
triangular and tetrahedral mesh.   
Step 4:  Adjust the coordinates of the Gambit mesh to correspond to the coregistered 
image.  The coordinate system of the mesh generated in Gambit is independent of the 
coordinate system of the coregistered image.  The Gambit mesh was imported into the post-
process coregistration software and locked to the location of the geometry during imaging.  
The positional information preserved in the coregistered data that was acquired during live 
imaging was used to coregister the image at the same location in the Gambit mesh.   
Step 5:  Determine the nodes and coordinates of the breast mesh that correspond to 
the source and detector positions in the coregistered probe location.  The positional 
information of the coregistered probe location was used to find the closest nodes in the 
unstructured breast mesh to each source and detector in the probe, and the coordinates of 
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those nodes were assigned as the coordinates of the sources and detectors.  The procedure 
developed for performing this step ensures that the source and detector positions assigned 
to the mesh correspond to the data collected with the probe and coregistered to the tissue 
during live imaging.    
Step 6:  Eliminate duplicate nodes from the breast mesh (as exported from the 
coregistration software) and assign the adjusted node numbers appropriately to each 
element.   
Step 7:  Convert text files and source/detector positional information into data files 
that will be used in the reconstruction code.  This step must be performed for each new 
mesh geometry and each different probe position within the same geometry.   
Step 8:  Acquire the intensity data for each detector position in the 3D breast mesh 
from the coregistered image data.  A code was written in MATLAB to extract the 
intensity data from the coregistered mesh at the detector nodes located in Step 5 and 6 and 
generate a data file containing the coordinates of the detector nodes and the corresponding 
intensity values from the breast data.  
Step 9:  Use the intensity data acquired from Step 8 to generate the data files used in 
the AEKF algorithm.  These data files contain the AC, DC, phase, and modulation depth 
information (or DC only for CW data) along with the optical properties of the background 
tissue.  In this case, average optical property values of human breast tissue acquired from the 
literature [134] were used in the reconstruction.   
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Step 10:  Use the AEKF based algorithm to reconstruct the fluorescent/absorption 
intensity values within the 3D discretized geometry of the breast tissue.  The AEKF 
algorithm is detailed in Chapter 7. 
13.2.2  Fluorescence Tomography in a Healthy Human Subject 
A 3D reconstruction was performed using data acquired from a healthy human subject with 
a 0.45 cm3 spherical target containing 1 !M ICG placed underneath the flap of the breast 
tissue at the 6 o’clock position (Case #1 in Section 12.3).  The data was acquired by 
automated self-coregistered imaging with the acoustic tracker using the initial imaging set-up 
where the subject sat in a vertical upright position and the geometry was acquired by the 
motorized 3D scanning technique.  The geometry consisted of both sides of the breast tissue 
and part of the chest wall and ribcage.  In order to reduce computational time, the geometry 
was cut to include only the breast tissue region in the vicinity where the data was acquired 
with the optical imager (as described in Section 13.2.1).  The reduced geometry was manually 
placed at the appropriate location within the coordinate system using the post-process 
coregistration software.  The ten steps described in Section 13.2.1 were executed in order to 
acquire the 3D meshed geometry and perform 3D tomography in human breast tissue.  The 
initial p-value in the AEKF reconstruction algorithm was set to 0.01.  The input optical 
property values were 0.05 cm-1 for !ax and !am, and 8.0 cm
-1 for !sx’ and !sm’ (average values 
of breast tissue optical properties obtained from the literature [134].  The initial guess for the 
optical property distribution (in this case, !axf) was uniformly set to 0.003 cm
-1.  The 
modulation frequency (�) was set to zero for CW based reconstruction and only the real 
part of the equations were used. 
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13.3  RESULTS 
The experimental data used for the reconstruction is shown in Figure 13.4, where the yellow 
dashed line shows the probe location with respect to the disctretized tissue geometry.  The 
fluorescent signal from the target was detected close to the target location (6 o’clock 
position).   
 
Figure 13.4:  Automated coregistered image of a fluorescent target placed beneath the breast tissue 
in a normal subject which was used to perform the 3D reconstruction. 
Figure 13.5 shows the experimental result of the reconstruction plotted in Tecplot.  Figure 
13.5A shows the 3D tetrahedral unstructured mesh of the breast tissue geometry and Figure 
13.5B shows the recovered fluorescence intensity as a series of slices in the x-plane.  The 
slices are plotted in profile view to show their location within the tissue geometry.  
Individual detailed slices are shown in frontal view in Figure 13.6.   
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Figure 13.5:  (A) Plot of the 3D tetrahedral unstructured mesh used in the reconstruction.  (B) Side 
view of contour slices in the x-plane.  
The coronal slices in Figure 13.6 begin at the tissue surface close to the central (nipple) 
region and progress depth-wise toward the chest wall.  The initial slices at depths below 1.0 
cm (slices 1-3) show signal from the 2D target location although the depth of the signal is 
less than the true target depth (~2.5 cm).  At a depth of 1.0 cm and greater (slices 4-12), 
additional signal appears to the left side of the breast tissue away from the target location. 
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Figure 13.6:  Contour slices in the x-plane at 0.25 cm intervals.  Slice depth is indicated as depth 
from the tissue surface at the center (nipple) region. 
Figure 13.7 shows slices in y-plane representing the sagittal view.  Slice 4 in the 
center gives the sagittal slice at the y=0 location which is the central part of the tissue.  The 
other slices represent the locations in 0.25 cm increments to the left (slices 1-3) and right 
(slices 5-7) of the center.  The images show that within this central region, there is a 
maximum signal intensity at the central location of the tissue which corresponds to the 6 
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o’clock position of the fluorescent target, and the signal diminishes in either direction away 
from the center.   
 
Figure 13.7  Contour slices in the y-plane at 0.25 cm intervals. 
The quantitative results for the in vivo 3D reconstruction are provided in Table 13.1.  The 
recovered !axf value (9.17) is much larger than expected, which is due to the presence of 
signals from artifacts which are all included in the total !axf value.  The true target location 
was approximated at (x,y,z)=(2.5,0,0) since the target was placed in the center underneath 
the flap of the tissue and the approximate tissue depth (x-dimension) was 2.5 cm (as 
measured by a Vernier caliper).  The recovered target location was (x,y,z)=(3.0,-3.3,-1.8) and 
the total distance off was 3.75 cm.  The distance off can be due to two factors: (i) inaccuracy 
in the estimation of the true target location, and (ii) the artifacts that appear toward the left 
side of the reconstruction (as shown in Figure 13.6) which can be mistaken as the true 
location due to the high intensity of the signal.  Reduction in artifacts and better estimation 
of the true target location will likely improve the quantitative results. 
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Table 13.1  Quantitative results for the in vivo 3D reconstruction: recovered !axf, true target 
volume, recovered target volume, approximate true target location, recovered target location, 
total distance off. 
 
13.4  DISCUSSION 
Three-dimensional tomography of breast tissue in a human subject using a hand-held based 
optical imager was demonstrated for the first time.  The reconstructed result shows 
recovered signal at the true target location but at a shallower depth than the true target 
location.  This depth recovery limitation is a common phenomenon when reflectance based 
measurements are used.  More accurate depth recovery may be achieved by using a 
combination of transilluminated and reflected measurements or by using multiple 
projections in reflectance mode.  
Additional signal away from the target location was also present on the left side of 
the tissue.  This artifact signal might be the result of poor contact with the tissue on one side 
of the probe causing detection of excitation light that was reflected off the tissue surface.  
The subtraction based post-processing technique was applied to eliminate excitation leakage; 
however, the probe might have shifted during removal of the target causing the background 
image to have a different noise distribution from the image with the target.  
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For this initial preliminary tomography study, a coarse mesh was used in order to 
reduce computational time and effort while the reconstruction procedure was developed.  
Use of a finer mesh could produce a more accurate reconstruction result.  In addition, a 
varied mesh might be used which is more refined close to the target location and more 
coarse away from the target location which would further reduce the noise away from the 
target.  This would be applicable in a clinical setting since FDOT is not currently used for 
screening and hence the region of tissue suspected of containing a tumor would be known. 
This study used data from a normal human subject with a fluorescent target placed 
noninvasively beneath the flap of breast tissue, between the breast tissue and the ribcage.  
Hence the light passed through two layers of skin and a full layer of breast tissue during both 
the incident and returning path which would produce a different result than an actual tumor 
embedded within the breast itself under a few centimeters of tissue.   
This preliminary study demonstrates the feasibility of performing 3D tomography in 
human breast tissue using the ten step procedure developed herein.  In the case presented 
here, the true target location was roughly estimated and the results analyzed qualitatively.  
Future work will involve extensive tomography studies in healthy subjects and breast cancer 
patients to improve the accuracy of the quantitative results.   
13.5  SUMMARY AND CONCLUSION 
A procedure for performing 3D tomography in human tissue using automated self-
coregistered experimental data was developed.  A preliminary reconstruction study was 
performed using the self-coregistered data from a normal human subject with a fluorescent 
target placed underneath the breast tissue.  The result shows fluorescent intensity signal 
reconstruction close to the true target location along with artifact signal away from the target 
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location.  This study demonstrates the feasibility of performing 3D tomographic imaging in 
human breast tissue using a hand-held based optical imaging system. 
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CHAPTER 14                                                                                                   
Study VII:  In v ivo Imaging of Breast Cancer Subjects 
14.1  INTRODUCTION 
The studies described in the previous chapters involved preclinical testing of a hand-held 
optical imaging system for breast cancer diagnosis.  The final stage of this dissertation 
involves testing the performance of the device in actual breast cancer subjects.  This chapter 
describes preliminary studies designed to demonstrate the feasibility of imaging breast 
tumors in human subjects using our hand-held optical imager. 
14.2  MATERIALS AND METHODS 
Diffuse optical imaging studies were performed with two subjects (age 64 and 51) with 
breast cancers masses confirmed by prior image modalities (i.e. x-ray mammography, 
ultrasound, MRI).  The studies were approved by the FIU Institutional Review Board and 
the subjects signed a consent form prior to the study and a HIPAA authorization form (for 
release of the medical records).  For the diffuse optical studies (non-fluorescent) one neutral 
density filter (OD 4) was used to uniformly attenuate the collected laser light.  Continuous 
wave based images were collected (average of 5 frames) using an exposure time of 200 msec.  
The gain on the image intensifier was set while the probe was placed at the initial probe 
location and held constant during the entire study performed at various probe locations.      
 The studies were performed using the modified imaging set-up described in Chapter 
12, where the subject lay in the supine position in a recliner chair at a 45º angle.  The probe 
was placed at different locations on the ipsilateral (tumor-containing) and contralateral (non-
tumor-containing) breast and images of continuous-wave absorption-based measurements 
were collected.  The probe positions were determined visually to cover the entire breast 
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tissue.  Initially the probe was centered over the 12 o’clock position covering the upper 
region of the breast tissue and part of the chest wall (probe location #1 in Figure 14.1), then 
moved vertically down toward the 6 o’clock position (probe location #4 in Figure 14.1).    
The four imaging locations relative to the subject are shown in Figure 14.1 (not to scale).   
 
Figure 14.1:  Schematic showing the probe locations during the imaging studies.  The probe was 
placed at four different locations on the left breast tissue followed by the same four locations on the 
right breast tissue.  All probe positions were estimated with reference to the nipple location and are 
not drawn to scale in the schematic. 
Currently, a more structured and accurate approach is developed for measuring and marking 
the probe locations using the same method in all subjects (described in detail in Section 11.2 
and Figure 11.2).  For the studies describe herein, the positions were estimated at the 
following locations corresponding to Figure 11.2:  UM4 (location 1), UM2 (location 2), LM2 
(location 3), and LM4 (location 4).  In each case, both the left and right breast tissues were 
imaged at the same symmetrical probe locations and the images from the contralateral breast 
were normalized and used in subtraction based post-processing.  In every case, the 
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normalized intensity data from the ipsilateral breast was subtracted from the normalized 
intensity data from the contralateral breast so that the signal due to higher absorption shows 
as a higher (more red) signal in the 2D contour plot.    
For subject #1 a second set of images were collected from the outer side of the 
breast tissue under the arm because the medical records indicated lymphatic spread to the 
axillary lymph nodes.    The subject was asked to lie on the right side while resting the left 
arm above the head and the probe was placed under the arm for location #1.  The probe 
was then moved down toward the ribcage and images were collected at four different 
locations as shown in Figure 14.2.  The axillary lymph nodes are located in the outer chest 
wall region under the arm as indicated in Figure 14.2.  The entire set of images was repeated. 
 
Figure 14.2  Probe locations for second set of images in subject #2.  The subject was asked to lie on 
the right side and rest the left arm above the head while the probe was placed at four different 
locations on the outer side of the left breast starting under the arm and moving down toward the 
ribcage.  The procedure was repeated on the right breast at symmetric locations.  All probe positions 
were estimated with reference to the nipple location and are not drawn to scale in the schematic. 
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14.3  RESULTS 
The optical images from both subjects were compared to the medical records provided.  For 
subject #1, a palpable mass in the left breast produced a negative result in x-ray 
mammography.  However, MRI images showed a region of abnormal tissue behind the 
nipple in the left breast which was determined by needle biopsy to be invasive ductal 
carcinoma with lymphatic spread.  Figure 14.3 shows slices from an MRI scan.  The yellow 
arrows indicate the abnormal tissue located in the periariolar region (i.e. near the nipple 
area).   
 
Figure 14.3:  Three slices of an MRI scan from 64 year-old breast cancer patient.  The yellow arrows 
indicate the location of abnormal tissue behind the nipple region. 
Figure 14.4 shows the first set of continuous-wave absorption-based images collected from 
subject #1 using the hand-held optical imager (repetition #1).  For each of the four probe 
locations (indicated in Figure 14.1), an image was collected from the left breast (on left) and 
right breast (center) and the data were subtracted to yield the post-processed images (on 
right).  The optical signal due to absorption is indicated by the dashed yellow line.  The 
location of the signal corresponds to the location of abnormal tissue indicated in the MRI 
images (Figure 14.3).  The probe locations began at the top part of the breast and moved 
down toward the bottom of the breast tissue (as described in the previous section).  Since 
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the region of abnormal tissue was located in the central part of the breast tissue behind the 
nipple, the optical signal from that region of tissue would be visible in the lower part of the 
image for probe position #1, in the center of image for probe positions #2 and #3, and 
toward the top of the image for probe position #4.  These areas are indicated in the images 
by a yellow dotted circle.  Additional signal appears in the lower right corner of each post-
processed image which is likely due to incomplete contact of the outer edge of probe with 
the tissue.  Figure 14.5 shows the results from the second repetition of images collected at 
the same locations and post-processed.  The images show similar result to Figure 14.4 which 
demonstrates repeatability of the data collected. 
 
Figure 14.4:  Continuous-wave absorption-based optical images collected from subject #1 at four 
probe locations (first repetition of images).  The images on the left were collected from the left breast 
tissue and the images in the center were collected from the right breast tissue.  The post-processed  
images on the right represent the normalized intensity data from the ipsilateral (left) breast subtracted 
from the normalized intensity data from the contralateral (right) breast showing the optical signal due 
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to absorption as a higher (red) signal in the images.  The yellow dotted circle was hand-drawn to 
represent the region of interest in each image. 
 
Figure 14.5  Continuous-wave absorption-based optical images collected from subject #1 at four 
probe locations (second repetition of images).  The images on the left were collected from the left 
breast tissue and the images in the center were collected from the right breast tissue.  The post-
processed  images on the right represent the normalized intensity data from the ipsilateral (left) breast 
subtracted from the normalized intensity data from the contralateral (right) breast showing the 
optical signal due to absorption as a higher (red) signal in the images.  The yellow dotted circle was 
hand-drawn to represent the region of interest in each image. 
Figure 14.6 shows ultrasound images from subject #1 of suspicious enlarged lymph nodes in 
the axillary region (indicated in Figure 14.2).  Needle biopsy confirmed that at least three 
lymph nodes in the axillary region contained lymphatic spread of carcinoma.   
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Figure 14.6   Ultrasound images from subject #1 of suspicious enlarged axillary lymph nodes.  (The 
axillary region is indicated in Figure 14.2.) 
The second set of four optical images collected from the outer part of the tissue under the 
arm in the axillary region and the side of the breast tissue (probe locations indicated in 
Figure 14.2) are shown in Figure 14.7.  The first image from probe location #1 shows a 
strong absorption signal (indicated by the dashed yellow circle) which might be from an 
enlarged axillary lymph node.  Additional (weaker) absorption signals in images from probe 
locations #2 and #3 might also indicate regions of affected lymph nodes.  The fourth image 
from probe location #4 no longer covered the axillary region and was located over the 
breast tissue.  The diffused signal in the fourth image is likely from the abnormal tissue 
located behind the nipple (similar to the signal in Figure 14.4).  Figure 14.8 shows the results 
from the second repetition of images collected at the same locations and post-processed.  
The images show similar result to Figure 14.7, however there is also the presence of artifacts 
because the probe was not in full contact with the tissue. 
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Figure 14.7 Continuous-wave absorption-based optical images collected from subject #1 at the 
second set of four probe locations (repetition #1).  The images on the left were collected from the 
left breast tissue and the images in the center were collected from the right breast tissue.  The post-
processed (subtracted) images on the right show the optical signal due to absorption.  The yellow 
dotted circle was hand-drawn to represent the region of interest in each image. 
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Figure 14.8  Continuous-wave absorption-based optical images collected from subject #1 at the 
second set of four probe locations (repetition #2).  The images on the left were collected from the 
left breast tissue and the images in the center were collected from the right breast tissue.  The post-
processed (subtracted) images on the right show the optical signal due to absorption.  The yellow 
dotted circle was hand-drawn to represent the region of interest in each image. 
Figure 14.9 shows x-ray mammography images from the left breast of a 51 year-old 
breast cancer patient (subject #2).  Figure 14.9A is the axial view where the top of the image 
is toward the left side of the breast and the bottom of the image is toward the right side of 
the breast.  Figure 14.9B is the oblique view where the top of the image is toward the 
patient’s head and left side and the bottom of the image is toward the patient’s feet and right 
side.  The images show the presence of 3 masses in the outer quadrant of the tissue 
(indicated by the yellow arrows).  The medical reports indicated that two of the masses were 
cancerous with regions of abnormal tissue between the three masses.   
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Figure 14.9  X-ray mammography images of the left breast from a 51 year-old breast cancer patient.  
(A) The top of the image is the left side and the bottom of the image is the right side of the breast 
tissue.  (B)  Oblique image where the top of the image is toward the patient’s head and left side and 
the bottom of the image is toward the patient’s feet and right side.  The yellow arrows indicate 3 
lesions (labeled as L1, L2, and L3) located in the 1 o’clock to 2 o’clock region of the breast. 
Figure 14.10 shows ultrasound images from the left breast of the same subject.  The image in 
Figure 14.10A was collected from the 1 to 2 o’clock position at 2-3 cm from the nipple and 
the image in Figure 14.10B was collected from the 1 to 2 o’clock position at 6 cm from the 
nipple.  The three tumor masses in the outer quadrant of the tissue are indicated by the 
yellow arrows. 
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Figure 14.10  Ultrasound images of the left breast from a 51 year-old breast cancer patient.  Both 
images were collected in the 1 to 2 o’clock location where image (A) was 2-3 cm from the nipple and 
image (B) was 6 cm from the nipple.  The yellow arrows indicate 3 lesions (labeled as L1, L2, ans L3 
corresponding to Figure 14.7) located in the 1 o’clock to 2 o’clock region of the breast. 
Figure 14.11 shows the continuous-wave absorption-based images collected using 
the hand-held optical imager.  The images on the left were collected from the ipsilateral 
breast and the images in the center were collected from the contralateral breast.  The images 
on the left were subtracted from the images in the center to yield the resulting postprocessed 
images on the right.  In the post-processed images, the area of higher absorption shows as a 
higher (or more red) signal.  The post-processed images from locations 1-3 show high 
intensity signal (greater absorption) in the outer quadrant of the left breast tissue which 
corresponds to the location of the 3 tumor masses indicated in the x-ray mammogram and 
ultrasound images.  The image from location 4 which is from the lowest part of the tissue 
does not show higher absorption.  
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Figure 14.11  Optical images collected from the breast tissue of a 51 year-old breast cancer patient.  
The images in Set #1 were collected from the ipsilateral breast and the images in Set #2 were 
collected from the contralateral breast.  The images from Set #1 were subtracted from Set #2 so that 
the area of higher absorption shows as a higher (or more red) signal in the post-processed images.   
The yellow dotted circle was hand-drawn to indicate the region of interest. 
The subject returned for a second study 42 days following the initial study.  The 
same set of images was collected at the same locations on the breast tissue and the post-
processed images from the two studies are compared in Figure 14.12.  The images from 
study #2 show intensity signal (absorption) located in the outer quadrant of the left breast 
tissue; however, the signal is reduced and diffused compared to the images from study #1.  
The subject had been undergoing treatment therapy during the time that the images were 
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collected and the results in Figure 14.12 might be indicative of reduction of the tumor 
masses due to the treatment.  
 
Figure 14.12  Comparison of the results from two different image sets collected on different dates 
from subject #2.  Study #2 was performed 42 days after Study #1 in the same breast cancer subject.  
Four images were collected at the same probe locations (see Figure 14.1).  For each study, images 
were collected from both the right and left breast tissues and used to subtract the excitation leakage.  
All images are the final post-processed images.  The probe locations were estimated with respect to 
the nipple location. 
14.4  DISCUSSION 
This chapter presented preliminary data from the first studies performed using our hand-
held optical imager with actual breast cancer subjects.  Subject #1 had invasive ductal 
carcinoma with lymphatic spread which was not detected by x-ray mammography.  The first 
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set of optical images show absorption signal corresponding to the region of abnormal breast 
tissue indicated in the MRI images.  The second set of optical images show absorption signal 
corresponding to the location of axillary lymph nodes in the region where needle biopsy 
confirmed lymphatic spread of carcinoma.  This study shows the potential of the hand-held 
device to image cancerous tissues that are undetectable by MRI as well as affected lymph 
nodes in the axillary region. 
 The images from subject #2 show absorption signal corresponding to the location of 
tumors in a subject undergoing chemotherapy treatment for invasive ductal carcinoma.  In a 
subsequent study with the same subject 42 days following the first study, the signal in the 
same region was weaker and more diffused.  This possibly indicates shrinkage of the tumor 
masses due to the chemotherapy treatment.  These results show the potential of the device 
in monitoring of response to treatment. 
 All of the images show artifacts located outside the region of interest.  These artifacts 
might be due to improper contact of the probe with the tissue or the uneven source intensity 
distribution among the six sources.  Additionally, the subtraction post-processing to 
eliminate excitation leakage was performed using images from two different breast tissues.  
Hence, differences in the signal distribution due the different composition of the tissue 
would produce artifacts after subtraction.  Filtration methods will be applied in the future to 
reduce the number of artifacts (Chapter 16). 
The hand-held optical imager described herein has potential as a complementary 
imaging modality for breast cancer imaging in the clinical setting.  Currently most breast 
masses are found by x-ray mammography and/or breast ultrasound and then diagnosed as 
malignant or benign by surgical biopsy.  Since 80% of biopsies turn out to be negative [2] 
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there is a clear need for a method of noninvasively imaging breast tumors to gain more 
information.  Optical imaging provides functional information without any additional harm 
or discomfort to the patient. 
 In addition to breast cancer diagnosis, another potential application for optical 
imaging is for monitoring the progression of tumor response to treatment therapy.  Since 
optical imaging does not use harmful radiation like x-ray and nuclear techniques, the patient 
can be imaged more frequently.  This will reduce the distress of the patients who currently 
have to wait several months between imaging scans to determine if the treatment therapy is 
effective.  The results shown in the previous section show potential of our hand-held optical 
imager for use in this application. 
14.5  SUMMARY AND CONCLUSION 
The performance of our hand-held based optical imager was tested in the clinical setting for 
the first time on actual breast cancer patients.  These preliminary results indicate the ability 
of the device to detect tumors via continuous-wave absorption-based imaging.  In addition, 
multiple studies during treatment therapy demonstrate the potential application of the device 
to be used to monitor tumor progression at different stages of therapy.  Extensive studies 
will be performed in the future to demonstrate coregistered imaging and 3D tomography in 
cancer subjects as well as determine the sensitivity and specificity of the device. 
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CHAPTER 15                                                                                               
Summary and Conclusion:  Overall Discussion and Significance of the 
Work 
 
A hand-held probe based optical imaging device has been developed in our Optical Imaging 
Laboratory towards breast cancer imaging.  It is distinctive from other hand-held optical 
devices in its ability to perform 3D tomography in complex human breast tissues via unique 
self-coregistration capabilities.  In the past, our device has demonstrated 3D tomography 
using manual coregistration in simple cubicle phantoms.  The overall goal of this dissertation 
was towards translation of our device to the clinical setting for 3D tomographic imaging in 
human breast tissues with complex geometries.  A systematic experimental approach was 
designed and executed to evaluate the performance of the device at each stage of clinical 
translation.  The major objectives of the studies were to demonstrate fast 2D imaging, 
coregistered imaging, and 3D tomography in tissue phantoms, in vitro, and in vivo with human 
subjects.   
 The first major goal was to perform fast 2D imaging in order to determine if the 
device could detect and estimate the 2D location of a target even prior to 3D tomographic 
analysis.  In the clinical setting, fast 2D imaging is useful to quickly gain a visual picture of 
the entire breast tissue and determine the specific “areas of interest” to which more in-depth 
analysis will be applied.  For the phantom, in vitro, and in vivo studies performed herein, the 
term “fast imaging” is used to describe the acquisition and initial post-processing to visualize 
the target or tumor in a 2D contour plot.  Each image was acquired in near-real time (~5 
seconds).   
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 Fast 2D imaging was initially demonstrated in the simple case of homogeneous tissue 
phantoms composed of 1% Liposyn solution.  A 0.45 cm3 spherical target filled with 1 !M 
Indocyanine green (ICG) fluorescent contrast agent was detectable up to a depth of 2.5 cm 
under perfect uptake conditions (Section 8.3.1).  The next step was to introduce a 
heterogeneous background which better mimicked the properties of actual human tissue.  
Studies were performed in vitro using minced chicken breast combined with 1% Liposyn.  
Spherical targets of 0.45 and 0.23 cm3 volume filled with 1 !M ICG were detectable up to 
2.0 cm deep under perfect uptake conditions (Section 8.3.2).  The final step was to see if a 
target could be detected through actual human breast tissue.  Healthy female subjects above 
age 21 were recruited for the IRB-approved study.  Spherical targets of 0.45 and 0.23 cm3 
filled with 1 !M ICG were noninvasively placed underneath the flap of the breast tissue and 
were detected through ~ 2.5 cm of human breast tissue (Section 11.3).   
 The fast 2D imaging studies demonstrated that small targets (0.23-0.45 cm3) could be 
detected in near-real time using our hand-held optical imager in tissue phantoms, in vitro, and 
in vivo.  It is interesting to note that the deepest target detected for in vitro studies was at a 
depth of 2.0 cm, whereas in the more complex human subject case, the target was detected 
through ~2.5 cm of tissue.  Chicken breast tissue is composed primarily of muscle whereas 
human breast tissue has various components such as mammary glands, milk ducts, and fatty 
tissue.  Hence, while phantom and in vitro experiments are useful for preliminary 
investigations of the capabilities of a device and optimization, they do not accurately predict 
what result will occur in a true human subject case.  The scattering coefficient of the in vitro 
phantom ranged between 6 and 12 cm-1 which is close to the average value of human breast 
tissue (~ 8 cm-1).[134]  Extensive clinical studies are required to fully define the performance 
  
 173 
of the device in order to account for the wide variability between subjects.  The research 
performed for this dissertation has effectively translated the device from the laboratory 
testing stage to the clinical studies phase and the imaging set-up and protocol have been 
methodically structured to be conducive now for a continuous flow of human subject 
studies.    
 Fast 2D imaging in near-real time is useful to gain an initial estimation of the area of 
interest to be interrogated in more detail.  In order to proceed with further analysis, it is 
necessary to determine the location of the probe image with reference to the geometry of the 
tissue (i.e. coregister the images).  The second major goal was to demonstrate automated 
coregistered imaging which is necessary to perform 3D tomography.  The optical 
tomography studies performed by other research groups typically used bulky 
instrumentation with the breast placed within a fixed geometry (between two compression 
plates or in a ring).[22,110]  The fixed location and geometry enables the image location 
relative to the breast geometry to be known, allowing for tomography.  Only one research 
group has demonstrated 3D tomography using a dual optical/ultrasound hand-held 
device.[66]  The additional data from the ultrasound was used as structural a priori 
information for tomography.  Our device is unique in that is has self-coregistration 
capabilities enabling 3D tomography to be performed using a hand-held optical-only device, 
without requiring a second imaging modality.   
 An acoustic based tracking system was implemented with the hand-held device and 
automated coregistration software (developed in-house using MATLAB/LabVIEW) was 
used to perform self-coregistered imaging.  Automated coregistered imaging was 
quantitatively validated in tissue phantoms and the average distance off between the 
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measured location and true location of the probe with respect to the phantom was ~0.19 
cm.  The discrepancy was attributed to instability of the tracking system.  Coregistered 
imaging was performed in tissue phantoms and in vitro where multiple coregistered images 
were summed in order to increase the signal from the target while relatively reducing the 
random artifacts enabling deeper target detection.  The depth of detection for tissue 
phantoms was improved from 2.5 to 3.5 cm in tissue phantoms under perfect uptake and 3.0 
cm under imperfect (T:B=100:1) uptake.  The depth of detection in vitro was improved from 
2.0 cm to 3.5 cm under perfect uptake and 2.5 cm under imperfect (T:B=100:1) uptake for 
target volumes of 0.23 – 0.45 cm3 (Section 9.3). 
 Coregistered imaging was performed in vivo in healthy human subjects.  Tracking of 
the probe was quantitatively validated by automatically inserting reference points into the 3D 
meshed geometry via code developed in MATLAB.  The average total distance off between 
the measured location and true location was ~1 cm.  The much larger discrepancy 
(compared to the discrepancy in phantoms) was attributed to movement of the subject, 
deformation of the breast tissue, and probe-operator error.  The imaging set-up was 
modified to minimize human error during in vivo imaging (by scanning and imaging the 
subject in supine position at a 45º degree angle, Section 12.2.3).  Currently efforts are made 
by others in our lab to develop an optical tracking system to reduce the error due instability.  
Future work will involve testing the total reduction in error using the new tracking method 
(as described in Chapter 16).  Automated coregistered imaging was performed on a healthy 
human subject with a spherical target (0.45 cm3) filled with 1 !M ICG placed noninvasively 
underneath the flap of the breast tissue.  Due to increased instability of the acoustic tracking 
system, a manual coregistration approach was temporarily implemented and performed in a 
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healthy human subject with a 0.45 cm3 spherical target filled with 0.08% and 0.04% India ink 
placed underneath the flap of the breast tissue.  The results demonstrated the ability to 
detect both fluorescent and absorption based targets through human breast tissue and 
coregister the image at the appropriate tissue location using both automated and manual 
coregistered imaging (Section 12.3). 
 Coregistered images provide the appropriate positional information to enable 3D 
tomographic analysis.  The third major goal was to perform 3D tomography in tissue 
phantoms, in vitro, and in vivo using our hand-held optical imager.  Initially, 3D tomography 
was performed using manual coregistration of the fast 2D images of fluorescent targets in 
vitro with the simple cubicle geometries.  The targets were recovered close to the true 
location; however, the recovered optical property (!axf) values were very low which could be 
due to the highly diffused signal from depths of 2-2.5 cm in a heterogeneous background 
(Section 10.3.1).  Subsequent tomography studies were performed using the summated 
coregistered data.  The reconstruction results showed many artifacts and it could not be 
conclusively determined that the target was recovered (Section 10.3.2).  Future work will be 
performed to apply some filtration techniques and to use frequency-domain data for the 
reconstructions which provides additional phase information that is not present in CW 
imaging employed in the current research studies (as described in Chapter 16).   
 The major challenge in performing 3D tomography in human tissue as opposed to 
simple phantoms is to generate the discretized volume geometry (or mesh) for the human 
breast tissue.  For simple cubicle phantoms, the geometry and mesh were generated within a 
single software (Gambit) and the same mesh was used for each phantom reconstruction.  In 
the case of human subject studies, the various breast tissue geometries must be acquired for 
  
 176 
each subject and discretized into tetrahedral volume mesh.  Complications occurred in the 
process of trying to import an acquired surface scan into appropriate software to generate 
the 3D volume and mesh.  Meshing softwares are typically designed such that a geometry is 
both generated and meshed within that same software.  However, our application presented 
a unique complication in that we required an externally acquired complex geometry to be 
imported into the software and used to generate a 3D volume and mesh.  A ten-step 
procedure was developed to acquire the tetrahedral volume mesh of the breast tissue and 
extract the experimental information corresponding to the individual volume breast mesh 
needed to input into the reconstruction algorithm (Section 13.2.1).   
 Three-dimensional (3D) tomography was performed using the data from a healthy 
human subject with a fluorescent target placed underneath the flap of the breast tissue.  The 
signal from the target was recovered close to the true location along with artifacts (Section 
13.3).  The artifacts could be caused by improper contact of the probe with the tissue 
surface, uneven intensity distribution among the six sources in the probe face, or noise in the 
experimental data.  Efforts will be made to reduce the artifacts as part of the future work 
(Chapter 16).  The result demonstrates for the first time the feasibility of performing 3D 
tomography in breast tissue of a human subject using a hand-held optical imager. 
 The final stage of the dissertation involved preliminary studies using the hand-held 
optical imager on actual breast cancer subjects.  Diffuse optical imaging studies were 
performed in two female patients with invasive ductal carcinoma.  The images showed 
higher absorption signals in the regions of the tumor locations along with artifacts (Section 
14.3).  The results demonstrate the potential of the device to detect the presence of cancer 
within a known region of interest which has clinical application towards prognostic imaging 
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since the location of the tumor versus surrounding artifacts will be known.  In order for the 
device to be used for diagnostic purposes, the artifacts that have occurred in the images must 
be minimized.  Future work will involve efforts to improve the instrumentation as well as 
the imaging procedure in order to reduce the artifacts.  
 There are several unique advantages of our hand-held optical imager.  The probe 
contains six illumination points and 165 detection points (distributed over a 4x9 cm) area 
which illuminate and collect the signal simultaneously to enable rapid data acquisition in 
large volumes of tissue.  The probe is designed with a flexible face to contour to the 
curvature of the breast tissue allowing maximum patient comfort.  Self-coregistration 
facilities are implemented with the probe to accurately position the image on the complex 
3D breast tissue geometry.  The hand-held optical imager is the only one of its kind that is 
capable of performing 3D tomography in human breast tissue. 
 There are also several limitations of the hand-held device.  The probe uses a sub-
surface based imaging configuration which limits the collected signal to reflectance 
measurements only.  The physics of reflectance based imaging leads to recovery of targets 
closer to the imaging surface limiting the ability to accurately recover the true target depth.  
The acoustic tracking system proved unstable causing error in image coregistration.  The 
bulky design of the bench-top hand-held imaging device is not portable and operator-
friendly for efficient bedside imaging.  The next chapter will describe the efforts to 
overcome these limitations as part of our ongoing and future work.   
 The significance of the work presented in this dissertation is towards the clinical 
translation of a hand-held optical imager for bedside imaging and 3D tomography of human 
breast tissue.  The process of clinical translation of our hand-held optical imager involved 
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modification of the experimental set-up and method from bench-top phantom studies to 
bedside human subject imaging.  The performance of the device was evaluated using 
progressively more complex subjects, beginning with the simple case of homogeneous tissue 
phantoms, then using more complex heterogeneous in vitro phantoms, and finally testing in 
actual human breast tissue.  While phantom and in vitro studies are useful for gaining some 
insight into how the device will perform, extensive human subject studies are integral to 
gaining a true assessment of the device performance in the clinical setting.  The hand-held 
optical imager has potential impact for women with breast cancer by providing a safe and 
patient comfortable method for functional imaging of breast tissue towards cancer diagnosis 
and prognosis.  
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CHAPTER 16                                                                                            
Ongoing and Future Work 
 
 The work performed for this dissertation has brought the development of our hand-
held optical imager from the stage of bench-top testing in simple cubical phantoms to the 
stage of performing extensive bedside human subject studies.  Through collaboration with a 
breast surgeon and a cancer center, we are continuously recruiting breast cancer patients to 
participate in our research studies.  Parallely, we will continue to perform studies in healthy 
subjects as a control group, and in the future we will recruit subjects with various types of 
non-cancerous breast lesions (e.g. cysts, fibroadenoma, etc.)  Our imager must be tested on 
many subjects over a wide range of demographics in order to determine the sensitivity, 
specificity, positive predictive value, and negative predictive value of the device. 
 The three major aspects that the ongoing and future work will focus on to improve 
the imaging results are (i) instrumentation, (ii) data acquisition, and (iii) post-processing.  The 
current limitations in the instrumentation are the bulky bench-top design of the optical 
imaging system, the heavy and awkward hand-held probe, and the unstable tracking system.  
In order to address the limitations in the bulky bench-top system and probe design, a second 
generation of the hand-held optical imager is being developed which has a more sleek and 
portable design.  The instrumentation is more compact and fits on a portable cart for ease of 
bedside imaging.  The hand-held-probe has a two-piece design which is smaller and lighter 
for comfort and better control of operation as well as the addition of transillumination based 
measurements to improve target depth recovery.  Another limitation of the first generation 
device is the uneven source intensity distribution which causes artifacts in the images.  The 
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second generation device will contain six independent laser diodes to enable a uniform 
source intensity distribution.  This second generation device will be tested extensively in 
healthy human subjects and breast cancer patients.     
 Another limitation in the instrumentation is the instability of the tracking system,. An 
alternate optical-based tracking system is being developed to enable more accurate image 
coregistration.  Once the optical-based tracking system is developed, coregistered imaging in 
human subjects will be reevaluated quantitatively to determine how much the discrepancy 
between true and measured probe locations was reduced by the combined efforts of (i) 
improving the stability of the tracking system and (ii) modifying the imaging set-up to reduce 
human error.   
 Efforts will be made to improve the methods of data acquisition in order to 
systemize the imaging approach across multiple human subjects. To this end, a structured 
imaging approach will be implemented which uses a template of predefined locations of the 
probe which are marked on each breast tissue to ensure continuity of imaging among 
repetitions with each subject and across multiple subjects.  In order to reduce the movement 
and conformation of the breast tissue, an optically clear custom-built garment will be used 
with the Generation II system to confine the breast tissue.  The hand-held 3D scanner will 
be used as the motorized system with the subject seated in an upright position. 
 Post-processing techniques will also be applied as part of the future work in order to 
minimize the presence of artifacts.  Filtration will be applied to the data to try to remove 
noisy data points that contribute to artifacts.   Since each image represents an average of 5-
10 repetitions, there may be noisy data in one of the repetitions which can be identified by 
the magnitude of the standard deviation and removed.[157] 
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 Several challenges were encountered and lessons were learned throughout the 
dissertation process.  One lesson is the importance of maintaining a systematic experimental 
approach at every stage in the research.  If a new method or idea is applied that produces an 
improved result it can be tempting to immediately try it to the most extreme case to see the 
improvement.  However, any new method must be systematically applied at each 
incremental stage in order to see the effect on the experimental results.  During preparation 
for human subject studies, experience was gained while assisting in writing the IRB proposal.  
It can be a strenuous process and it is important to think ahead and cover every possible 
aspect of the experimental procedure.  The procedure will naturally be altered as limitations 
are discovered and more effective methods are implemented and every detail must be 
documented in the IRB protocol.  There is also the challenge of collaborating with other 
institutions requiring an additional IRB approval from the other institutions which can be a 
lengthy process.   
 Several major lessons were learned during this process occurred during the transition 
from phantom and in vitro studies to human subject studies.  During the experience acquired 
throughout the dissertation research, many things have been discovered that must be taken 
into consideration when performing human subject studies as opposed to phantom studies.  
In phantom studies there is much more control over the experiment in that the phantom is 
made the same way each time, and once it is set in place it remains fixed for the extent that is 
required during data collection and troubleshooting.  With a human subject, there is much 
more variability and many more unknowns.  The tissues of human subjects differ widely in 
size and density.  The imaging procedure must be generalized enough to account for the 
differences. Although the subject is asked to remain still during the imaging procedure, there 
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inevitably will be some movement which can impact the results.  Human subject studies 
must be performed in a limited amount of time, so if problems occur, troubleshooting must 
be done quickly on the spot or the data cannot be collected at that time.  Another lesson is 
that the behavioral conduct of the researchers performing the experiment must be much 
more formal than during phantom studies.  Problems inevitably occur and it is important not 
to cause tension or panic in subject who does not understand the operation of the 
instrumentation and might worry that the problem would affect them.  It is also important 
to maintain awareness of the demographics in the area where the subjects will be recruited.  
The studies described here were performed in an area that has a high Hispanic population 
and some of the subjects spoke very limited English.  It was necessary to have the consent 
forms prepared in both English and Spanish so the subject could be informed in their 
preferred language.  Another aspect that is required for human subject studies is the 
confidentiality of sensitive information.  The identity of the subject is never associated with 
the data collected, and the medical records must be kept locked to protect the privacy of the 
subject. 
 The lessons learned during the dissertation process will be incorporated in the 
ongoing and future work with the hand-held optical imager.  Clinical studies with patient 
trials are integral to the translation of any device.  Extensive clinical trials will provide a 
broader scope of the device capabilities and expected performance in a true clinical setting. 
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lasers           (5-
25 mW)                    
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946, 973 
nm 
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CW - fiber-
coupled 
spectrogra
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linear 
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detector 
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subject 
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al 
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n) 
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[36]  
NIR 
Spectrosc
opy 
CW & 
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modulated 
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CW - high-
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tungsten 
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830, 850 
nm 
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coupled 
spectrogra
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Hsiang
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NIR 
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(w/ MRI 
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modulated 
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(10-20 mW)                       
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tungsten 
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coupled 
spectrogra
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linear 
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detector 
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abnormal 
human 
subjects 
(breast 
tissue) 
2,2             
(sequenti
al 
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n) 
Ceruss
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Spectrosc
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CW & 
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FD - amplitude 
modulated 
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CW - 150 W 
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661, 686, 
786, 808, 
822, 852 
nm 
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CW - fiber-
coupled 
spectrogra
ph w/ 
linear 
CCD 
detector 
 N/A 
57 
abnormal 
human 
subjects 
(breast 
tissue) 
2,2             
(sequenti
al 
illuminatio
n) 
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Ceruss
i, 2007              
[39] 
NIR 
Spectrosc
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CW & 
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MHz) 
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modulated diode 
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CW - fiber-
coupled 
broadband 
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source 
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nm 
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CW - fiber-
coupled 
spectrogra
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linear 
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detector 
 N/A 
11 
abnormal 
human 
subjects 
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2,2             
(sequenti
al 
illuminatio
n) 
                      
D
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ic
e 
# 
2 
No, 
2005               
[40] 
NIR 
Spectrosc
opy 
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(50 mW) 783 nm 
photodete
ctor  N/A Phantom 1,1 
 
 
No, 
2006            
[41]  
NIR 
Spectrosc
opy 
FDPM                        
(50-300 
MHz)          
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(20 mW) 
681, 783, 
806, 823 
nm 
APD  N/A 
breast 
phantom 
& muscle 
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4,1      
(sequenti
al 
illuminatio
n)               
No, 
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[42] 
NIR 
Spectrosc
opy 
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(50-300 
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(20 mW) 
681, 783, 
823, 850 
nm 
APD  N/A N/A  
4,1     
(sequenti
al 
illuminatio
n) 
                      
D
ev
ic
e 
# 
3 
Chanc
e, 
2005               
[43] 
NIR 
Spectrosc
opy 
CW 
light emitting 
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(10-15 mA) 
760, 805, 
850 nm 
8 silicon 
diode 
detectors 
4.0 cm 
116 
abnormal 
human 
subjects 
(breast 
tissue) 
1,8 
 
 
Nioka, 
2005                
[44] 
NIR 
Spectrosc
opy 
CW 
light emitting 
diodes                   
(10-15 mA) 
735, 805, 
850 nm 
8 silicon 
diode 
detectors 
4.0 cm 
116 
abnormal 
human 
subjects 
(breast 
tissue) 
1,8 
Sao, 
2003               
[45]  
NIR 
Spectrosc
opy 
CW 2 light emitting diodes 
730, 850 
nm 
8 
photodete
ctors 
 N/A Phantom 2,8 
                      
  
 202 
D
ev
ic
e 
# 
4 
Chanc
e, 
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NIR 
Spectrosc
opy 
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diode 
detector 
5.0 cm Phantom & Human 
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n) 
 
                      
D
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e 
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Liu, 
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[47]  
NIR 
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Spectrosc
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4 light emitting 
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eous 
illuminatio
n) 
 
                      
D
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e 
# 
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 Xu, 
2005           
[48]   
NIR 
Spectrosc
opy 
CW laser diodes                    (100 mW) 
690, 830 
nm 
silicon-
based 
photodiod
es 
1.5 cm Simulation 8,8 
 
 
Xu, 
2005              
[49]   
NIR 
Spectrosc
opy (w/ 
ultrasoun
d) 
CW laser diode 690, 830 nm 
photo 
diode  N/A 
abnormal 
human 
subjects    
(breast 
tissue) 
8,8 
D
ev
ic
e 
# 
6b
 
Xu, 
2007             
[50]   
NIR 
Spectros
copy 
CW laser diodes            (0.15 W/cm2) 
690, 830 
nm 
silicon-
based 
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es 
 N/A 
phantom 
& 2 
normal 
human 
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(calf 
muscle & 
breast 
tissue) 
16,8 
 
                      
D
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e 
# 
7 
Choe, 
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[51] 
NIR 
Spectrosc
opy 
CW 
long coherence 
laser coupled 
to 1x4 optical 
switch 
785 nm 
4 fast 
photon-
counting 
avalanche 
photodiod
es 
 N/A 
5 
abnormal 
& 2 
normal 
human 
subjects         
(breast 
tissue) 
4,4 
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Durdur
an, 
2005            
[52] 
NIR 
Spectrosc
opy 
CW 
long coherence 
laser coupled 
to 1x4 optical 
switch 
785 nm 
4 fast 
photon-
counting 
avalanche 
photodiod
es 
1.0 cm Human 4,4 
                      
D
ev
ic
e 
# 
8 
Liebert
, 2005            
[53] 
NIR 
Spectrosc
opy 
TDPM 2 picosecond diode lasers 
803, 807 
nm PMTs  N/A 
2 normal 
& 2 
abnormal 
human 
subjects          
(brain 
tissue) 
2,4 
 
 
                      
D
ev
ic
e 
# 
9a
,b
 
Sunar, 
2006             
[54]   
Diffuse 
Correlatio
n 
Spectrosc
opy* 
(DCS)  & 
Diffuse 
Reflectanc
e 
Spectrosc
opy** 
(DRS) 
DCS - 
CW          
DRS - 
FDPM       
(70 MHz)   
DCS - long 
coherence 
laser                          
DRS - laser 
diodes 
CW - 785 
nm  FDPM - 
690, 785, 
830 nm 
CW - 4 
fast 
photon-
counting 
avalanche 
photodiod
es        
FDPM - 2 
avalanche 
photodete
ctors 
1.5 cm 
8 
abnormal 
human 
subjects            
(head & 
neck 
tissue) 
CW - 2,4             
FDPM - 
2,4 
 
                      
D
ev
ic
e 
# 
10
a 
Zhu, 
1999            
[55]  
NIR & 
Ultrasoun
d 
FDPM                  
(200 
MHz) 
12 light 
sources from 
single diode 
laser  
776, 834 
nm 4 APDs 2.6 cm 
Breast 
Phantom 12,4 
 
D
ev
ic
e 
# 
10
b 
Guo, 
2000          
[56]  
NIR & 
Ultrasoun
d 
FDPM                     
(140 
MHz) 
12 dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs  N/A 
Breast 
Phantom 12,8 
 
 
Zhu, 
2000             
[57] 
NIR & 
Ultrasoun
d 
FDPM                 
(140 
MHz) 
12 dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs 2.5 cm 
Breast 
Phantom 12,8 
Chen, 
2001           
[58] 
NIR & 
Ultrasoun
d 
FDPM                
(140 
MHz) 
12 pairs of dual 
wavelength 
laser diodes 
760, 830 
nm  8 PMTs 2.5 cm 
Breast 
Phantom 12,8 
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D
ev
ic
e 
# 
11
 
Zhu, 
2003           
[59] 
NIR & 
Ultrasoun
d 
FDPM                
(140 
MHz) 
12 pairs of dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs  N/A 
abnormal 
human 
subjects    
(breast 
tissue) 
12,8 
 
 
Zhu, 
2003                
[60] 
NIR & 
Ultrasoun
d 
FDPM                
(140 
MHz) 
12 pairs of dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs  N/A 
abnormal 
human 
subjects    
(breast 
tissue) 
12,8 
Chen, 
2004            
[61] 
NIR & 
Ultrasoun
d 
FDPM                     
(140 
MHz) 
laser diodes          
(~10 mW) 
660, 780, 
830 nm 
silicon 
avalanche 
photodiod
es 
3.7 cm 
abnormal 
human 
subjects    
(breast 
tissue) 
9,10 
Zhu, 
2005              
[62] 
NIR & 
Ultrasoun
d 
FDPM                  
(140 
MHz) 
12 pairs of dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs  N/A 
64 
abnormal 
human 
subjects    
(breast 
tissue) 
12,8 
Zhu, 
2005              
[63] 
NIR & 
Ultrasoun
d 
FDPM                  
(140 
MHz) 
12 pairs of dual 
wavelength 
laser diodes 
780, 830 
nm 8 PMTs  N/A 
6 
abnormal 
human 
subjects       
(breast 
tissue) 
12,8 
Xu, 
2007                
[64]  
NIR & 
Ultrasoun
d 
FDPM 
9 pairs of triple 
wavelength 
sources 
690, 780, 
830 nm 8 PMTs 1.5 cm 
Simulatio
n & 
Breast 
Phantom 
9,8 
                      
D
ev
ic
e 
# 
12
 
Jayach
andran, 
2007                      
[21] 
NIR 
fluoresce
nce 
tomograp
hy 
FDPM laser diode 785 nm ICCD Camera  N/A 
Simulatio
n & 
Breast 
Phantom 
6,165          
(simultan
eous      
illuminatio
n) 
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APPENDIX B  Fluorescence-enhanced Diffuse Optical Tomography; Experimental Studies 
(Adapted from Ge, 2008 [154]) 
 
 
 
Refer
ence 
 
Phantom/Animal Measur
e 
method 
 
Instrument  2D 
or 
3D 
 
Forward 
Method 
 
Inverse 
Method Background 
Target 
 
Contrast Source 
(geometr
y) 
Detector 
(geometry) Agent Ratio 
(Wu et 
al., 
1995) 
Cylinder 
R = 3. 5 
cm  glass 
beaker 
Sphere 
R = 1.5 
mm 
Diethylthi
atricarboc
yanine 
1:0 TDPM 
Ti: 
Sapphire 
laser 
(point ) 
Streak 
camera 
(sim point) 
3D None Localization 
(Wu et 
al., 
1997) 
Cylinder 
R = 3.2 
cm glass 
beaker 
Glass 
cell 
HITCI 
Iodide dye 1:0 TDPM 
Ti: 
Sapphire 
laser 
(point) 
Streak 
camera 
(sim.  point) 
2D Analytical Laplace transform 
(Chan
g et 
al., 
1997) 
Cylinder 
R = 4 cm 
H = 50 cm 
Balloon 
V = 
0.5mL 
Rhodamin
e 6G dye 500:1 CW 
Argon ion 
laser 
(area) 
CCD camera 
(area) 2D NS 
POCS, 
CGD, 
SART 
(Hull 
et al., 
1998) 
Slab 
14.5 cm 
!29.5 cm 
! 15.5 cm 
Spheric
al glass 
bulb 
R = 3.0 
mm 
Nile blue 
A 1:0 CW 
Dye laser 
(area) 
CCD camera 
(sim. point) 2D Monte carlo 
Localizatio
n 
(Chern
omord
ik et 
al., 
1999) 
Delrin 
phantom 
NS for 
size 
V = 1 
mm3 
Rhodamin
e 1:0 CW 
Argon 
laser 
(area) 
CCD camera 
(area) 
2D/
3D NS 
Random 
walk 
theory 
(Hawr
ysz et 
al., 
2001; 
Eppste
in et 
al., 
Slab 
S = 82 cm2 
H = 4 cm 
Cube 
1 cm3 ICG 
1:0 &  
imper
fect 
uptak
e 
FDPM 
Laser 
diode 
(seq. 
point) 
PMT 
(seq. point) 3D MFD AEKF 
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2002) 
(Ntzia
christo
s and 
Weissl
eder, 
2001) 
Cylinder 
R = 1.25 
cm 
H = 15 cm 
Cylinde
r 
R = 
1.75mm 
H = 
1,:3.5 
cm 
ICG in 
backgroun
d and 
Cy5.5 as 
contrast 
tumor 
1:0 CW 
Laser 
diode 
(seq.point) 
CCD camera 
(sim. Point) 3D FD SIRT 
(Ntzia
christo
s et 
al., 
2002) 
In vivo 
(rat) 
Tumor 
NS for 
size 
Enzyme 
activatabl
e 
fluorochro
mes 
1:0 CW 
Laser 
diode 
(seq. 
point/ 
area) 
CCD camera 
(area) 3D FD 
Constraine
d ART 
(Lee 
and 
Sevick
-
Murac
a, 
2001; 
2002) 
Slab 
V = 
8!8!8 
cm3 
V = 
8!4!8 
cm3 
Cube 
V = 
1cm3 
ICG 100:1 FDPM 
Laser 
diode 
(seq. 
point) 
PMT 
(seq.point) 3D MFD 
Leverberg-
Marquardt 
(Grave
s et 
al., 
2003) 
In vivo 
(rat) 
Tumor 
R = 1.5 
mm 
Cy5.5 
based 
activatabl
e 
fluorescen
t probe 
1:0 CW 
Laser 
diode 
(seq. 
point/area
) 
CCD camera 
(area) 3D FD SVD 
(Goda
varty 
et al., 
2003; 
Godav
arty et 
al., 
2004b; 
Godav
arty et 
al., 
Breast 
phantom 
V = 1087 
cm3 
& Semi-
infinite 
phantom 
Target 
V = 
1cm3 
ICG 
100:1
, 
1:0 
FDPM 
Modulate
d laser 
diode 
(seq./sim. 
Point) 
CCD camera 
(sim.point) 3D FEM AEKF 
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2004a) 
(Klose 
et al., 
2005) 
Slab 
S = 42  
cm2 
H = 1.3 
cm 
Tube 
R = 
0.1cm 
H = 4 
cm 
Cy5.5 1:0 CW 
Laser 
diode 
(seq. 
point/ 
area) 
CCD camera 
(area) 3D 
FD based on 
ERT 
Nonlinear 
optimizatio
n 
(Wu et 
al., 
2005b; 
Wu et 
al., 
2005a) 
Cylinder 
R = 25mm 
H = 
100mm 
Tube 
R = 7 
mm 
Metal 
nanoshell; 
Hybrid 
virus-dye 
nanopartic
le 
1:0 CW 
Laser 
diode 
(seq.point) 
PMT 
(seq. point) 2D FEM 
Newton’s 
iterative 
method 
(Roy, 
2005) 
Cube 
V=83cm3 
Cube 
V=1cm3 ICG 
Perfe
ct and 
100:1 
 
FDPM 
Laser 
diode 
(area) 
CCD camera 
(area) 3D 
Experimenta
l method 
PMBF/CO
NTN 
 
(Goda
varty 
et al., 
2005) 
Breast 
phantom 
V = 
1087cm3 
V = 1 
cm3 
ICG; 
3-3’-
Diethylthi
atricarboc
yanine 
iodide 
 
70:1 
100:1 
Lifeti
me 
1:1 
2.1:1 
FDPM 
Laser 
diode 
(area) 
CCD camera 
(area) 3D FEM AEKF 
(Chen 
et al., 
2005) 
Slab 
phantom 
V = 12 ! 
5 ! 12 
cm3 
In vivo 
 
Cube 
V = 
1cm3 
NIR804-
2-D 
Glucosam
ide 
1:0 FDPM 
Laser 
diode 
(sim. 
Point) 
PMT 
(seq. point) 2D Analytical 
Back-
projection 
(Patwa
rdhan 
et al., 
2005) 
In vivo 
(mice) 
Tumor 
up to 5 
mm 
ICG N/A CW 
Laser 
diode 
(seq. 
point0 
CCD camera 
(area) 3D NS ART 
(Zacha
rakis 
et al., 
2005) 
In vivo 
(mice) 
A thin 
glass 
capillar
y tube 
fluorescei
n 
isothiocya
nate 
1:0 CW 
Laser 
diode 
(seq. 
point/ 
CCD camera 
(area) 3D FD ART 
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 area) 
(Fedel
e et 
al., 
2005) 
Breast 
phantom 
1087 cm3 
Cube 
1cc ICG 100:1 FDPM 
Modulate
d laser 
diode 
(seq. 
point) 
CCD camera 
(sim. Point) 3D BEM AEKF 
(Joshi 
et al, 
2006) 
Cube 
phantom 
V=8x8x8c
m3 
Bulb 
(dia: 3-
4mm) 
Depth: 
1-2cm 
(edge) 
ICG 1:0 FDPM 
Laser 
diode 
(area ) 
CCD 
camera 
(area) 
3D FEM AEKF 
(Roy 
et al, 
2006) 
Breast 
phantom 
V = 
1087cm3 
Bulb 
(0.5-
1.0cm3) 
ICG 1:0 100:1 FDPM 
Laser 
diode 
(seq.point) 
CCD camera 
(sim.point) 3D FEM 
PMBF/CO
NTN 
(Schul
z et al, 
2006) 
cylindrical 
phantom [ 
D=4 cm, 
height 10 
cm; 
hollow 
tubes( 
D=4 
mm) 
Cy5.5 1: 0 CW 
Laser 
diode 
(seq.point 
& 
Area) 
CCD camera 
(sim. point 
& 
 
3D FEM 
Normalized 
Born 
approach 
(Yuan 
and 
Zhu et 
al 
2006) 
Semi-
infinite 
phantom 
Spheric
al(R=0.
4cm) 
Cube 
(0.8x0.8
x0.8cm3
) 
Cy5.5 
1:0 
100:1 
200:1 
FDPM 
Laser 
diode 
(seq.point) 
PMT(seq.po
int) 3D 
Normalized 
Born 
Approximati
on 
(analytical) 
Total least 
square 
/Conjugate 
gradient 
technique 
(Moha
jerani 
et al, 
2007) 
 
Cylinder 
(D=7.5 
cm, H = 6 
cm) 
Small 
glass 
cuvetts 
(1 mm 
! 1 mm 
! 3 
mm) 
Rhodamin
e 6G 
 
1 : 0 CW 
Solid-state 
laser (seq. 
point) 
PMT (seq. 
Point) 3D FEM 
Sparse 
model 
(Corlu 
et al, 
2007) 
In vivo 
(human) Tumor ICG 
3.5-
5.5:1 
 
CW 
Laser 
diode 
(seq. 
CCD camera 
(Area) 3D FEM GMRES 
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point) 
(Davis 
et al, 
2007) 
Rounded 
epoxy 
solid 
phantom 
(D=5.5cm
) 
14mm 
hole Lutex 
2.0:1 
3.3:1 
CW/FD
PM 
Laser 
diode 
(seq.point) 
CCD camera 
sim.point) 3D FEM 
Adjoint 
Method 
(MR-
guided) 
(Delio
lanis 
et al, 
2007) 
in vivo 
(mice) 
9mm 
tube 
(0.75m
m 
diamete
r) 
Alexa 
Fluor 750 1:0 CW 
Laser 
diode 
(seq. 
point) 
CCD camera 
(area) 3D Analytical 
Analytical 
(Normalize
d Born 
solution) 
(Herve 
et al, 
2007) 
Solid 
phantom 
 
And in 
vivo 
(mice) 
Glass 
tube 
(D=3 
mm, L= 
3 cm) 
and 14-
day 
lung 
tumor in 
mice 
Alexa 750 1 : 0 CW 
Laser 
diode 
(seq. 
point) 
CCD camera 
(area) 3D FD ART 
(Keps
hire et 
al, 
2007; 
2008) 
Tank 
filled with 
2% India 
ink and 
5% 
Tween-20 
(V= 
3!4!1 cm 
3  ) 
Cyclind
rical 
target 
(D=8m
m) 
Pp-IX 
3.5 :1
, 5 :1 
and 
10 :1 
CW 
Laser 
diode 
(seq. 
point) 
CCD camera 
(area) 3D FEM 
Non-liniear 
Newton 
minimizati
on 
(Mont
et et 
al, 
2007) 
In vivo 
(mice) 
5-7 day 
tumor 
(D=3 – 
5 mm) 
Angiosens
e 680 and 
750 
/ CW FMT-Solaris FMT-Solaris 3D 
Normalized 
Born N/A 
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(Meye
r et al, 
2007.) 
In vivo 
(transgeni
c mice) 
tumor CD2-GFP / CW Ar
+ laser 
(area) 
CCD camera 
(area) 3D FD ART 
(Roy 
et al, 
2007) 
Breast 
shape 
phantom 
(V = 1081 
cm3) 
Spheric
al target 
(V= 1.0 
cm3) 
ICG 
 
Fluor
escen
ce 
absor
ption: 
212: 
1 
70:1 
Lifeti
me: 
1: 2.1 
2.1 : 
1 
FDPM 
Laser 
diode 
(seq. 
point) 
CCD camera 
(sim. point) 3D FEM 
PMBF/CO
NTN 
 
(Ge et 
al, 
2008) 
Cube 
filled with 
1% 
Liposyn 
solution 
(V=10 
!10!6.5 
cm 3  ) 
Sphere 
(D=0.95
cm) 
ICG 1:0 FDPM 
Laser 
diode 
(sim. 
point) 
CCD camera 
(sim. point) 3D FEM AEKF 
(Keren 
et al, 
2008) 
Cylindrica
l Phantom 
Inclusio
n (D= 3 
mm) 
Cy 5.5 1: 0 TD 
Pulsed 
diode 
laser (seq. 
point) 
PMT (seq. 
point) 3D 
Born 
approximati
on 
N/A 
(Tan 
et al, 
2008) 
Solid 
phantom 
(V= 3 ! 3 
! 9 cm3) 
Cylindri
cal 
target 
(D= 6 
mm) 
ICG 1 : 0 CW 
Laser 
diode 
(seq. 
point) 
CCD camera 
(area) 3D FEM 
Newton’s 
iterative 
method 
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APPENDIX C 
Summary of the experiment parameters for various experimental cases including the average 
measured source intensities, the gain setting on the image intensifier, the actual target 
location in cm, the actual target volume, the measured optical property values of the 
phantom at the excitation and emission wavelengths, the target to background ratio (T:B), 
the recovered target location in cm, the recovered !axf values in cm
-1, the recovered target 
volume, the number of iterations executed before convergence, and the breakpoint (cutoff 
value selected on the first breakpoint of a histogram plot of the recovered !axf values).  
Results from experimental cases 26 and 27 (highlighted in yellow) are presented in Section 
10.3. 
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